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Metformin, a biguanide, is widely accepted to be the preferred first-line 
oral antihyperglycaemic agent to manage type 2 diabetes. There is considerable 
concern that patients receiving metformin therapy may be at an increased risk of 
developing lactic acidosis. The risk has traditionally been assumed to be 
increased in patients with chronic renal impairment, resulting in many patients 
being denied access to an effective first-line treatment agent. The overarching 
aims of this thesis were to explore the safe use of metformin and to create a renal 
dosing guideline that will mitigate the risk of lactic acidosis. 
The safe use of metformin was explored by formally evaluating the 
association between metformin therapy and lactic acidosis in published case 
reports of metformin associated lactic acidosis (MALA) using two causality 
assessments. Metformin was found to play only a possible role in the 
development of lactic acidosis based on the results from the causality 
assessments. Almost all cases presented with other risk factors that could on 
their own have caused lactic acidosis.  
A subgroup analysis was performed in MALA cases with a history of 
chronic renal impairment to explore the relationship between metformin dose, 
plasma concentration and lactic acidosis. Most cases presented with acute renal 
failure, confounding the relationship between metformin dose and plasma 
concentrations. The prescribed metformin dose exceeded the dosing 
recommendations in over 60% of cases with an estimated glomerular filtration 
rate of <60 mL/min by a median of 1000 mg/day. Despite this, based on 
simulations, the pre-admission plasma metformin concentrations measured pre-
dose did not exceed the proposed upper limit of the therapeutic range of 5 mg/L.  
A quantitative analysis was performed to explore the relationship between 
plasma metformin and lactate concentrations. Plasma metformin concentrations 
greater than 4.5 mg/L were found to be associated with severe hyperlactatemia. 
These findings suggest that metformin doses should be adjusted to maintain 




A noncompartmental pharmacokinetic analysis was performed to explore 
the pharmacokinetics of metformin in renal impairment, from which an 
empirical renal dosing guideline for metformin was developed. Patients with 
poorer renal function were found to have lower apparent and renal clearance for 
metformin. These findings support the notion that metformin can be used safely 
for the treatment of type 2 diabetes mellitus in patients with chronic renal 
impairment provided plasma metformin concentrations are maintained within 
a safe therapeutic range.  
A population pharmacokinetic model for metformin was developed and 
evaluated. A covariate analysis found that renal function and total body weight 
could describe patient variability in the apparent clearance and central 
compartment volume for metformin, respectively. The developed population 
pharmacokinetic model was used to assess the safety of the empirical renal 
dosing guidelines and the current published renal dosing guidelines in the New 
Zealand Formulary. Based on the simulations, plasma metformin concentrations 
are not expected to exceed the upper limit of safety of 4.5 mg/L under either of 
the dosing guidelines. 
The influence of flip-flop pharmacokinetics in population pharmacokinetic 
models was explored using metformin as a motivating example. Approaches to 
address problems arising due to flip-flop in population pharmacokinetic models 
are presented in this thesis.  
In conclusion, the findings in this thesis support the notion that metformin 
can be used safely for the treatment of type 2 diabetes mellitus provided plasma 
metformin concentrations are maintained within a safe range. In addition, an 
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1.1. Introduction to the thesis 
Each patient has the right to be treated with respect, privacy and services 
that take into account their individual needs, values and beliefs. In clinical 
practice, when pharmacological therapy is indicated, this involves upholding the 
biomedical ethical principles of beneficence (to do good) and non-maleficence 
(to avoid harm) through the selection of the right medication prescribed at the 
right dose and right time for the right patient. To achieve this goal of providing 
patients with the best care it requires that appropriate steps are taken to optimise 
medicines-related health outcomes for the patient as a fundamental principle. 
Type 2 diabetes mellitus is a chronic metabolic condition characterised by 
hyperglycaemia due to an inadequate insulin response. The global prevalence of 
type 2 diabetes mellitus is increasing with a more rapid increase in low and 
middle income countries [1-4]. Chronic hyperglycaemia is recognised to result 
in a wide range of long term microvascular and macrovascular complications, 
including cardiopathy, nephropathy, retinopathy and neuropathy [5, 6]. The risk 
of hyperglycaemia related complications increases with the duration of diabetes 
and poor glycaemic control [7], highlighting the importance of effective glucose 
control in diabetic patients. 
Metformin is an oral antihyperglycaemic agent widely regarded as the first 
line pharmacological treatment for type 2 diabetes mellitus. Metformin therapy 
may have several advantages over other antidiabetic treatments (e.g. insulin, 
sulfonylureas, thiazolidinediones), including a lower propensity to cause weight 
gain, a lower incidence of hypoglycaemia as well as a reduced risk of diabetes 
related cardiopathy, nephropathy, neuropathy and all-cause mortality [5, 8-11]. 
These benefits have been reported to persist in patients with a glomerular 
filtration rate as low as 30 mL/min/1.73m2 [10], highlighting the usefulness of 
metformin therapy in patients with renal impairment.  
There is concern that patients receiving metformin therapy may be at an 
increased risk of developing lactic acidosis – a rare but life-threatening metabolic 
condition. The risk has traditionally been assumed to be increased in patients 




with renal impairment, resulting in many patients being denied access to an 
effective treatment. In the setting of acute overdose metformin is recognised to 
cause lactic acidosis [12, 13]. However, the relationship between the therapeutic 
use of metformin at usual doses and the risk of lactic acidosis is poorly 
understood. Furthermore, the relationship between metformin exposure and 
lactic acidosis risk is not well established. 
In the setting of renal impairment, the use of standard doses is expected to 
lead to elevated plasma metformin concentrations [11]. It is suggested that the 
subsequent elevated metformin exposure will consequently result in an 
increased risk of lactic acidosis. While dose reduction should mitigate this risk, 
current renal dosing guidelines for metformin lack consensus and none appear 
to be evidence-based [14-16]. The result is considerable confusion for prescribers 
about the best practice for prescribing metformin to achieve plasma 
concentrations that are safe and effective, whilst mitigating the risk of adverse 
events. In this thesis, a systematic approach will be employed to understand how 
to safely dose metformin in patients with renal impairment. The evidence-base 
will be explored to better understand lactic acidosis risk, the influence of renal 
function on this risk, and to determine the safety limit for metformin plasma 
concentrations. Pharmacokinetic analyses will be conducted to understand 
metformin handling in renally impaired patients and to predict doses that will 
mitigate the risk of harm. 
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1.1.1. Aims of the thesis 
The overarching goals of this thesis were to explore the safe use of 
metformin and to create a renal dosing guideline that will mitigate the risk of 
lactic acidosis. The specific objectives were to: 
1. Investigate the causal role of metformin therapy in the development of lactic 
acidosis (Chapter 2) 
2. Explore the role of pre-existing renal impairment in the development of 
metformin associated lactic acidosis in published case reports (Chapter 3) 
3. Explore the association between metformin concentrations and the risk of 
lactic acidosis using lactate as a marker of lactic acidosis risk (Chapter 4) 
4. Explore the pharmacokinetics of metformin in renal impairment (Chapter 5) 
5. Explore the concentration time profile of metformin in renal impairment 
(Chapter 6) 
6. Develop a population pharmacokinetic model for metformin and simulate 
different metformin dosing regimens in patients with varying degrees of 
renal function (Chapter 7) 
7. Explore the absorption dependent pharmacokinetics of metformin (flip-flop) 
in population pharmacokinetic models (Chapter 8) 
1.1.2. Overview of the introduction 
The introduction chapter to the thesis is divided into four sections: 
• Section 1.2 Metformin 
• Section 1.3 The renal system 
• Section 1.4 Acid-base homeostasis 
• Section 1.5 Pharmacometrics 
  





Metformin is an oral antihyperglycaemic agent that is widely accepted as 
the first-line pharmacological treatment for type 2 diabetes mellitus. Metformin 
is part of the biguanide family and was developed from galegine, a guanidine 
derivative found in Galega officinalis [17, 18]. It works predominantly by 
inhibiting hepatic gluconeogenesis [19, 20]. In the clinical setting metformin is 
the preferred agent because unlike other anti-hyperglycaemic agents available it 
has a lower propensity to induce weight gain and is associated with a lower 
incidence of hypoglycaemia [9, 21, 22]. 
1.2.1. History of metformin 
 
Figure 1.1 Galega offinalis plant  
Copyright Malcolm Storey, www.bioimages.org.uk, photograph taken in England, 1 
July 2000 licensed under Creative Commons Attribution License 4.0. 
 
The herbal lineage of metformin descents from the use of the plant Galega 
officinalis (shown in Figure 1.1), also known as French lilac, goat’s rue, Italian 
fitch, professor weed and Spanish sainfoin [17, 18]. Galega officinalis was first 
used and indicated as a traditional medicine in medieval Europe for epilepsy, 
fever, pestilence and worms. It was only in 1772 that Galega officinalis was first 
recommended by John Hill to treat symptoms of diabetes – in particular thirst 
and urination [17]. 
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Chemical analyses from the mid 1800’s revealed Galega officinalis to be rich 
in guanidine and other related compounds, such as monoguanidines, 
diguanidines and biguanides. In 1918 guanidine was reported to reduce blood 
glucose concentrations in animals. Further investigations on galegine (a 
monoguanidine) and diguanidines during the 1920’s were similarly found to 
exhibit an anti-hyperglycaemic effect in animals. Disappointingly, the 
therapeutic use of these compounds were restricted by their toxic effects [17]. 
The chemical genesis of metformin began in the 1800’s. During the 1840’s 
to 1860’s Adolph Streker worked on the chemical synthesis of guanidine. 
Successive work conducted by Bernhard Rathke in 1879 focussed on fusing two 
guanidines to form a biguanide. However, it was only in 1922 that metformin 
was chemically synthesised by Werner and Bell. Despite the chemical structural 
similarities to monoguanidines and diguanidines, metformin and other 
biguanides were shown to exhibit antihyperglycaemic effects in rabbits and 
dogs, and, were reportedly less toxic than the monoguanidine and diguanidine 
moieties [17]. 
In 1957 Jean Sterne published an article describing the use of metformin to 
treat diabetes. Following this, metformin was first introduced in the United 
Kingdom and other European countries for the treatment of diabetes in 1958. 
However, it was only in 1994 that metformin was approved for use in the United 
States of America and introduced in 1995 [17].  
1.2.2. Therapeutic use 
Metformin is indicated as an antihyperglycaemic agent for the treatment of 
type 2 diabetes mellitus in adults and children over 10 years of age [23, 24]. It 
may also be used in combination therapy with sulfonylureas, DPP-4 inhibitors 
and SGLT-2 inhibitors [23]. Metformin is also accepted as an adjuvant therapy in 
type 1 diabetes mellitus (i.e. insulin-dependent diabetes), particularly in obese 
patients [25]. Metformin therapy is used in some patients with anovulatory 
infertility due to polycystic ovary syndrome (an unapproved indication) [23, 24].  
 




1.2.3. Physicochemical properties 
Metformin (1,1-dimethylbiguanide) is a guanidine derivative. The chemical 
formula of metformin is C4H11N5 (structure shown in Figure 1.2) and its 
molecular weight is 129.17 g/mol. The guanidine moiety in the chemical 
structure of metformin is a strong base and has an acid dissociation constant 
value (pKa) of 11.5 [18, 26]. Under physiological conditions metformin exists as 
a hydrophilic, cationic form (99% ionised) [18, 26]. Metformin exhibits poor 
lipophilicity with a logP value of -1.43 [18].  
 
 
Figure 1.2 Chemical structure of metformin 
1.2.4. Pharmacokinetics 
1.2.4.1. Absorption 
The majority of metformin absorption is reported to take place within 6 
hours of drug administration [27]. The duodenum is reported to be the 
predominant site of metformin absorption, however, the entire small intestine is 
involved and vital for sufficient absorption [27, 28]. Only approximately 13 
percent of the metformin dose is reported to be absorbed by the stomach over a 
4 hour period [28]. The absorption of metformin from the gastrointestinal tract 
is incomplete with mass balance studies reporting around 30% of the drug 
recovered in the faeces [27, 29]. The absorption half-life of metformin is reported 
to be 2.63±0.18 hours [29]. 
The bioavailability of metformin is highly variable and has been reported 
to range between 0.32 and 0.61 [27, 29, 30]. An increase in the dose of metformin 
ingested has been associated with a decrease in bioavailability [27, 31]. In 
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addition, concomitant food intake was found to decrease the bioavailability of 
metformin, whereby the time to peak metformin concentration was prolonged 
[31]. 
1.2.4.2. Distribution 
The apparent volume of distribution of metformin has been reported to 
range from 63 to 276 litres [27, 29, 30]. Metformin has not been found to bind to 
plasma proteins [27, 29, 30]. Metformin has been shown to distribute and 
accumulate in the liver, kidney, ureter, bladder, salivary glands, skeletal muscle, 
stomach, small intestine and red blood cells [18, 26, 32]. No uptake of metformin 
into the gallbladder, myocardium and brain has been observed [32]. An 
illustration of the main transporters involved in the distribution of metformin is 
shown in Figure 1.3. 
 
Liver. The hepatic uptake of metformin occurs rapidly post drug administration 
resulting in significant accumulation of the drug in the liver [32]. Uptake of 
metformin into hepatocytes is mediated by organic cation transporter 1 (OCT1) 
and postulated to be mediated by organic cation transporter 3 (OCT3) [18, 20, 32-
36]. Both transporters, OCT1 and OCT3, are located on the basolateral membrane 
[18, 33-35]. Multidrug and toxin extrusion protein 1 (MATE1) had previously 
been suggested to be involved in the transport of metformin from the hepatocyte 
to the biliary ducts [35], however, following a radiation and dosimetry 
biodistribution study of metformin, no uptake of metformin into the gallbladder 
has been observed [32, 33]. 
 
Kidney, ureter and bladder. Significant and rapid uptake, accumulation and 
excretion of metformin in the kidneys, ureter and bladder has been reported. The 
renal uptake of metformin from the blood to the renal epithelial cell has been 
shown to be mediated by organic cation transporter 2 (OCT2) and possibly OCT1 
[18, 20, 32, 33, 35, 36]. Elimination of metformin by the kidneys into urine is 
mediated by MATE1 and multidrug and toxin extrusion protein 2-K (MATE2-K) 




transporters [20, 33, 35, 36]. Reabsorption of metformin from the renal tubules 
into the renal epithelial cell is suggested to occur via the transporters OCT1 and 
plasma membrane monoamine transporter (PMAT) [32, 33]. 
 
Salivary glands. Metformin has been reported to accumulate in the salivary 
glands [32]. 
 
Skeletal muscle. The distribution of metformin into skeletal muscles occurs 
slowly [32]. Accumulation of metformin in skeletal muscle was minimal with 
concentrations being slightly greater than that of plasma [32]. 
 
Stomach and intestine. Following oral administration metformin was found in 
the stomach and intestine. A slow, steady accumulation of metformin was noted 
in the intestine. This has been suggested to be due to the low transport capacity 
of the basolateral membrane transporters [32]. The uptake of metformin into the 
enterocyte from the gastrointestinal lumen has been shown to be mediated by 
PMAT and is postulated to be mediated by OCT3 [18]. Whereby, the transport 
of metformin from the enterocyte into the systemic circulation has been 
postulated to be mediated by OCT1 [18].  
1.2.4.3. Metabolism 
Metformin has not been reported to undergo metabolism [29, 30]. 
1.2.4.4. Elimination 
Metformin is predominantly cleared as unchanged drug by the kidneys [27, 
29, 30]. The total plasma clearance of metformin was found to be similar to its 
renal clearance and is approximately four to five times creatinine clearance [27, 
29]. It has been suggested that 80% of metformin is cleared via tubular secretion 
and the remaining 20% by glomerular filtration [32]. Pharmacokinetic studies in 
humans have shown that the terminal elimination phase of metformin was 
dissimilar following intravenous and oral administration. Following 
Chapter 1: Introduction 
 10 
 
intravenous administration the elimination half-life of metformin was reported 
to lie between 1.5 to 1.7 hours [29, 30], whilst following oral administration the 
half-life of metformin has been reported to range from 4 to 20 hours [18, 26]. 
These findings suggest that metformin exhibits flip-flop pharmacokinetics – the 
term ‘flip-flop’ is used to describe the scenario where the rate constant of 
absorption and elimination can swap around for extravascularly administered 
drugs. In addition, following an intravenous dose, metformin was completely 
recovered from urine 48 hours post administration with no traces of the drug 
found in the faeces [29].  
1.2.4.5. The role of genetic variation in drug transporters as a contributing 
factor for variability in the pharmacokinetics of metformin 
Genetic variation in drug transporters involved in the absorption, 
distribution and elimination of metformin have been reported to be a source of 
variability in the pharmacokinetics of metformin. 
Polymorphisms in OCT1 have been associated with variations in the 
pharmacokinetic profile of metformin [37, 38]. In a study in healthy Caucasian-
American volunteers an increase in the area under the concentration time curve 
and peak concentration and, decrease in the apparent volume of distribution was 
demonstrated in volunteers carrying reduced-function OCT1 alleles (G401S, 
G465R, M420del and R61C) relative to individuals carrying the reference allele 
[37]. Genetic variation in the OCT1 allele may have an influence on renal 
clearance, however more evidence is required to fully elucidate the impact of 
genetic variations in OCT1 on renal clearance [38, 39]. 
OCT2 has been shown to mediate the renal uptake of metformin from the 
systemic circulation to the renal epithelial cell. Hence, genetic variants in OCT2 
are anticipated to influence the renal clearance of metformin. Several studies 
have associated specific genetic variants in OCT2 with changes in renal clearance 
and drug exposure. Three nonsynonymous single nucleotide polymorphisms 
(T199I, T201M and A270S) were associated with decreased metformin renal 
clearance and increased exposure, whereby, the renal clearance of metformin 
was found to decrease with each copy of the A270S variant of OCT2 [40-42].  




MATE1 and MATE2-K are involved in the renal elimination of metformin. 
Polymorphisms in MATE1 and MATE2-K have been reported to contribute to 
variation in the disposition of metformin in healthy volunteers and patients with 
























































Figure 1.3 Summary of the transporters involved in the distribution of metformin into 
and out of enterocytes, hepatocytes and renal epithelial cells. The arrows represent the 
movement of metformin via a transporter. In the diagram OCT1 is organic transporter 
1, OCT2 is organic transporter 2, OCT3 is organic transporter 3, PMAT is plasma 
membrane monoamine transporter, MATE1 is multidrug and toxin extrusion 1, and, 
MATE2-K is multidrug and toxin extrusion 2-K. 
  




Metformin predominantly exerts its antihyperglycaemic effect by 
inhibiting hepatic gluconeogenesis and enhancing insulin suppression of 
endogenous glucose production [20]. To a lesser extent, metformin may also 
exert its effect by decreasing intestinal glucose absorption and possibly 
improving glucose uptake and use by peripheral tissues [20]. 
Metformin is actively transported into hepatocytes predominantly via 
OCT1 and to a lesser extent OCT3, where it goes on to partially inhibit 
mitochondrial respiratory-chain complex 1 [20]. This results in an accumulation 
of adenosine monophosphate (AMP) and a reduction in the concentration of 
adenosine triphosphate (ATP) [20]. This subsequent change and increase in the 
ratio of AMP to ATP limits hepatic gluconeogenesis by the following 
mechanisms: (i) decreased ATP concentrations result in an ATP deficit which 
otherwise would be required for glucose synthesis to occur, (ii) increased AMP 
concentrations resulting in reduced activity of fructose-1,6-bisphosphatase 
(FBPase) - a critical enzyme involved in gluconeogenesis, (iii) inhibition of 
mitochondrial glycerophosphate dehydrogenase (mGPD) resulting in an altered 
redox state as well as a decreased conversion of glycerol to glucose, and (iv) 
inhibition of adenylate cyclase cyclic AMP (cAMP) to protein kinase A (PKA) 
signalling [20]. In addition, the metformin caused change in the AMP to ATP 
ratio results in the activation of AMPK which ultimately goes on to suppress 
lipogenesis and exerts insulin sensitising effects [20]. 
1.2.6. Dosing recommendations 
Metformin is available as an oral tablet in an immediate and controlled 
release formulation. It is also available in fixed-dose combinations containing 
dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors 
and sulfonylureas. Note that only the 500 mg and 850 mg immediate release 
metformin tablets available in New Zealand are discussed in this thesis.  
The dosing recommendations for metformin are indication specific. For the 
treatment of diabetes mellitus the usual starting dose for a patient initiating an 




immediate release formulation of metformin is 500 mg once to thrice daily [23, 
24]. This is followed by slow dose titration as tolerated by the patient to the 
maximum daily dose to achieve desired glucose control [23]. The usual starting 
dose for patients initiating a controlled release formulation of metformin is 500 
mg once daily with slow dose titration [23]. For the treatment of polycystic ovary 
syndrome patients are initiated at 500 or 850 mg of metformin (immediate 
release) taken once daily with gradual weekly dose titration from once to thrice 
daily as tolerated [23]. The defined daily dose for metformin is 2,000 mg taken 
via oral administration. 
1.2.6.1. Renal dosing recommendations 
The safe use of metformin in patients with renal impairment is not well 
established. This is largely because until recently metformin was contraindicated 
in renally impaired patients with a creatinine clearance (CLcr) of <60 mL/min 
or a serum creatinine ≥1.5 mg/dL (≥132.6 μmol/L) in males and ≥1.4 mg/dL 
(≥123.8 μmol/L) in females [44, 45]. Recent work has proposed that metformin 
might be safe to use in patients with a CLcr of 30 mL/min or even as low as 15 
mL/min [24, 46, 47]. Table 1.1 presents a summary of several renal dosing 
guidelines for metformin published worldwide showing a lack of consensus 
about the best dosing strategy in this patient group.  
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Table 1.1 Summary of metformin renal dosing guidelines and contraindications published worldwide 
Country Ref Year Renal estimation method Renal dose adjustment Renal contraindication 
    Renal function Recommended dose  
Australia [44] 2016 CLcr   <60 mL/min 
 [48] 2016 eGFR 30-60 mL/min/1.73m2 
Use with caution 
Reduce dose 
<30 mL/min/1.73m2 
 [49] 2016 CLcr 
60-90 mL/min 
30-60 mL/min 
Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
<30 mL/min 
 [23] 2017 CLcr 
<90 mL/min 
15-30 mL/min 
Reduce maximum dose 
Metformin may be 
considered for patients 
with stable renal function 
15 mL/min 
Canada [50] 2015 eGFR <60 mL/min Reduce dose - 




No dose adjustment 
≤29 mL/min 
 [47] 2016 
CLcr 
eGFR 
<60 mL/min Caution <30 mL/min 




Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Maximum: 500 mg/day 
<15 mL/min 








Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Maximum: 500 mg/day 
<15 mL/min 




Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Maximum: 500 mg/day 
<15 mL/min 





Maximum: 3000 mg/day 
Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Discuss with specialist 
Quantitative – significant 
impairment or renal failure 




Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Maximum: 500 mg/day 
<15 mL/min 




Maximum: 2000 mg/day 
Maximum: 1000 mg/day 
Maximum: 500 mg/day 
<15 mL/min/1.73m2 
United States  
of America 
[58] 2016 eGFR 30-45 mL/min/1/73m2 
Not recommended 
Reassess benefit to risk 
30 mL/min/1.73m2 
 [45]    Dose individualisation 
Serum creatinine above 
normal upper limit for age 
Males: ≥1.5 mg/dL 
Females: ≥1.4 mg/dL 
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 [59] 2016 eGFR 30-45 mL/min/1.73m2 Dose reduction 
Stop medication if GFR is 
low 








Referral to a nephrologist 
<30 mL/min/1.73m2 
United Kingdom [60] 2015 eGFR 45 mL/min/1.73m2 Review dose 30 mL/min/1.73m2 





Initial dose: 500 or 850 mg 
OD 
Maximum: 2000 mg/day 
- 




Maximum: 3000 mg/day 
Maximum: 2000 mg/day 








1.2.7. Adverse reactions 
Mild gastrointestinal adverse effects are very common in patients on 
metformin therapy (probable incidence: >1% of patients on metformin 
experience these symptoms) [45, 49, 53, 54]. The gastrointestinal adverse effects 
include abdominal pain, anorexia, nausea, vomiting and diarrhoea [24, 45, 53, 
54]. These side effects are generally transient in nature and resolve on their own 
with continued therapy [53, 54]. However, these gastrointestinal side effects can 
be minimised by initiating metformin therapy in patients at a low dose with slow 
titration, and, taking metformin doses with food [49, 53, 54]. In some patients the 
gastrointestinal side effects of metformin are severe enough to stop therapy. 
Infrequent adverse effects of metformin (probable incidence: 0.1-1%) 
include skin disorders, such as mild erythemia, puritus and urticarial rash [49, 
53, 54]. Rare adverse effects (probable incidence <0.1%) include lactic acidosis 
(for a more detailed discussion on the relationship between metformin and lactic 
acidosis refer to section 1.2.7.1.) and acute hepatitis [49, 53, 54]. 
1.2.7.1. Metformin and lactic acidosis 
There is concern that patients receiving metformin therapy may be at an 
increased risk of developing lactic acidosis, a rare but fatal metabolic condition. 
Metformin is recognised to cause lactic acidosis when ingested in supra-
therapeutic doses, however when taken therapeutically its causal role is not well 
understood [12, 13, 63]. A more detailed look at the relationship between 
metformin therapy and lactic acidosis will be presented in Chapter 2.  
1.2.8. Contraindications 
Metformin is contraindicated in patients with severe hepatic impairment, 
significant renal impairment, cardiac and/or respiratory insufficiency, any 
hypoxic conditions, severe infection, alcohol abuse, use of radiographic contrast 
agents and pregnancy. Patients on metformin therapy should stop metformin 
prior to surgery and replace it with insulin; metformin should be restarted only 
when the patient is no longer fasting and renal function recovers to baseline [49].  
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1.3. The renal system 
The renal system, also known as the urinary system, serves a principle role 
in regulating body homeostasis. In clinical practice, where pharmacological 
treatment is indicated, an understanding of the renal system is essential as 
approximately one-quarter of drugs available on the market are almost entirely 
renally cleared.  
In this section a general overview of the anatomy, physiology and 
pathology of the renal system, as well as the methods used in clinical practice to 
estimate renal function is described. 
1.3.1. Anatomy 
The renal system comprises the kidneys, ureters, urinary bladder and 
urethra [64, 65]. The excretion of urine produced by the kidneys travels through 
the ureters, urinary bladder and urethra, respectively, prior to being eliminated 
from the body [64]. In the renal system, the kidneys are the principle functioning 
organ, whilst the ureters, urinary bladder and urethra are considered to be 
accessory organs [64]. A schematic of the gross anatomy of the renal system is 
shown in Figure 1.4. 
 





Figure 1.4 General anatomy of the renal system [66] 
Schematic from Encyclopedia Britannica licensed under Creative Commons 
Attribution ShareAlike 2.5 (Generic). 
1.3.1.1. The kidney 
The kidneys are paired solid organs that are situated in the retroperitoneal 
cavity on either side of the vertebral column [64, 67, 68]. The kidneys are encased 
by a fibromuscular capsule that is surrounded by an additional protective 
adipose layer, known as peri-renal fat [68]. However, each kidney is held in 
position in the retroperitoneal space by additional layers comprising of a fibrous 
capsule of connective tissues known as the renal fasciae, and, a second layer of 
adipose cushion encasing each kidney known as the pararenal fat [64, 68]. 
The parenchyma of each kidney comprises two layers, which are: (i) an 
outer renal cortex and (ii) an inner renal medulla [68]. In the kidney, the renal 
cortex surrounds individual sections of the renal medulla, known as the renal 
pyramid [67].  
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Each kidney comprises approximately one million nephrons, known as the 
functional unit of the kidney (a schematic of a nephron is shown in Figure 1.5) 
[65, 68]. An individual nephron comprises two major structures: the renal 
corpuscle and the renal tubules [65, 68]. 
The renal corpuscle is the first segment of the nephron [64]. It is situated in 
the renal cortex and comprises the glomerulus and Bowman’s capsule (also 
known as the glomerular capsule) [64, 65]. The glomerulus is a highly 
vascularised capillary network that is supplied blood via the afferent arteriole 
[64, 65, 68]. Blood from the glomerulus returns to the central bloodstream via the 
efferent arterioles [64, 65, 68]. The glomerular capillaries are made up of a single 
layer of fenestrated endothelial cells; the increased porosity of the glomerular 
capillaries are important as it permits filtration to occur at a rate critical for 
normal kidney function [64]. The Bowman’s capsule is a hollow, cup-shaped 
structure that encloses the glomerulus [64]. The Bowman’s capsule is composed 
of two layers: a parietal (outer) simple squamous epithelium layer and a visceral 
(inner) podocyte layer [64]. The gap between the glomerulus and the Bowman’s 
capsule is known as the Bowman’s space [64, 65]. 
The renal tubules are a hollow conduit extension of the renal corpuscle [64]. 
The renal tubules are divided into four main segments: the proximal convoluted 
tubule, loop of Henle, distal convoluted tubule, and collecting duct [64, 68]. The 
proximal convoluted tubule is a continuous extension of the Bowman’s capsule 
[64, 65]. It is composed of a single layer of epithelial cells with a brush border, 
formed by microvilli, on its luminal surface to optimise the surface area available 
for the absorption and secretion of substances between the tubules and 
bloodstream [64]. The loop of Henle follows the proximal convoluted tubule and 
comprises three segments [64, 65]. The initial segment comprises an initial thin 
descending limb that extends into the renal medulla, which then bends back 
towards the renal cortex in a U-shape manner firstly via the thin ascending limb 
followed by the thick ascending limb (forming the ascending loop of Henle) [64, 
65]. The renal tubules return back to the renal cortex and form the distal 
convoluted tubules [64, 65].  




The collecting duct system follows the distal convoluted tubules – this 
comprises an initial cortical collecting duct, followed by a medullary collecting 
duct [64, 65]. From here, several collecting ducts merge together to form a 
continuous conduit with the ureter [64]. The renal tubules are supplied blood via 
the peritubular capillaries [64]. 
 
 
Figure 1.5 General anatomy of a nephron [69] 
Schematic from Anatomy and Physiology by OpenStax licensed under Creative 
Commons Attribution License v4.0. 
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1.3.1.2. The ureter 
The ureters are paired hollow conduits that are responsible for the travel of 
urine from the kidneys to the urinary bladder [64, 67]. A single ureter is 
connected to the renal pelvis of each kidney and courses through to the bottom 
of the urinary bladder [64]. The ureter extends a further two centimetres into the 
bladder wall and opens at the floor of the bladder at a lateral angle to prevent 
the backflow of urine [64]. 
The ureter comprises the following tissue layers: (i) an inner mucosa 
transitional epithelium, (ii) a smooth muscle middle layer and (iii) a fibrous outer 
layer [64]. The inner transitional epithelium lining allows the ureter to stretch 
without injuring the epithelial lining [64] and the smooth muscle layer is 
important for transport of urine from the kidneys to the urinary bladder by 
peristalsis [64]. 
1.3.1.3. The urinary bladder 
The urinary bladder serves two primary functions, which are: to serve as a 
storage reservoir for urine prior to being expelled, and, to expel urine alongside 
the urethra to outside of the body [64]. The urinary bladder is situated behind 
the pubic symphysis and below the parietal peritoneum [64].  
The urinary bladder has a collapsible bag-like structure with three 
openings on the floor of the bladder; two openings from the ureters and a single 
opening into the urethra [64]. The wall of the urinary bladder is predominantly 
made up of smooth muscle tissue, commonly known as the detrusor muscle [64]. 
The urinary bladder is lined with mucous transitional epithelium - this inner 
layer is lined with rugae which allow for the extension and distension of the 
bladder [64].  
1.3.1.4. The urethra 
The urethra is a tube-like structure lined with transitional epithelium that 
extends from the bottom of the urinary bladder to the exterior of the body [64]. 




The position and structure of the urethra is different for females and males due 
to the different anatomical structure of the sex-specific organs.  
In females the urethra is situated posterior to the pubic symphysis and 
anterior to the vagina [64]. The urethra extends from the bottom of the urinary 
bladder and courses through the muscular floor of the pelvis and ends at the 
external urinary meatus [64]. In males, the urethra extends from the urinary 
bladder and passes through the center of the prostate gland and penis before 
ending as the urinary meatus at the distal end of the penis [64]. In males, there 
are an additional two openings in the urethra - where it connects with the 
ejaculatory ducts as it passes through the prostate gland [64]. 
1.3.2. Physiology 
The primary function of the renal system is to regulate body homeostasis. 
This involves the following fundamental physiological processes: (i) excretion, 
(ii) regulation, (iii) metabolism and (iv) endocrine functions. A description of 
each of the physiological processes is described below: 
 
Excretion. The renal system is involved in the removal of metabolic (e.g. urea, 
uric acid and creatinine) and xenobiotic products from the bloodstream and 
elimination from the body [68]. It is also responsible for the formation of urine. 
 
Regulation. The renal system is involved in the regulation and maintenance of 
fluid, electrolytes, osmolality, acid-base balance and blood pressure [68]. 
 
Metabolism. The renal system is involved in the metabolism of lactate, 
carbohydrates, proteins, lipids and other nutrients [70]. 
 
Endocrine. The renal system plays a fundamental role in the production and 
secretion of hormones and enzymes, such as erythropoietin and renin [68]. The 
renal system is also involved in glucose homeostasis via glucose utilisation, 
gluconeogenesis and glucose reabsorption from the glomerular filtrate [71]. 
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The nephron, the functional unit of the kidney, is involved in the following 
processes; filtration, tubular reabsorption, tubular secretion and metabolism 
[65]. Note that glomerular filtration is widely used as an indicator for renal 
function. 
1.3.3. Pathology 
Renal impairment is a global health issue with increasing prevalence and 
health burden [72]. Renal impairment is divided into two broad categories based 
on the aetiology and duration of renal pathology, which are: (i) acute renal 
impairment and (ii) chronic renal impairment. 
 
Acute renal impairment. Acute renal impairment is a potentially life-
threatening clinical condition that is characterised by an abrupt decline in renal 
function, resulting in an accumulation of nitrogenous waste products (such as 
creatinine and urea nitrogen) with or without a decrease in urine output [73]. It 
is also known as acute kidney injury (AKI) and acute renal failure (ARF) [73]. 
The pathophysiology of acute renal impairment is described to occur by one or 
more of the three following mechanisms:  
1. Prerenal acute kidney injury. This is characterised by a reduced, 
insufficient blood supply to the kidneys [73]. Common causes of 
reduced blood delivery to the kidneys include: a depletion in 
intravascular volume (i.e. haemorrhage, dehydration or 
gastrointestinal fluid loss), reduced cardiac output (i.e. congestive 
heart failure and myocardial infarction), hypotension and drugs 
[73].  
2. Intrinsic acute kidney injury. Intrinsic acute kidney injury is caused 
by diseases or direct trauma that damage the integrity of the kidneys 
[73]. Common causes of intrinsic acute kidney injury include: toxins, 
drugs ingested in toxic amounts (e.g. aminoglycosides), as well as 
glomerular, interstitial and blood vessel diseases [73]. 




3. Postrenal acute kidney injury. Postrenal acute kidney injury is a 
result of an obstruction to urinary outflow [73]. Common causes 
include: pelvic tumours, benign prostatic hypertrophy and 
precipitation of renal calculi [73].  
 
Chronic renal impairment. Chronic renal impairment - also known as 
chronic kidney disease (CKD), progressive kidney disease or nephropathy - is 
the term used to describe the presence of kidney damage or decreased 
glomerular filtration rate (GFR) that persists over a period of 3 months or more 
[73]. Chronic renal impairment is a progressive decline in renal function that is 
often irreversible and may persist for months to years [73]. The initiation of 
chronic renal impairment can arise from numerous risk factors, such as diabetes 
mellitus, hypertension, autoimmune disease, polycystic kidney disease, urinary 
tract abnormalities (including obstructions, stones and infections), and, drug 
toxicity [73]. However, it is worth noting that there is a natural decline in renal 
function following the second to forth decade of life; with an estimated decline 
in glomerular filtration rate by approximately 8 mL/min/1.73m2 per each 
decade of life [74, 75]. Hence, it is possible for individuals to present with chronic 
renal impairment without presenting with any of the listed initiation risk factors. 
 
The progressive nature of chronic renal impairment highlights the 
importance of its diagnosis, management and prevention from further 
deterioration. In clinical practice, chronic renal impairment is commonly 
classified using the Kidney Disease: Improving Global Outcomes (KDIGO) 
Chronic Kidney Disease guideline (shown in Table 1.2) into categories defined 
by a glomerular filtration rate range [76]. 
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Table 1.2 Chronic kidney disease classification categories published by the Kidney 
Disease: Improving Global Outcomes guideline [76] 
GFR category Description 
GFR range 
(mL/min/1.73m2) 
G1 Normal or high ≥90 
G2 Mildly decreased 60-89 
G3a Mildly to moderately decreased 45-59 
G3b Moderately to severely decreased 30-44 
G4 Severely decreased 15-29 
G5 Kidney failure <15 
GFR: represents glomerular filtration rate 
1.3.4. Estimating renal function 
A reliable estimate of renal function is important in clinical practice and 
research for the diagnosis of pathology, monitoring of disease progression, and, 
for further evaluation and management of pathology. In addition, an estimate of 
renal function is important for the dose adjustment of renally cleared drugs. 
1.3.4.1. Markers of renal function 
In clinical practice, markers to estimate glomerular filtration rate as well as 
the use of urinary sediments are commonly used as a means to estimate renal 
function. A general overview of the markers and urinary sediments used to 
estimate renal function is described in this section. 
1.3.4.1.1. Endogenous markers of renal function 
The steady-state serum concentrations of endogenous markers are related 
to the reciprocal of glomerular filtration rate and hence, are used to estimate 
glomerular filtration rate. It is important to note that the synthesis and 
elimination of endogenous markers (e.g. tubular secretion, tubular reabsorption 
and extra-renal elimination) can change their serum concentrations within and 
between individuals significantly. Hence, the estimation of renal function using 
an endogenous serum marker concentration may vary significantly. 




In the clinic, the use of endogenous markers is routinely used as it allows 
for a simple screening test that does not require the administration of an 
exogenous substance. A brief overview of the endogenous markers commonly 
used is provided as follows: 
 
Creatinine. Creatinine is an amino acid derivative that is a metabolic breakdown 
product of creatine phosphate in skeletal muscle [77-79]. Creatinine synthesis is 
determined largely on muscle mass and dietary intake, which is likely to account 
for the variation in serum creatinine concentrations seen amongst various age 
groups, ethnicities and racial groups [77-79]. Creatinine is predominantly 
eliminated via glomerular filtration with up to fifteen percent being eliminated 
via active tubular secretion by the proximal tubular cells; hence, creatinine 
clearance exceeds glomerular filtration rate [77, 78]. The tubular secretion of 
creatinine varies within and between individuals, particularly in patients with 
mild to moderate renal impairment [77]. Extrarenal elimination of creatinine 
may be increased in advanced renal impairment due to increased degradation of 
creatinine by gastrointestinal bacteria [77, 78]. Note that some drugs, such as 
trimethoprim and cimetidine, are reported to inhibit creatinine clearance and 
hence, result in reduced creatinine clearance and elevated serum creatinine 
concentrations without influencing glomerular filtration rate [77].  
 
Cystatin C. Cystatin C is a non-glycosylated basic protein that is produced at a 
fairly constant rate by all nucleated cells [77, 79]. It is freely filtered by the 
glomerulus, and, reabsorbed and catabolised by the tubular epithelial cells [77-
79]. However, the serum concentration of Cystatin C is predominantly 
determined by glomerular filtration rate, making it a possible endogenous 
marker of glomerular filtration rate [79]. Only small amounts of Cystatin C are 
excreted in urine, hence its urinary clearance cannot be measured using urine 
excretion data [77].  
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Urea. Urea is a nitrogenous end product of amino acid and protein catabolism 
[79]. It is produced by the liver and is distributed in intracellular and 
extracellular fluid [79]. Urea is filtered by the glomerulus and is partially 
reabsorbed with water [79]. The clearance of urea is a poor marker for glomerular 
filtration rate as its synthesis is dependent on non-renal factors, such as urea 
cycle enzymes and diet [78, 79].  
1.3.4.1.2. Exogenous markers of renal function 
The use of exogenous markers is considered the gold standard as it 
provides a more accurate measure of glomerular filtration. This is because the 
exact amount of the exogenous marker administered is known and its 
concentration is not affected by other factors (e.g. physiological processes and/or 
dietary intake). However, the use of exogenous markers to measure renal 
function is not routinely used due to complexity associated with the 
administration and handling of the exogenous markers, cost and, onerous on 
health practitioners. The use of an exogenous marker of renal function is more 
commonly used in clinical situations where an accurate estimate of renal 
function is required (e.g. dosing of prescribed chemotherapy). A brief overview 
of the exogenous markers commonly used in the clinical practice to measure 
renal function is outlined as follows: 
 
Inulin. Insulin is a polysaccharide fructose polymer that is found in dahlias, 
chicory and Jerusalem artichoke [78, 79]. Inulin is an ideal marker for measuring 
glomerular filtration rate as it is freely filtered at the glomerulus and does not 
undergo renal tubular reabsorption, secretion and metabolism [78]. However, 
the clinical use of inulin is limited as it is time consuming and requires a 
continuous intravenous infusion [78].  
 
Radioisotopes. The use of an exogenous radioisotope is considered the gold 
standard for measuring glomerular filtration rate. The use of radioisotopes as 
markers of renal function have advantages over inulin as they do not require a 




constant infusion nor do the radioisotopic methods necessitate the need for urine 
samples. However, the use of exogenous radioisotopes is disadvantageous as it 
requires additional precautions in handling and discarding of the radioactive 
substances [78]. Examples of exogenous radioisotopes commonly used in clinical 
practice include: 51Cr-EDTA, 125Iodine (i)-iothalamate and 99mTc-DTPA. 
 
Radiocontrast agents. The use of radiocontrast agents as markers of renal 
function have been used since the 1960s [78]. Historically, the use of these agents 
had been limited due to analytical difficulties and their relatively high amounts 
of free iodine, making radioisotopes the more favourable exogenous marker of 
renal function [78]. The majority of these problems have now been solved, with 
radiocontrast agents providing benefits over radioisotopes as they do not require 
extra precautions associated with radioactive substances [78]. Examples of 
exogenous radiocontrast agents used in practice include: iothalamate, siatrixoate 
meglumin and iohexol. 
1.3.4.2. Methods to estimate renal function 
For the purposes of this thesis, the methods for determining glomerular 
filtration rate have been divided into two categories: (i) estimated glomerular 
filtration rate (eGFR) and (ii) measured glomerular filtration rate (mGFR). An 
overview of these methods is provided in this section.  
1.3.4.2.1. Estimated glomerular filtration rate 
Regression equations have been developed to estimate glomerular 
filtration rate to circumvent the complexity and practical difficulties of formally 
measuring clearance (e.g. bolus dose followed by constant infusion required for 
inulin). The developed regression equations are simple straight-forward 
formulas that allow for routine clinical use. In this thesis, these equation based 
methods for determining glomerular filtration rate are referred to as estimated 
glomerular filtration rate (eGFR). An overview of the three more commonly used 
equations in the clinic (and equations used in this thesis) is given as follows: 
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Cockcroft and Gault equation. The Cockcroft and Gault equation was 
developed to predict creatinine clearance from serum creatinine, age, weight and 
sex [80]. The equation allows for a quick prediction of creatinine clearance using 
a single blood sample without the need for timed urine samples yielding it more 
convenient for routine clinical use. The equation is shown as follows;  
 
𝐶𝐿𝑐𝑟𝐶𝐺(𝑚𝐿 𝑚𝑖𝑛⁄ ) =
(140 − 𝑎𝑔𝑒) ∙ (𝑤𝑡)
72 ∙ 𝑆𝑐𝑟
∙ [0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒] 
Equation 1.1 Cockcroft and Gault equation [80] 
 
where, 𝐶𝐿𝑐𝑟𝐶𝐺 is creatinine clearance calculated using the Cockcroft and Gault 
equation in mL/min, 𝑎𝑔𝑒 is age in years, 𝑤𝑡 is weight in kg and 𝑆𝑐𝑟  is serum 
creatinine concentration in mg/L. The Cockcroft and Gault equation was 
developed in a population of 249 males using their creatinine excretion data. The 
range of renal function in the study population ranged from 30 to 130 mL/min. 
Hence, a correction factor was empirically included to allow for its application 
to females. It is important to note that the Cockcroft and Gault equation 
systematically overestimates glomerular filtration rate due to the tubular 
secretion of creatinine. Furthermore, the equation tends to overestimate 
creatinine clearance in severe renal impairment, elderly and obese. The equation 
is likely to overestimate creatinine clearance in patients with severe renal 
impairment due to the equation being developed in patients with normal renal 
function. In addition, the Cockcroft and Gault equation is likely to overestimate 
creatinine clearance in obese patients if total body weight is used in the 
calculation.  
 
Modification of Diet in Renal Disease formula. The Modification of Diet in 
Renal Disease (MDRD) equation was developed to determine glomerular 
filtration rate adjusted for body surface area. The MDRD equation was 
developed in 1,628 patients with chronic kidney disease. The original MDRD 
equation was referred to as the 6-variable MDRD as it included 6 variables in the 




equation, which were: age, sex, race, and, serum concentrations of creatinine, 
urea and albumin [81]. This equation was later simplified to include 4 variables 
(i.e. age, sex, race and serum creatinine concentration) and was referred to as the 




= 1.75 ∙ 𝑆𝑐𝑟
−1.154 ∙ 𝑎𝑔𝑒−0.203 ∙ [0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒]
∙ [1.212 𝑖𝑓 𝐴𝑓𝑟𝑖𝑐𝑎𝑛 𝐴𝑚𝑒𝑟𝑖𝑐𝑎𝑛] 
Equation 1.2 4-variable Modification of Diet in Renal Disease equation 
 
where, 𝑆𝑐𝑟 is serum creatinine concentration in mmol/L and 𝑎𝑔𝑒 is age in years. 
Due to the MDRD equations being developed in patients with chronic renal 
failure their reliability in estimating glomerular filtration rate in patients with 
normal or mild kidney disease is questionable. Hence, the use of the MDRD 
equations is not recommended in patients with an estimated glomerular 
filtration rate greater than 60 mL/min/ 1.73m2. 
 
Chronic Kidney Disease Epidemiology Collaboration equation. The Chronic 
Kidney Disease Epidemiology Collaboration (CKD-Epi) equation was 
developed to better predict glomerular filtration rate in patients with normal to 
poor renal function [83]. The equation was developed using data from 8,254 
study participants with and without renal impairment (i.e. mean measured 
glomerular filtration rate ranged from 2 to 190 mL/min/1.73m2). The CKD-Epi 
equation predicts glomerular filtration rate from serum creatinine concentration, 




= 141 ∙ 𝑚𝑖𝑛(𝑆𝑐𝑟 𝜅, 1⁄ )
𝛼 ∙ 𝑚𝑎𝑥(𝑆𝑐𝑟 𝜅, 1⁄ )
−1.209 ∙ 0.993𝑎𝑔𝑒
∙ [1.018 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒] ∙ [1.159 𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
Equation 1.3 Chronic Kidney Disease Epidemiology Collaboration equation 
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where, 𝑆𝑐𝑟 is serum creatinine in mg/dL, 𝑎𝑔𝑒 is age in years, 𝜅 is 0.7 for females 
and 0.9 for males, 𝛼 is -0.329 for females and -0.411 for males, 𝑚𝑖𝑛 indicates the 
minimum of 𝑆𝑐𝑟 𝜅⁄  or 1, and, 𝑚𝑎𝑥 indicates the maximum of 𝑆𝑐𝑟 𝜅⁄  or 1. 
1.3.4.2.2. Measured glomerular filtration rate 
In this thesis, the term measured glomerular filtration rate (mGFR) is used 
to define any method used to determine glomerular filtration rate that involves 
a pharmacokinetic experiment. The different mGFR methods can be divided into 
two categories: (i) noncompartmental analysis and (ii) compartmental analysis. 
 
Noncompartmental analysis. Noncompartmental analysis, also known by its 
acronym NCA, provides a means for analysing pharmacokinetic data that do not 
make assumptions about hypothetical body compartments. The 
noncompartmental methods generally involve the use of algebraic equations to 
estimate pharmacokinetic metrics. Examples of commonly used non-
compartmental analyses are described as follows: 
• Area under the plasma concentration-time curve. The area under the 
plasma concentration-time curve method requires multiple plasma 
samples to characterise and describe the concentration time profile of the 
substance of interest. Using the plasma concentrations glomerular 






Equation 1.4 Area under the plasma concentration-time curve equation for 
estimating glomerular filtration rate 
 
where, 𝑚𝐺𝐹𝑅 is measured glomerular filtration rate, 𝑑𝑜𝑠𝑒 is the dose of 
the marker of renal function administered to determine glomerular 
filtration rate, and, 𝐴𝑈𝐶0−∞ is the area under the plasma concentration 
curve from time zero to infinity. 




• Renal clearance of a marker determined using urine and plasma data. 
This method involves the collection of urine samples over a period of at 
least 6 to 12 hours and a single blood sample. Using the collected urine 
and blood, the concentration of the renal function marker in plasma and 
urine, as well as the volume of urine excreted over the period of time is 






Equation 1.5 Equation for determine measured glomerular filtration rate using 
urine and plasma data 
 
where, 𝑚𝐺𝐹𝑅  is measured glomerular filtration rate, 𝑈  is the 
concentration of the marker of renal function in urine, 𝑉𝑢𝑟𝑖𝑛𝑒  is the 
volume of urine excreted and 𝑃 is the plasma concentration of the marker 
of renal function. 
Compartmental analysis. A compartmental analysis involves fitting a 
compartmental model to the drug concentration time data using hypothetical 
compartments. To estimate glomerular filtration rate, the concentration of a 
marker of renal function is fit to a compartmental model and the estimated 
clearance of the marker is measured glomerular filtration rate.  
1.3.5. Renal drug dosing 
Chronic renal impairment alters the clearance of renally cleared drugs and 
drug disposition, highlighting the importance for dose adjustment in patients 
with renal impairment to avoid potential drug accumulation, toxicity and/or 
treatment failure [84]. In patients with chronic renal impairment doses are 
adjusted according to renal function (calculated as creatinine clearance (CLcr) or 
glomerular filtration rate (GFR)) [84]. This makes the assumption that renal drug 
clearance is proportional to GFR (and/or CLcr), and, that the administered drug 
is entirely renally cleared via glomerular filtration. It is important to bear in mind 
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that this does not necessarily hold true for all drugs, as many drugs may also be 
cleared renally via tubular secretion such as metformin. Depending on the 
pharmacological treatment prescribed, recommended dose adjustment methods 
include a dose reduction and/or lengthening of the dosing interval [84]. 
  




1.4. Acid-base homeostasis 
Acid-base homeostasis is important in the regulation and maintenance of 
pH for physiological processes to occur optimally [85]. In clinical practice acid-
base balance is measured using the pH scale. Under normal physiological and 
steady state conditions a blood pH of 7.35 to 7.46 is required for biological 
systems to function [86]. To maintain acid-base homeostasis the human body has 
numerous physiological adaptations. In this section an overview of the 
physiology and pathophysiology of acid-base homeostasis is described. 
1.4.1. Physiology 
The homeostatic control of acid-base balance is controlled by intricate 
buffering systems to maintain physiological pH. In the context of acid-base 
homeostasis a buffer is defined as a substance that mediates and minimises 
substantial changes in pH. The two primary control systems involved in 
maintaining physiological pH are the chemical and physiological buffer systems. 
1.4.1.1. Chemical buffer system 
The chemical buffer system provides an immediate response to changes in 
body pH. In the body chemical buffers work by reacting with a relatively strong 
acid (or base) to transform it into a relatively weaker acid (or base) [64]. Hence, 
chemical buffers act by preventing drastic changes in physiological pH. In the 
body most buffers are present in pairs – commonly consisting of a weak acid and 
a salt of the corresponding weak acid [64]. The key chemical buffer systems (and 
buffer pairs) in the body include [64]: 
• Bicarbonate buffer system 
o Example of buffer pair: 𝑁𝑎𝐻𝐶𝑂3 and 𝐻2𝐶𝑂3 
• Phosphate buffer system 
o Example of buffer pair: 𝑁𝑎2𝐻𝑃𝑂4 and 𝑁𝑎𝐻2𝑃𝑂4 
• Protein buffer system 
o Example of buffer pair: 𝑁𝑎 ∙ 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑎𝑡𝑒 and 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠 
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1.4.1.2. Physiological buffer system 
Physiological buffers serve as the secondary control mechanism when 
chemical buffers do not adequately prevent drastic changes to physiological pH. 
The respiratory and renal system are the main systems involved in regulating 
acid-base homeostasis in the physiological buffer system. 
 
Respiratory system. Respiration plays a fundamental role in maintaining pH. 
Cellular metabolism processes in the body produce large amounts of carbon 
dioxide daily [86]. The produced carbon dioxide can go on to form hydrogen 




→               𝐻2𝐶𝑂3 → 𝐻
+ + 𝐻𝐶𝑂3
− 
Equation 1.6 An equation describing the production of hydrogen ions from carbon 
dioxide 
 
where, 𝐶𝑂2  is carbon dioxide, 𝐻2𝑂  is water, 𝐻2𝐶𝑂3  is carbonic acid, 𝐻
+ 
represents hydrogen ions and 𝐻𝐶𝑂3
−  is bicarbonate [64]. The process of 
expiration results in carbon dioxide and water leaving the body in expired air 
[64]. The carbon dioxide used in this process diffuses from venous blood in the 
lungs, resulting in lower concentrations of carbon dioxide in arterial blood 
leaving the lung capillaries [64]. Hence, in the setting of hyperventilation there 
is a net loss of carbon dioxide and hydrogen ions in the body which may result 
in an increase in arterial pH. Whilst in the setting of hypoventilation there is a 
net retention in carbon dioxide and hydrogen ions in the body which may lead 
to a decrease in arterial pH. 
 
Renal system. The renal system regulates pH by reabsorbing and excreting 
substances that influence acidity or basicity. In the nephron, carbon dioxide 
diffuses from the tubule capillaries into renal tubule cells where it reacts with 
water to produce carbonic acid, which then dissociates to form bicarbonate and 




hydrogen ions - note that this is the same reaction from which carbon dioxide 
produces hydrogen ions in red blood cells (shown in Equation 1.6)[64]. From 
here, the produced bicarbonate ions then travel down its concentration gradient 
from the tubular epithelial cells into the blood, whilst the hydrogen ions are 
secreted into the lumen [64]. In the lumen the hydrogen ions may combine with 
a bicarbonate buffer or a non-bicarbonate buffer (such as a phosphate buffer) 
[64]. Hydrogen ions that combine with a bicarbonate buffer produce both carbon 
dioxide and water which may be excreted or reabsorbed by the renal tubules, 
whilst, hydrogen ions that combine with a non-bicarbonate buffer form a 
hydrogen ion conjugate which is then excreted from the body [64].  
1.4.2. Pathophysiology 
Any disturbance and deviation of acid-base balance from physiological pH 
will result in either acidosis or alkalosis. Acidosis is the process in which there is 
an elevated hydrogen ion concentration in the arterial plasma [86]. Alkalosis 
describes the physiological state where there is a decrease in hydrogen ions in 
the arterial plasma [86]. For the purposes of this thesis only acidosis will be 
described.  
1.4.2.1. Acidosis 
Acidosis is the process in which there are excess hydrogen ions in the 
arterial plasma [86]. In clinical practice acidaemia is diagnosed in patients 
presenting with an arterial blood pH of less than 7.35. Acidosis can be 
categorised into two broad categories: respiratory acidosis and metabolic 
acidosis. 
1.4.2.1.1. Respiratory acidosis 
Respiratory acidosis occurs when there is a change in alveolar respiration 
that results in the retention of carbon dioxide in the blood [64]. It may occur as a 
result of hypoventilation or respiratory malfunction owing to a clinical condition 
such as pneumonia or emphysema [64]. In this altered state of ventilation the 
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rate carbon dioxide is eliminated by the respiratory system is slower than the 
production of carbon dioxide; hence, resulting in a net gain of carbon dioxide. 
1.4.2.1.2. Metabolic acidosis 
Metabolic acidosis is the term used to describe patients presenting with 
elevated arterial hydrogen ion concentration in the absence of a respiratory 
cause. Metabolic acidosis may occur during starvation or as a result of an 
underlying medical condition (e.g. diarrhoea, diabetes mellitus) [64]. Metabolic 
acidosis is characterised by an inverse relationship between arterial partial 
pressure of carbon dioxide and hydrogen ion concentrations [86]. 
Lactic acidosis is a subdivision of metabolic acidosis. It is characterised by 
the temporarily related events of an elevated lactate concentration (i.e >5 
mmol/L) and a decreased arterial pH to less than 7.35 [87]. The Cohen and 
Woods classification categorises the causes of lactic acidosis into two broad 
groups, named Type A and Type B lactic acidosis [88]. Type A lactic acidosis 
describes causes of lactic acidosis where the patient presents with clinical 
evidence of tissue hypoxia (e.g. anaerobic muscle activity, post myocardial 
infarction and shock) [88]. Type B lactic acidosis is when a patient presents with 
lactic acidosis but no clinical evidence of hypoxia [88]. Type B lactic acidosis may 
occur as a result of an underlying medical condition (e.g. diabetes mellitus, 
malignancy, renal failure) or as a result of exposure to drugs (e.g. phenformin) 
or toxins [88]. 
  





Pharmacometrics is a science concerned with the analysis and 
interpretation of data arising from pre-clinical and clinical drug studies. The 
discipline of pharmacometrics uses mathematical models to describe and 
quantify the complex interaction between xenobiotics and a system. 
Pharmacometric models may be used to describe and predict drug exposure, 
physiological and/or pathophysiological processes, drug action, clinical 
outcomes as well as disease progression. Note that pharmacometric models may 
also be used in pharmacoeconomics to better understand the economic impact a 
particular drug may have and hence, these pharmacometric techniques are not 
solely limited to use in biological systems. 
1.5.1. Models 
A pharmacometric model is a mathematical representation of a system 
given by a function (𝑓) that describes the relationship between the input (i.e. 
independent variables) and the output (i.e. dependent variables), as follows;  
 
𝑌 = 𝑓(θ, 𝑥) + 𝜀 
Equation 1.7 General form of a fixed effect mathematical model 
 
where, 𝑌 is an n-by-1 vector of dependent variables, θ is an np-by-1 vector of 
fixed effects parameters that describes the relationship between 𝑌 and 𝑥, 𝑥 is an 
n-by-np matrix of independent variables and 𝜀 is a vector the same size as 𝑌 that 
describes residual error.  
1.5.1.1. Structural model 
1.5.1.1.1. Pharmacokinetic model 
Pharmacokinetics (PK) is the science that describes the movement of drugs 
into, within and out of the body. It is the study that relates the dose of an 
administered drug to its concentration in the body as a function of time. The 
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concentration time profile of a drug is governed by the pharmacokinetic 
processes absorption, distribution, metabolism and excretion.  
A pharmacokinetic model describes drug concentration as a function of 
administered dose and time, and, is dependent on unknown pharmacokinetic 
parameters.  In mathematical form, a general pharmacokinetic model is given as 
follows,  
 
𝐶(𝑡) = 𝑓(𝐷, 𝑡, 𝜃𝑃𝐾) 
Equation 1.8 General mathematical form of a pharmacokinetic model 
 
where, 𝐶(𝑡) is drug concentration, 𝑓 represents function, 𝐷 is the administered 
dose of drug administered, 𝑡  is a vector of time points and 𝜃𝑃𝐾  are 
pharmacokinetic parameters.  
A fundamental part of pharmacokinetic modelling analyses involves 
estimating pharmacokinetic parameters that describe and characterise the 
concentration time profile of drugs following administration. The primary 
pharmacokinetic parameters of interest include clearance (𝐶𝐿), apparent volume 
of distribution (𝑉), absorption rate constant (𝑘𝑎 ), bioavailability (𝐹 ) and the 
secondary pharmacokinetic parameter elimination rate constant (𝑘), which is 
derived from clearance divided by apparent volume of distribution (i.e. 𝐶𝐿/𝑉). 
From a dosing perspective the most important primary and secondary 
pharmacokinetic parameters are clearance (determines the maintenance dose 
rate), apparent volume of distribution (determines the loading dose) and half-
life (determines dosing interval and time to steady state). Note that clearance is 
a proportionality constant that describes the relationship between drug 
concentration and the rate of elimination. Apparent volume of distribution is the 
apparent volume into which a drug distributes. Bioavailability is the fraction of 
an extravascularly administered drug that reaches the systemic circulation. 
Pharmacokinetic models can be built using compartment structure models. 
Compartment pharmacokinetic models describe the body by a finite number of 
compartments to characterise the time-course of drug movement into, within 




and out of the body (i.e. the pharmacokinetic processes absorption, distribution, 
metabolism and elimination). Note that these hypothetical compartments do not 
necessarily represent true physiological tissues, spaces or organs. It is assumed 
that the drug homogenously distributes through all compartments. 
The number of compartments in a pharmacokinetic model characterise the 
disposition kinetics of a drug. For instance, a one-compartment model is used to 
describe drugs that exhibit drug disposition that occurs very rapidly so that the 
process appears instantaneous. For drugs that exhibit one-compartment kinetics 
it is assumed that the drug distributes evenly throughout the body, as if it were 
a single, uniform compartment (refer to Figure 1.6 for a schematic of a one-
compartment model). For drugs that exhibit one-compartment kinetics given via 
an intravenous bolus or a single extravenous dose it is anticipated that drug 
absorption (for extravenously administered drugs) and distribution is 
instantaneous. Drug elimination begins immediately after drug administration 
and would occur concurrently with drug absorption and distribution. For a one-
compartment model, drug elimination would exhibit a mono-exponential 
decline if graphed on a semi log plot (shown in Figure 1.7). In a two-
compartment model (schematic shown in Figure 1.8) an additional peripheral 
compartment is added to characterise the slower rate of distribution of some 
drugs, resulting in a bi-exponential decline in drug concentration (shown in 
Figure 1.9). 
  







Figure 1.6 A schematic representation of a one-compartment model for a drug 
administered intravenously (a) and extravenously (b). CL represents clearance, Vc 
represents the central compartment volume, F represents bioavailability and ka 









Figure 1.7 Concentration time profile for a one-compartment model with first-order 
elimination for an intravenous bolus dose (red) and extravenously administered dose 
(blue) with first-order absorption on a Cartesian plot (a) and on a semi-log plot (b). 
Parameters: Dose = 5 units, F = 1, CL = log(2) h-1, V = 1 L, ka = 1 h-1 and k = CL/V. F 
represents bioavailability, CL represents clearance, V represents volume of distribution, 












Figure 1.8 A schematic representation of a two-compartment model for a drug 
administered intravenously (a) and extravenously (b). CL represents clearance, Vc 
represents the central compartment volume, Vp represents the peripheral compartment 
volume, F represents bioavailability, ka represents the absorption rate constant and Q 








Figure 1.9 Concentration time profile for a two compartment model with first-order 
elimination for an intravenous bolus dose (red) and extravenously administered dose 
(blue) with first-order absorption and on a Cartesian plot (a) and on a semi-log plot (b). 
Parameters: Dose = 5 units, F = 1, CL = log(2) h-1, Vc = 1 L, Q = 1 h-1, Vp = 1 L and ka 
= 1 h-1. F represents bioavailability, CL represents clearance, Vc represents central 
compartment volume, Q represents intercompartmental clearance, Vp represents 
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The time course of drug concentrations for pharmacokinetic compartment 
models can be illustrated by a series of ordinary differential equations. For 
instance, for drug given extravenously a one-compartment model can be 




= −𝑘𝑎 ∙ 𝐴1  ; at 𝑡 = 0, 𝐴1 = 𝐹 ∙ 𝐷 
𝑑𝐴2
𝑑𝑡
= 𝑘𝑎 ∙ 𝐴1 − 𝑘 ∙ 𝐴2    ; at 𝑡 = 0, 𝐴2 = 0 
Equation 1.9 Ordinary differential equations for a one-compartment pharmacokinetic 





 is the rate of change in amount of drug from the administration site, 
𝑑𝐴2
𝑑𝑡
 is the rate of change in amount of drug from the central compartment, 𝑘𝑎 is 
the absorption rate constant, 𝐴1 is the amount of drug at the administration site, 
𝑘  is the elimination rate constant, 𝐴2  is the amount of drug in the plasma, 𝑡 
represents time, 𝐷  represents dose and 𝐹  represents bioavailability. If the 
ordinary differential equations for the central compartment in Equation 1.9 are 
solved it provides the closed-form algebraic solution shown in Equation 1.10.  
 
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉 ∙ (𝑘𝑎 − 𝑘)
∙ (𝑒−𝑘∙𝑡 − 𝑒−𝑘𝑎∙𝑡) 
Equation 1.10 Closed-form algebraic solution for a one-compartment pharmacokinetic 
model with first-order absorption and elimination 
  




1.5.1.1.2. Pharmacodynamic model 
Pharmacodynamics (PD) is the science that relates drug concentrations 
with effect. It is the study of the relationship between the drug concentration at 
the site of action and the observed biochemical and physiological effect. A 
pharmacodynamic model describes drug effect as a function of drug 
concentration and pharmacodynamic parameters. A mathematical form of a 
general pharmacodynamic model is given as follows; 
 
𝐸(𝐶) = 𝑓(𝐶, 𝜃𝑃𝐷) 
Equation 1.11 General mathematical form of a pharmacodynamic model 
 
where, 𝐸  represents drug effect, 𝐶  represents drug concentration, and 𝜃𝑃𝐷 
represents pharmacodynamic parameters. Note that drug effect is independent 
of time.  
The relationship between drug concentration and pharmacological effect is 
commonly found to be non-linear. In other words doubling the drug 
concentration does not double the pharmacological effect. Rather, a hyperbolic 
function is commonly used to characterise the relationship between drug 
concentration and response. The extent of the response is dependent on drug 
concentration. However, as most drugs exhibit non-linear concentration to 
response relationships, the drug response will increase with increasing drug 
concentration until it reaches a maximum effect (𝐸𝑚𝑎𝑥 ) after which the drug 
effect asymptotes with increasing drug concentrations. 
Most of the principles used to describe the relationship between drug 
exposure and response are based on classical receptor-binding theory. In 
classical receptor theory a ligand is assumed to bind reversibly to a receptor, 
which subsequently results in a series of biochemical and physiological changes 
ultimately leading to an observed effect. From a pharmacometric perspective the 
ligand mentioned here can be interpreted as a drug, whereby the drug binds to 
a receptor resulting in a series of events that lead to pharmacological effect. 
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Bearing this interpretation of classical receptor theory in mind the relationship 
between drug concentration and effect can be given using the following model, 
known as the 𝐸𝑚𝑎𝑥 model; 
 




Equation 1.12 The Emax model 
 
where, 𝐸  represents drug effect, 𝐸𝑚𝑎𝑥  represents the maximum effect of the 
drug, 𝐶  represents drug concentration and 𝐶50  is the drug concentration at 
which the drug exhibits 50% of its maximum response. The primary 
pharmacodynamic parameters of interest are 𝐸𝑚𝑎𝑥 and 𝐶50. 
Several modifications have been made to the 𝐸𝑚𝑎𝑥  model to increase its 
application to more settings. An example of a modification to the general 𝐸𝑚𝑎𝑥 
is the sigmoidal 𝐸𝑚𝑎𝑥  model (shown in Equation 1.13). In the sigmoidal 𝐸𝑚𝑎𝑥 
model an empirical exponent, named the Hill coefficient (𝜆), was added to the 
𝐸𝑚𝑎𝑥 model to change the shape and steepness of the exposure-response curve. 
Another example of a modification to the general 𝐸𝑚𝑎𝑥  model includes the 
addition of a physiological constant baseline (𝐸0) to predict what physiological 
conditions would be like in the absence of the drug (shown in Equation 1.14). 
 





Equation 1.13 The sigmoidal Emax model 
 




Equation 1.14 The Emax  model with physiological constant baseline 
  




1.5.1.2. Statistical models 
The statistical model describes variability. In pharmacometrics a statistical 
model is commonly made up of two levels of hierarchy, which are: (i) between 
subject variability and (ii) residual unexplained variability. 
1.5.1.2.1. Residual unexplained variability 
Residual unexplained variability (RUV), also known as ‘uncertainty’, 
describes the variability of observations around model predictions. Residual 
unexplained variability may arise from: (i) measurement error, (ii) process error, 
(iii) within subject variability (also known as intraindividual variability) and, (iv) 
model misspecification.  
A mathematical form of the residual error model is shown as follows;  
 
𝑦𝑖 = 𝑓(𝑡𝑖, 𝛽𝑖) + 𝜀𝑖 
Equation 1.15 General form of a residual error model 
 
where, 𝑦𝑖  is a ni-by-1 vector of the observations from the 𝑖
𝑡ℎ  individual and 
𝑓(𝑡𝑖, 𝛽𝑖) is the individual prediction given by the function (𝑓) where 𝑡𝑖 is a ni-by-
1 vector of sampling time and 𝛽𝑖  is a p-by-1 vector of individual parameters. 
Note that ni refers to the number of observations from the 𝑖𝑡ℎ individual and p is 
the number of parameters. The distribution of 𝜀𝑖  is assumed to be normally 




Equation 1.16 The distribution of εi 
 
1.5.1.2.2. Between subject variability 
The second level in the statistical model hierarchy is between subject 
variability (BSV), also known as interindividual variability (IIV). Between subject 
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variability describes unexplained variability that can be related to individual 
subject specific factors. A mathematical form of the between subject variability 
model is given; 
 
𝛽𝑖 = 𝑔(𝜃, 𝑍𝑖; 𝜂𝑖) 
Equation 1.17 General form of a between subject variability model 
 
where, 𝛽𝑖 is a p-by-1 vector of individual parameters for the 𝑖
𝑡ℎ individual that 
is given by a function (𝑔) where 𝜃 is a p-by-1 vector of population typical values 
of parameters, 𝑍𝑖 is a p-by-z vector of covariates and 𝜂𝑖 is a p-by-1 vector that 
accounts for the random deviation of 𝛽𝑖  from 𝜃 . The distribution of 𝜂𝑖  for all 
subjects in the study population is often assumed to follow a normal distribution 
with a mean of zero (Equation 1.18) and a variance-covariance given by Ω 
(shown in Equation 1.19).  
 
𝜂𝑖~𝑁(0, Ω) 











Equation 1.19 Variance-covariance matrix 
 
An exponential function is commonly used to describe between subject 
variability as many pharmacological parameters are positive real numbers. The 
exponential function is shown in Equation 1.20. 
 
𝛽𝑖 = 𝜃 ∙ 𝑒𝑥𝑝(𝜂𝑖) 
Equation 1.20 Exponential function used to describe between subject variability 
  





The three main approaches for population analysis include: (i) naïve pooled 
data approach, (ii) two-stage approach and (iii) nonlinear mixed effects 
modelling. 
1.5.2.1. Naïve pooled data approach 
In the naïve pooled data approach all the data are combined (i.e. pooled) 
into a single dataset and the data analysed. In this method, data are analysed as 
if it had all arisen from a single individual, or, as if each observation had been 
collected from different individuals. The latter being the historical application of 
this method [89]. Due to all the data being pooled together in the naïve pooled 
approach there is only a single set of parameter values that is estimated for the 
corresponding model. 
The simplicity of the naïve pooled data approach eases its use and allows 
for straightforward computation. The fundamental problem with the naïve 
pooled data approach is that it completely ignores any random variation that 
exists between individuals (i.e. between subject variability). Hence, lumping any 
variation arising between subjects together with residual error making the two 
indistinguishable. Consequently, the naïve pooled data approach cannot 
estimate the interindividual variability of parameters, neither can it estimate 
residual error that arises solely from intraindividual variability and 
measurement error – resulting in biased parameter estimates and inflated values 
of residual error [90]. In addition, parameter estimates can be biased if 
individuals provide different amounts of data and if the model is very nonlinear. 
1.5.2.2. Two-stage approach 
The two-stage approach, as can be inferred from its name, involves two 
stages. In the first stage, data from each individual is singly analysed to estimate 
pharmacokinetic parameters for each individual. These individual parameter 
estimates are then combined in the second stage to calculate the central tendency 
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(i.e. mean, logarithmic mean or median) and variability (i.e. variance and 
covariance) to yield population parameter estimates. 
The two-stage approach provides a simple method to obtain estimates of 
population parameters and between subject variability. However, the problem 
with the two-stage approach is that it requires rich data from each individual. It 
has been shown that sparse data (i.e. up to 5 samples per individual) may result 
in poor individual parameter estimates, and, ultimately lead to biased and 
suboptimal results when combined with other individual parameter estimates 
[89]. In addition, the estimates of between subject variability tend to be inflated 
because the two-stage approach does not account for intraindividual variability.  
1.5.2.3. Nonlinear mixed effects modelling 
Nonlinear mixed effects modelling – also known as a full population 
approach – estimates population parameters, variability between individuals as 
well as residual variability. The hierarchical structure for this modelling 
approach includes the estimation of two types of effects – fixed effects and 
random effects – giving rise to the ‘mixed effects’ component of the name. The 
fixed effects represents structural parameters and the random effects represents 
the variance of distribution of a specific element of the model. This modelling 
approach for population analysis is robust as it is able to handle both sparse and 
rich data, as well as unbalanced/unstructured data. Nonlinear mixed effects 
modelling considers the population, as opposed to an individual, as the unit for 
the analysis. Hence, the individuality and variability between individuals is 
maintained.  
Nonlinear mixed effects modelling is considered to be the best approach 
for population analysis, however, it is also the most complex method. The 
superiority of nonlinear mixed effects modelling illustrates its advantage over 
the naïve pooled data approach and two-stage approach when there are sparse 
data (e.g. commonly seen in paediatrics, geriatrics, intensive care patients and 
outpatients), interest in understanding sources of variability, as well as wanting 




to develop a model to describe and/or to make future predictions using model-
based simulations. 
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2.1. Preamble to the chapter 
In this chapter the causal role of metformin therapy in the development of 
lactic acidosis was explored. A systematic literature review was performed to 
identify published case reports of metformin associated lactic acidosis. 
Demographic and clinical data were extracted from each identified case report 
and, the association between metformin therapy and lactic acidosis in the cases 
was assessed using two causality assessments. Case reports were also assessed 
for quality using a completeness scoring tool. 
2.2. Introduction 
Metformin is an oral antihyperglycaemic agent that is widely accepted as 
the first-line treatment for type 2 diabetes mellitus. It works predominantly by 
inhibiting hepatic gluconeogenesis [19, 20]. Metformin therapy may have several 
advantages over other antidiabetic treatments, including a neutral effect on body 
weight and a lower incidence of hypoglycaemia [9, 21, 22]. 
There is considerable concern that patients receiving metformin therapy 
may be at an increased risk of developing lactic acidosis, a rare but life 
threatening metabolic condition. The term “lactic acidosis” is used to 
characterise the temporarily related events of acidosis, characterised by a 
decreased arterial pH to less than 7.35, and hyperlactataemia, defined as a 
plasma lactate concentration of greater than 5 mmol/L [87]. Prompt diagnosis 
and management of lactic acidosis is critical to reduce mortality as it is associated 
with poor clinical outcomes [91, 92].  
While the ingestion of supra-therapeutic metformin doses (e.g. > 20,000 
mg) in the setting of intentional overdose has been known to cause lactic 
acidosis, the risk when metformin is taken chronically in standard therapeutic 
doses of 1,000-3,000 mg daily is not clear [12, 13, 63]. Phenformin, a predecessor 
of metformin, was removed from the market in the 1970s following reports of an 
association with fatal cases of lactic acidosis [93, 94]. The incidence of 
phenformin associated lactic acidosis was estimated to be 129 cases per 100,000 




patient years, which is substantially higher than the incidence reported for 
metformin at 3.3-9 cases per 100,000 patient years [94-98]. Regardless, the 
possibility that lactic acidosis is causally related to metformin use at therapeutic 
doses has led to restricted use in some patient groups [99]. 
The incidence of lactic acidosis in diabetic patients not taking metformin is 
estimated to be about 9.7 cases per 100,000 patient years, a value roughly the 
same as the incidence reported for metformin [95-98]. This raises the possibility 
that metformin therapy may not be the primary cause of lactic acidosis in 
reported cases of metformin associated lactic acidosis. Indeed, other risk factors 
for lactic acidosis have been proposed as the primary drivers, including acute 
gastrointestinal illness, dehydration, and heart failure [100].  
To date, a systematic review of the evidence-base around metformin 
associated lactic acidosis as presented in published case reports has not been 
undertaken. Well-presented case reports can provide sufficient detail to assess 
the impact of risk factors, other than metformin use, on the development of lactic 
acidosis in cases attributed to metformin therapy.  
2.3. Objectives 
The aims of this research were (i) to formally evaluate the association 
between metformin therapy and lactic acidosis in published case reports using 
two causality scoring systems, (ii) to determine the frequency of pre-existing 
independent risk factors in published metformin associated lactic acidosis cases, 
and, (iii) to investigate the association between risk factors and mortality in 
metformin associated lactic acidosis cases.  
  




2.4.1. Data sources and search strategy 
A systematic literature review was performed to identify case reports of 
metformin associated lactic acidosis. The literature search was conducted in 
Ovid MEDLINE (Ovid MEDLINE 1946 to July 2017), Ovid EMBASE (Ovid 
EMBASE 1946 to July 2017), Google Scholar (to May 2017) and SCOPUS (to May 
2017). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) criteria were used as a guide for conducting and reporting the 
literature review [101]. Articles were identified using three search strategies; 
1. A static search in MEDLINE using Medical Subject Heading (MeSH) 
terms; ‘Metformin’, ‘Biguanides’, ‘Acidosis, Lactic’, ‘Acidosis’, 
‘Lactic Acid’, ‘Hyperlactatemia’, ‘Case reports’ and key words 
‘Antidiabetic agent’, ‘Antihyperglycemic’, ‘Case series’ and ‘Case’. 
The static search was also conducted in EMBASE using the MeSH 
terms; ‘Metformin’, ‘Biguanide derivative’, ‘Oral antidiabetic agent’, 
‘Biguanide’, ‘Antidiabetic agent’, ‘Lactic acidosis’, ‘Acidosis’, ‘Lactic 
acid’, ‘Hyperlactatemia’, ‘Case report’, ‘Case study’ and keywords 
‘Antihyperglycemic’ and ‘Case’. Google Scholar and SCOPUS were 
searched for completeness. The Boolean operators ‘AND’ and ‘OR’ 
were used to search for all relevant literature. The software 
Harzing’s Publish or Perish (Windows 6.1.7601, version 
6.16.7601.18837) was used to aid database searching for articles in 
Google Scholar. 
2. A learning based approach was performed in Ovid MEDLINE. A 
detailed description of the learning based approach has been 
published elsewhere [102]. An article by Luft et al was used as the 
index article to search for relevant MeSH terms in Ovid MEDLINE 
[103]. Relevant MeSH terms obtained from the index article – 
‘Acidosis’, ‘Biguanides’, ‘Buformin’, ‘Diabetes complications’, 
‘Diabetes mellitus’, ‘Hypoglycaemic agents’, ‘Lactate’, ‘Metformin’ 




and ‘Phenformin’ – were combined using the Boolean operator 
‘AND’ to refine the search. A combination of five MeSH terms 
provided an acceptable number of article hits to review and all 
possible permutations were trialled. New relevant MeSH terms 
were added into subsequent searches in an iterative process until no 
new MeSH terms could be identified. 
3. Studies were mined from the reference lists of identified review 
articles. 
Note the learning based approach was used in addition to the standard static 
search and reference list mining. The learning based approach has the following 
advantages over the static search: (i) it is an iterative process with an adaptive 
feedback step so that each article located is reviewed for potential MeSH terms 
that were not previously identified to help increase search coverage, (ii) it 
involves the effective utilisation of MeSH terms by focussing on MeSH terms of 
relevance and (iii) it can link similar articles together without any previously 
known relationship between the articles. Hence, in theory the addition of the 
learning based approach should be able to identify articles that would not have 
been located if just a static search and/or reference list mining were performed. 
Details of the static and learning based approach search strategies are 
summarised in Appendix A1.1. Searches were limited to articles published in the 
English language and human studies. Duplicate studies sourced were removed 
using Endnote X8. 
2.4.2. Article selection 
The articles were initially screened by study title and abstract for relevance 
to metformin and lactic acidosis. For the purpose of this analysis, a therapeutic 
dose of metformin was defined as any dose reported in the case histories that 
had been prescribed and was taken chronically for a medical condition, usually 
type 2 diabetes mellitus. Relevant articles were then subjected to a full text 
review and assessed for inclusion and exclusion.  
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Publications were included if the following were reported (i) prior 
metformin use, (ii) a stated diagnosis of lactic acidosis (regardless of the reported 
pH and lactate concentration), and (iii) relevant laboratory investigations, (e.g. 
pH). Studies were excluded if they (i) were published in a language other than 
English, (ii) did not report human data, (iii) described an acute supra-therapeutic 
ingestion of metformin (i.e. an intentional overdose), and, (iv) reported only 
summary data from multiple cases (e.g. case series that only presented summary 
data). Duplicate cases reported in more than one publication were also excluded, 
with only the original publication retained. Note that case reports that involved 
an acute metformin overdose were excluded as the purpose of this study was to 
understand non-overdose cases.  
Screening and study selection were initially conducted by I.H.S.K. 
Excluded studies and any discrepancies were resolved by a thesis supervisor. 
2.4.3. Data extraction 
The following data were extracted from each article where available; 
publication details (year of publication, author, title), case demographics (age, 
sex, weight, height and ethnicity), medical history (presenting complaints, 
diagnosis on admission, comorbidities, concomitant medications and dose, 
surgical/hospitalisation history), metformin maintenance dose, duration of 
metformin therapy to onset of lactic acidosis, metformin plasma concentrations, 
laboratory measurements (arterial blood gases, estimates of renal function (any 
estimate of glomerular filtration rate (GFR), including creatinine clearance 
(CLcr) calculated using the Cockcroft and Gault equation ([80]) or reported 
eGFR), and, plasma or serum concentrations of lactate, electrolytes (sodium, 
potassium, bicarbonate and chloride ions), creatinine, glucose and glycated 
haemoglobin (HbA1c), urea/blood urea nitrogen, concentrations of any 
concomitant intoxicants), medical interventions, and patient outcome. Clinical 
laboratory data presented in graphs were extracted using the MATLAB (R2016b, 
MathWorks, Natick, MA) script GRABIT. Data was extracted to three decimal 
points.  




2.4.3.1. Independent risk factors for lactic acidosis 
Pre-existing factors that are reported to increase the risk of developing 
lactic acidosis, other than metformin use, were extracted from each of the case 
reports. The risk factors were categorised as; (i) acute (presenting/diagnosis on 
admission), (ii) chronic (diagnosis of condition prior to admission) or (iii) acute 
on chronic (exacerbation of a chronic condition) at presentation. The risk factors 
used for this analysis are presented in Appendix A1.2 (Table A1.7). The list was 
developed by collating recognised risk factors summarised in standard medical 
texts [88, 104, 105] and was reviewed by two independent clinicians. 
Two additional risk factors; acute gastrointestinal illness and dehydration, 
were not listed in most references as independent risk factors for lactic acidosis, 
but have been proposed to increase risk specifically in patients taking metformin 
[99]. The risk of lactic acidosis in this setting is suggested to be due to 
dehydration and hypovolemia leading to the possibility of acute renal failure 
and hence metformin accumulation [18, 100]. Information about these additional 
risk factors from each of the case reports were extracted. 
2.4.4. Data analysis 
2.4.4.1. Summary description of cases 
Demographic and clinical features of cases with metformin associated lactic 
acidosis identified from the literature were summarised. The following graphs 
were plotted in R (version 3.3.3) for data visualisation: (i) arterial pH versus time, 
(ii) lactate concentration versus time, (iii) creatinine concentration versus time 
and (iv) metformin concentration versus time.  
2.4.4.2. Causality assessment 
The role of metformin in the development of lactic acidosis in each case 
report was assessed using the World Health Organisation-Uppsala Monitoring 
Centre (WHO-UMC) system for standardised case causality assessment [106] 
and the Naranjo adverse drug reaction (ADR) probability scale [107]. The two 
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causality assessments were applied to each identified case report of metformin 
associated lactic acidosis to allow for cross-validation and comparison between 
the results. 
2.4.4.2.1. WHO-UMC system for standardised case causality assessment 
The WHO-UMC system for standardised case causality assessment 
classifies the likelihood of a causal relationship between a pharmacological agent 
and an adverse event into six categories [106]. The tool assesses the causality 
likelihood based on clinical and pharmacological information provided in the 
case histories, as well as considering the quality of the information provided 
[106].  
The WHO-UMC system for causality assessment was annotated with lactic 
acidosis specific diagnostic criteria under each causality category to allow for 
replicability of the results. The adapted WHO-UMC system for causality 
assessment with additions under assessment criteria is presented in Appendix 
A1.3 (Table A1.8). 
2.4.4.2.2. Naranjo ADR probability scale 
The Naranjo ADR probability scale is a questionnaire that describes the 
relationship between a pharmacological agent and an adverse reaction using a 
scoring system presented in Appendix A1.4 (Table A1.9) [107]. The relationship 
between the pharmacological agent and outcome is described by four categories, 
which are ‘definite’, ‘probable’, ‘possible’ and ‘doubtful’ shown in Appendix 
A1.4 (Table A1.10) [107]. 
2.4.4.3. Completeness (quality) score for published case reports 
The information provided in the case reports was reviewed for quality 
using a bespoke completeness score. The completeness score was based on the 
quality scoring tool published by Stades et al [108]. 
Each case history was reviewed and a score assigned based on the 
availability of the following data; age, sex, height, weight, ethnicity, 
comorbidities, concomitant medications, doses of concomitant medications, co-




ingested substances (e.g. methanol), symptoms/illnesses prior to admission, 
ingested dose of metformin, duration of metformin therapy, time of last 
metformin ingestion, pH, partial pressure of carbon dioxide (pCO2), partial 
pressure of oxygen (pO2), anion gap, base excess, estimates of renal function 
(any estimate of GFR, including Cockcroft-Gault ([80])), medical interventions, 
patient outcome, and, plasma or serum concentrations of lactate, metformin, 
sodium, potassium, bicarbonate, chloride, creatinine, urea/blood urea nitrogen, 
and glucose. One point was allocated for each descriptor reported. An additional 
point was allocated to case histories with repeated measures data (e.g. serial 
plasma concentrations over time post-admission). The score could range from 0 
to 31.  
A sensitivity analysis was conducted to assess the influence of poor 
completeness scores on the causality assessment. Case reports with a 
completeness score in the lower quartile of possible scores (0 - 10) were excluded.  
2.4.4.4. The frequency of pre-existing risk factors in metformin associated 
lactic acidosis cases 
The overall frequency of each identified risk factor for lactic acidosis in the 
cohort of cases, stratified as acute, chronic or acute-on-chronic, was determined. 
For each individual case, the number of co-existing risk factors for lactic acidosis 
was tabulated and the frequency of identified risk factors per case was 
summarised.  
Evidence of gastrointestinal illness (including both acute and chronic 
symptoms) and dehydration were recorded for each case and their prevalence 
summarised.  
2.4.4.5. Risk factors and mortality in metformin associated lactic acidosis cases 
The risk of mortality was assessed by determining the percentage of cases 
who did or did not survive in the overall cohort, as well as in subgroups divided 
on the basis of the number of risk factors for lactic acidosis present per case. 
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The association between each risk factor and mortality was assessed using 
a multivariable logistic regression analysis. This was conducted in R (version 
3.3.3). The dependent variable was case outcome (i.e. mortality or survival) and 
the explanatory variables were the risk factors for lactic acidosis outlined in 
Appendix 1.2. Only explanatory variables reported in more than ten percent of 
cases were considered. 
Each explanatory variable was added to the model one at a time in a 
univariate analysis. Risk factors were considered significant if they resulted in a 
decrease in the Akaike information criterion (AIC) relative to the null model. 
Risk factors which were imprecisely estimated, with a percent relative standard 
error (RSE%) of greater than 50%, were not considered further. Identified 
significant explanatory variables were then added to the null model one at a time 
using forward selection (i.e. firstly adding the risk factor that resulted in the 
greatest decrease in AIC), until no further reduction in AIC was observed 
following subsequent addition of explanatory variables to the model. The model 
was then subject to backwards deletion, which involved removing one 
explanatory variable at a time to confirm statistical significance. All possible 
second-level interactions between explanatory variables were individually 
added to the logistic regression model and tested for significance. Significant 
interaction terms were retained in the final model.  
  





2.5.1. Literature search 
A total of 8,235 articles were identified. After the removal of duplicates, the 
remaining 4,166 articles were screened by study title and abstract. A total of 3,220 
articles were excluded following the screening process. Of the 946 remaining 
articles, 699 were excluded for the following reasons: reported an intentional 
overdose of metformin (n=84), cases published in more than one paper (n=58), 
cases in a language other than English (n=64), no record of a lactic acidosis 
diagnosis (n=128), no record of either a lactic acidosis diagnosis and no record of 
metformin use (n=217), no record of metformin use (n=43), no laboratory data to 
support lactic acidosis diagnosis (n=31), case series with summary data (n=51), 
and articles that could not be accessed or located (n=23). In total, 247 articles 
were included in the final literature review representing 559 cases of metformin-
associated lactic acidosis [8, 97, 100, 109-352]. A schematic of the PRISMA 
workflow for the systematic literature review is presented in Figure 2.1.  
2.5.2. Identified literature 
A total of 247 articles were identified in the literature. Identified articles 
included 181 case reports, 44 case series, 1 case control study, 2 cohort studies, 1 
poison centre database and 18 retrospective cohort studies. Several publications 
included multiple case reports with individual patient data. 




Figure 2.1 PRISMA flow diagram for the systematic literature review 
2.5.3. Identified metformin associated lactic acidosis cases 
A total of 559 metformin associated lactic acidosis cases were identified 
from the literature search. An online database of the metformin associated lactic 
acidosis cases was created and is available in the figshare repository, 
https://figshare.com/s/4a1129faa048322cfa0c. Please note that the online 
database also contains data extracted from 84 articles (of n=146 cases) that were 
excluded from this study due to having reported taking an intentional overdose 
of metformin. 
  




2.5.4. Data analysis 
2.5.4.1. Completeness scores 
The completeness score was applied to each case report. A summary table 
of the completeness scores is shown in Appendix A1.5 (Table A1.11).  
2.5.4.2. Demographics and clinical features of metformin associated lactic 
acidosis cases 
A summary of the extracted demographic and clinical features of the cases 
is presented in Table 2.1. Missing data not recorded in the published case reports 
is also included. The median prescribed daily dose of metformin and duration 
of metformin therapy prior to admission was 1700 mg and 12 months, 
respectively. The median arterial pH on admission was 6.97 (range: 6.00 – 7.50) 
and the median lactate concentration was 14.5 mmol/L (range: 1.1 – 60).  
A graph of arterial pH, creatinine, lactate and plasma metformin 
concentrations versus time post-admission is shown in Figure 2.2, 2.3, 2.4 and 2.5 
respectively. As shown in Figure 2.2, it can be seen that many MALA cases had 
presented with severe acidosis (i.e. pH less than 7.35) on admission, which had 
later recovered back to normal physiological pH levels. In addition, in Figure 2.3, 
2.4 and 2.5 it can be seen that many cases had presented with grossly elevated 
creatinine, lactate and metformin concentrations on admission which had 
subsequently returned back to normal physiological levels, respectively. The 
grossly elevated creatinine concentrations is likely to be a reflection of the fact 
that many of the cases had presented with acute renal failure. In the MALA cases, 
it is likely that the acidosis, as well as elevated concentrations of creatinine, 
lactate and metformin returned to normal values following medical 
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Cases with reported data 
(out of n = 559) [%] 
Demographics 
     Gender (F:M)  309:210 519 [93%] 

























Estimated GFR (baseline)   72 [13%] 








Key laboratory values on admission 


















History of diabetes (Y:N)  356:29 385 [69%] 
Patient outcome (Survived: Died)  393:160 553 [99%] 
Data presented as median [range] (interquartile range) unless otherwise specified. BMI = body 
mass index, GFR = glomerular filtration rate. aReference range for laboratory values for females. 
bReference range for laboratory values for males.   





Figure 2.2 Scatterplot of arterial pH versus time post-admission from metformin 
associated lactic acidosis cases (n=509). The dots represent single measures of pH and 
the lines link repeated measures data for a single case. Reported pH values below the 





Figure 2.3 Scatterplot of creatinine concentration versus time post-admission from 
metformin associated lactic acidosis cases (n=458). The dots represent single measures 
of creatinine concentration and the lines link repeated measures data for a single case. 
 




Figure 2.4 Scatterplot of lactate concentration versus time post-admission from 
metformin associated lactic acidosis cases (n=505). The dots represent single measures 
of lactate concentration and the lines link repeated measures data for a single case. 
Reported pH values above the limit of quantification were graphed as a lactate 




Figure 2.5 Scatterplot of plasma metformin concentration versus time post-admission 
from metformin associated lactic acidosis cases (n=215). The dots represent single 
measures of metformin concentration and the lines link repeated measures data for a 
single case. 
  




2.5.4.3. Causality assessment 
The results of the WHO-UMC and Naranjo causality assessments are 
presented in Table 2.2.  
The WHO-UMC system for standardised case causality assessment 
categorised metformin as a ‘probably/likely’ cause of lactic acidosis in 17 cases 
(3.0%), a ‘possible’ cause in 473 cases (84.6%), an ‘unlikely’ cause in 2 cases 
(0.4%), ‘conditional/unclassified’ in 49 cases (8.8%) and ‘not 
assessable/unclassifiable’ in 18 cases (3.2%). Similarly, the Naranjo ADR 
probability scale found that metformin was a ‘probable’ cause of lactic acidosis 
in 22 cases (3.9%), a ‘possible’ cause in 536 cases (95.9%) and a doubtful cause in 
1 case (0.2%). In the sensitivity analysis, where cases with a completeness score 
in the bottom quartile of possible completeness scores (≤10) were excluded, the 
causality scores did not change appreciably suggesting that cases of low quality 
did not influence the results (see Table 2.2).  
Table 2.2 Summary of the causality assessments using the World Health Organisation-
Uppsala Monitoring Centre (WHO-UMC) system and Naranjo adverse drug reaction 





(n = 559) 
Sensitivity analysis 
excluding cases with a 
completeness score of  ≤10 
(n = 386) 
WHO-UMC 
system 
Certain - - 
Probably/Likely 17 (3%) 11 (2.8%) 
Possible 473 (84.6%) 338 (87.6%) 
Unlikely 2 (0.4%) 1 (0.3%) 
Conditional/Unclassified 49 (8.8%) 24 (6.2%) 
Unassessable/Unclassifiable 18 (3.2%) 12 (3.1%) 
Naranjo ADR 
probability scale 
Definite - - 
Probable 22 (3.9%) 16 (4.3%) 
Possible 536 (95.9%) 369 (95.6%) 
Doubtful 1 (0.2%) 1 (0.3%) 
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2.5.4.4. Summary of independent risk factors for lactic acidosis 
Of 559 cases, 540 (96.6%) presented with at least one independent risk factor 
for lactic acidosis other than metformin use. Many cases presented with multiple 
risk factors. The median number of co-existing risk factors per case was 2, 
ranging from 0 to 5 (Table 2.3).  
A summary of the pre-existing ‘acute’, ‘acute on chronic’ or ‘chronic’ risk 
factors identified in the cases is presented in Table 2.4. Overall, the most 
prevalent pre-existing risk factors were renal impairment (n=454, 81%), shock 
(n=69, 12%), and hepatic impairment (n=55, 10%). When considering only acute 
conditions, acute renal impairment, shock and hypoglycaemia (n=292, n=69, 
and, n=49, respectively) were the most prevalent. It is worth bearing in mind that 
it may not be possible to tease apart some related acute conditions, such as shock 
and sepsis. Pre-existing chronic renal impairment, which did not progress to 
acute renal impairment, was reported to occur in only 36 cases. 
A total of 186 of the 559 cases with metformin associated lactic acidosis 
reported symptoms of gastrointestinal illness on admission. On presentation, 184 
of the 186 cases presented with acute symptoms of gastrointestinal upset, whilst 
the remaining 2 cases presented with chronic gastrointestinal symptoms that had 
lasted for 3 and 12 months. Dehydration was reported in 48 of the 559 cases on 
admission. In the cohort with acute gastrointestinal illness, 22/184 cases 
presented with dehydration. An additional analysis was conducted to explore 
the relationship between pre-existing gastrointestinal illness in patients on 
metformin therapy and lactic acidosis. However, due to the retrospective nature 
of the data a causal association between gastrointestinal illness, metformin 
therapy and lactic acidosis was difficult to establish. For more details refer to 
Appendix A1.6.  
Fifty-four cases reported ingesting drugs and/or toxins known to be risk 
factors for lactic acidosis (shown in Table 2.5). Acetylsalicylic acid and alcohol 
were the two most common substances ingested. 
  




Table 2.3 Frequency of multiple independent risk factors for lactic acidosis 








Table 2.4 Frequency of each risk factor for lactic acidosis 
Risk factor Acute 
Acute on 
chronic 
Chronic Total cases 
Type A     
     Anaemia 9 - 5 14 (2.5%) 
     Anaerobic muscle activity 3 - - 3 (0.5%) 
     Asthma - 1 6 7 (1.3%) 
     Heart failure 6 2 31 39 (7.0%) 
     Hypoxaemia 5 - - 5 (0.9%) 
     Post myocardial infarction 41 2 11 54 (9.7%) 
     Regional tissue ischemia 23 - 5 28 (5.0%) 
     Shock 69 - - 69 (12.3%) 
Type B     
     Hepatic impairment 37 4 14 55 (9.8%) 
     Human immunodeficiency virus - - 2 2 (0.4%) 
     Malignancy 2 - 21 23 (4.1%) 
     Renal impairment 292 126 36 454 (81.2%) 
     Sepsis 34 - - 34 (6.1%) 
     SIRS 1 - - 1 (0.2%) 
Miscellaneous     
     Diabetic ketoacidosis 5 - - 5 (0.9%) 
     Hypoglycaemia 49 - - 49 (8.8%) 
     Mitochondrial disease 2 - 1 3 (0.5%) 
     Gastrointestinal illness 184 - 2 186 (33.3%) 
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Table 2.5 Summary of drugs and toxins ingested 
Substance ingested Number of cases (n = 54) 

















2.5.4.5. Risk factors and mortality in metformin associated lactic acidosis cases 
A total of 160 of the 553 cases with reported patient outcome did not 
survive. A summary of the mortality of metformin associated lactic acidosis 
based on the presence of risk factors is shown in Table 2.6. 
Table 2.6 Apparent risk of mortality versus the number of risk factors for lactic acidosis 
present in cases with reported patient outcome 
Number of risk 
factors per case 
Death Total number of cases Cases that did not survive (%) 
0 8 18 44.4 
1 65 197 33.0 
2 45 193 23.3 
3 23 99 23.2 
4 16 37 43.2 
 




A small group of 19 cases were not reported to have any risk factors for 
lactic acidosis other than metformin use. Of these nineteen cases, 8 out of 18 
(44%) cases with reported patient outcome did not survive. It was noted that the 
completeness scores for 76% of these cases were all in the lower range of scores 
(≤12), and n=8 cases were classed as either ‘conditional/unclassified’ or 
‘unassessable/unclassifiable’ by the WHO-UMC causality assessment scheme. 
This suggests that the information presented in some of these cases was scant 
and may be unreliable. 
A summary of the logistic regression analysis assessing the influence of risk 
factors for lactic acidosis and mortality is presented in Table 2.7. Hepatic 
impairment was associated with an increased risk of mortality (odds ratio of 
1.926 (95% CI: 1.036-3.553)), whilst renal impairment was associated with a 
decreased risk of mortality (adjusted odds ratio of 0.305 (0.153-0.596)). 
Table 2.7 Logistic regression model for risk factors associated with mortality 
Covariate β se(β) P value Odds ratio (95% CI) 
Intercept 0.3449 0.3078 0.262467 1.411 (0.779-2.625) 
Renal impairment -1.1860 0.3461 0.000611 0.305 (0.153-0.596) 
Hepatic impairment 0.6553 0.3131 0.036332 1.926 (1.036-3.553) 
Shock 0.5372 0.2883 0.062444 1.711 (0.967-3.004) 
Renal0:DM1a -1.6358 0.4479 0.000260 0.195 (0.079-0.458) 
Renal1:DM1b -0.5841 0.2331 0.012206 0.558 (0.353-0.883) 
Note here that any form of renal impairment (i.e. chronic renal impairment or acute renal failure 
on admission) and hepatic impairment (i.e. chronic, acute or end stage hepatic failure) were 
included in the regression analysis. se: standard error, CI: confidence interval, aInteraction term 
used to describe when renal impairment is not present but diabetes mellitus is present. 
bInteraction term used to describe when both renal impairment and diabetes mellitus are present. 
  




The association between metformin and lactic acidosis remains 
controversial. Metformin is recognised to cause lactic acidosis when taken in 
supra-therapeutic doses, but when taken therapeutically its causal role is less 
clear. This study evaluated the association between metformin therapy and lactic 
acidosis and, investigated risk factors for lactic acidosis and their association 
with mortality in published metformin associated lactic acidosis cases. 
Metformin was found to only play a ‘possible’ role in the development of lactic 
acidosis when using two causality assessments. Almost all cases presented with 
risk factors for lactic acidosis other than metformin use.  
Hepatic impairment (including chronic, acute or end stage hepatic failure) 
was found to be associated with increased mortality in cases of metformin 
associated lactic acidosis, whilst renal impairment (including chronic renal 
impairment or acute renal failure on admission), paradoxically, was associated 
with a decreased risk of death. The mechanism behind these associations are 
unknown, however, similar findings have been reported where an association 
between end stage hepatic failure and mortality in cases presenting with 
metformin associated lactic acidosis has been reported [108]. 
There is a growing body of evidence to support the idea that metformin, 
when used in therapeutic doses, may not be a primary cause of lactic acidosis. 
This is supported by the findings in this study, where nearly all cases reviewed 
presented with other risk factors for lactic acidosis. In a recent Cochrane review 
no cases of metformin associated lactic acidosis could be identified in 209 
prospective comparative trials, 125 prospective cohort studies and 13 
retrospective cohort studies, representing 69,642 patients on metformin therapy 
[353]. While the Cochrane review included studies with controlled clinical trial 
populations, which may not be representative of patients with type 2 diabetes in 
standard clinical care, results from studies using pharmacovigilance data and 
other cohorts also cast doubt on metformin as a primary cause of lactic acidosis. 
In a longitudinal observational study by Kamber et al, the incidence of lactic 
acidosis in patients on metformin was found to be about the same as those 




treated with other anti-hyperglycaemic agents (i.e. 3 cases in 5,228 patient years 
and 2 cases in 7,238 patient years, respectively) [213]. In addition, the authors 
noted that most cases were in patients with risk factors for lactic acidosis other 
than metformin use [213]. Similarly, in a review of MALA case reports by Stades 
et al over 90% of the reviewed cases presented with acute risk factors for lactic 
acidosis leading the authors to conclude that the association between lactic 
acidosis and metformin is coincidental [108]. Findings from other published 
retrospective studies have collectively found that cases of MALA often presented 
with other risk factors that were more likely to account for the development of 
lactic acidosis [100, 233, 260]. Interestingly, current literature suggest that 
metformin may play a protective role in severe cases of lactic acidosis that are 
unrelated to metformin [14, 354]. 
The pathophysiology of metformin associated lactic acidosis is not well 
understood. It is generally assumed that excessive lactate production results in 
the release of free protons and thus leads to acidosis, although this hypothesis 
has been questioned by some researchers [355, 356]. At supra-therapeutic doses, 
metformin has been reported to interfere with the mitochondrial respiratory 
chain complex and increase lactate production which may be responsible for the 
development of lactic acidosis in patients who have taken large overdoses [298, 
357, 358]. It is noteworthy that these reactions have not been observed in patients 
taking therapeutic doses of metformin, nor do therapeutic doses have an 
appreciable impact on plasma lactate concentrations [358-361]. Whether elevated 
systematic exposure to metformin in those taking therapeutic doses due to, for 
example, reduced renal function is of a magnitude sufficient to interfere with 
mitochondrial respiration is not known.  
A total of nineteen published lactic acidosis cases were found with no other 
identifiable risk factors other than metformin use. These cases are of interest 
because they represent patients where metformin may be the primary cause of 
the lactic acidosis. However, it was found that many of these cases had lower 
completeness scores compared to the other reports (median: 10 (range: 5-25) 
versus median: 13 (range: 4-28), respectively). It is therefore possible that 
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additional information, such as other risk factors for lactic acidosis, were under-
reported. In addition, eight of the nineteen cases were categorised as 
‘conditional/unclassified’ or ‘unassessable/unclassifiable’ by the WHO-UMC 
causality assessment tool, indicating a lack of relevant information. It is therefore 
not possible to draw any conclusions about the role of metformin in these cases.  
An interesting implication of this study is that the causality assessment 
methods used may lead to biased results for this type of work. In keeping with 
the study outcomes other authors have noted that the same two causality 
assessment methods most frequently assign causality to “possible” [362, 363]. 
The key criteria for causality assessment are (1) metformin use prior to 
lactic acidosis onset, (2) whether other drugs or clinical conditions may have 
caused or contributed to lactic acidosis and to what degree, (3) outcome on 
metformin dechallenge and (4) objective evidence of lactic acidosis. The majority 
of case reports fulfilled criteria (1) and (4) but (3) can be difficult to assess as 
metformin will inevitably be discontinued but other potential causes will also be 
corrected where possible and lactic acidosis treated. Criteria (2) is the key and 
the reason why metformin causality has been so contentious. Whatever causality 
assessment method is used clinical judgement is required. For the Naranjo 
method a decision has to be made whether there were alternative causes that 
could on their own have caused the adverse reaction. Even if the answer is “yes” 
a “possible” score can be obtained if metformin was started prior to lactic 
acidosis onset and there was objective evidence of lactic acidosis which, of 
course, was the case in almost all of the published reports.  
The WHO-UMC criteria for “probable” include disease and other drugs 
being unlikely causes, “possible” criteria include disease and other drugs as 
potential alternative explanations and “unlikely” criteria include disease or other 
drugs providing plausible explanations. It is therefore evident that most reports 
with other risk factors for lactic acidosis will border between “possible” and 
“unlikely”, and, “unlikely” may have been under-ascertained. What is important 
is that there are very few reports where metformin was clearly the sole or most 
important cause of the lactic acidosis. Another difference leading to more reports 




being assigned to the “possible” category using the Naranjo algorithm was the 
absence in the latter of the WHO-UMC categories “unclassified” and 
“unclassifiable” which allow for reports to be categorised as unassessable if there 
is insufficient data. Including these in the “possible” category using the Naranjo 
algorithm is a bias towards a causal relationship. 
2.7. Limitations 
Lalau et al have provided a critical analysis of the pitfalls that will be 
encountered when examining the association between metformin and lactic 
acidosis [364]. The authors note that important diagnostic information such as 
the duration of metformin exposure, renal status, availability of a metformin 
assay, the ratio of metformin plasma to erythrocyte concentrations are required 
to fully assess metformin’s role in lactic acidosis. It is important to acknowledge 
that the lack of these data represents an important limitation for the analysis of 
published case reports. In this study, data analysis was restricted by the 
availability of data reported in the literature. Published case histories identified 
are inconsistent, often lacking complete clinical and diagnostic information. 
Potentially influential risk factors for lactic acidosis (e.g. comorbidities, 
concomitant medicines and supplements) may not have been consistently 
documented. For instance, only 13% of cases reported estimated renal function 
prior to admission, limiting any inference about the relationship between renal 
impairment and metformin accumulation in the lactic acidosis cases. 
Furthermore, due to the retrospective nature of the data, it is difficult to infer 
whether the cause of acute renal impairment in these cases were metformin-
related (i.e. toxicity) or metformin-independent. To better investigate the 
relationship between metformin therapy and renal impairment, it would be ideal 
to have a temporal series of pre-admission and post-admission estimates of renal 
function, as this would provide an insight on whether the cases’ renal function 
were stable or deteriorating prior to admission; unfortunately, such information 
was rarely reported. Information regarding compliance to metformin therapy 
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was limited and hence, it was assumed that the cases were taking metformin as 
prescribed. Similarly, the time of last metformin ingestion relative to hospital 
admission was commonly not reported.  
To account for the lack of consistency in the data presented in the case 
histories a sensitivity analysis was conducted, where the causality assessment 
results were re-analysed when case histories of poor quality (i.e. those with low 
completeness scores) were excluded.  
It is important to note that the estimates of renal function reported in the 
published cases were measured several years to days prior to the development 
of lactic acidosis. Indeed, in the majority of cases it was unknown when renal 
function was measured relative to hospital admission. 
2.8. Conclusion 
Metformin was found to play only a possible role in the majority of 
published metformin associated lactic acidosis cases at therapeutic doses. 
Almost all cases presented with other risk factors that could on their own have 
led to lactic acidosis. This supports the suggestion that metformin may not play 
a role or only a contributory, rather than a primary role in the development of 
lactic acidosis when used in therapeutic doses.  Traditionally, metformin had 
been contraindicated in patients with chronic kidney disease due to concerns of 
lactic acidosis. However, based on the findings from this study it suggests that 
many patients - particularly those with chronic kidney disease - may be denied 
metformin therapy, an otherwise effective therapy. This highlights the need for 
a formal evaluation of the relationship of between metformin therapy and lactic 
acidosis in patients with chronic renal impairment. 
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3.1. Preamble to the chapter 
In the systematic literature review of published MALA cases presented in 
Chapter 2, it was found that most cases involved other risk factors for lactic 
acidosis. This raises the possibility that metformin therapy may not be the 
primary cause of lactic acidosis in many reported MALA cases. The use of 
metformin in patients with chronic kidney disease (CKD) has traditionally been 
restricted on the grounds that elevated metformin plasma concentrations when 
standard doses are used in this population will increase the risk of lactic acidosis. 
However, this relationship is poorly understood and it can be proposed that 
other risk factors are the primary cause of lactic acidosis in CKD patients.  In this 
chapter, the database of MALA case reports generated in Chapter 2 will be 
interrogated for evidence of a relationship between chronic renal impairment, 
excessive metformin dosing and/or exposure and lactic acidosis. 
3.2. Introduction 
The safe use of metformin in patients with renal impairment is a matter of 
considerable debate. Traditionally, metformin was contraindicated in patients 
with an estimated creatinine clearance (CLcr) of <60 mL/min, but recent 
published guidelines suggest that this can be relaxed to CLcr <30 mL/min, or 
even as low as 15 mL/min [23, 24, 44, 59, 365, 366]. Regardless, there is a lack of 
consensus about the best dosing practice and little understanding of risk 
mitigation [14-16]. 
Metformin is primarily eliminated by the kidneys as unchanged drug so 
the use of standard doses in patients with impaired kidney function will result 
in increased plasma concentrations [19, 27, 29, 30]. Concentrations greater than 5 
mg/L have been postulated to increase the risk of adverse effects, particularly 
lactic acidosis a life-threatening metabolic condition [45, 99]. The term “lactic 
acidosis” is used to characterise the temporally related events of acidosis, 
characterised by a decreased arterial pH to less than 7.35, and hyperlactatemia, 
defined as a plasma lactate concentration of greater than 5 mmol/L [87]. This has 
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led to the wide-spread practice of withdrawing metformin therapy in patients 
with impaired kidney function [367]. However, poor kidney function due to 
diabetic nephropathy is a common comorbidity with Type 2 diabetes so many 
patients may be denied an otherwise effective therapy. In addition, the risk of 
lactic acidosis due to elevated plasma concentrations could be mitigated, in 
theory, with dose reduction based on an understanding of how metformin 
exposure is altered by reduced renal function. 
The relationship between chronic renal impairment, metformin dose 
and/or exposure and the development of lactic acidosis is poorly understood. A 
systematic review of published care reports to explore causality in these cases 
has not been conducted. 
3.3. Objectives 
The aims of this work were to; (i) formally evaluate the role of metformin 
therapy in the development of lactic acidosis in CKD patients reported in 
published case reports and (ii) explore the relationship between prescribed 
metformin doses, steady-state metformin plasma concentrations, and the 
development of lactic acidosis in CKD patients. 
  




3.4.1. Database source 
The case histories used in this analysis were sourced from the database of 
MALA cases generated in Chapter 2. In brief, the database was generated 
following a systematic literature review performed to identify cases of MALA. 
Relevant case histories were identified from Ovid MEDLINE (Ovid MEDLINE 
1946 to July 2017), Ovid EMBASE (Ovid EMBASE 1946 to July 2017), Google 
Scholar (to May 2017) and SCOPUS (to May 2017). Studies were included if the 
publication reported (i) prior metformin ingestion, (ii) a diagnosis of lactic 
acidosis and (iii) relevant laboratory investigations (e.g. pH). Studies were 
excluded if they (i) were not in English, (ii) were not a human study, (iii) 
involved an acute metformin overdose, and, (iv) only reported summary data 
from multiple cases. Note that case reports that involved an acute metformin 
overdose were excluded as the purpose of this study was to understand non-
overdose cases (i.e. the development of lactic acidosis in cases with chronic renal 
impairment prescribed therapeutic doses of metformin). 
3.4.2. Case selection from the metformin associated lactic acidosis database 
For the purposes of this analysis cases with a reported history of CKD prior 
to hospital admission for MALA were identified using the following criteria; (i) 
if pre-existing chronic renal impairment was reported as a comorbidity 
(regardless of the reported estimate of renal function), and/or, (ii) if pre-
admission CLcr or estimated glomerular filtration rate (eGFR) was less than 60 
mL/min or 60 mL/min/1.73m2, respectively.  
3.4.3. Data extraction 
The database comprised demographic and clinical data extracted from each 
identified case of MALA. The following data were extracted from the database: 
article details (year of publication, author, title), demographic information (age, 
sex, weight, height and ethnicity), medical history (presenting complaints, 
diagnosis on admission, comorbidities, concomitant medications and dose, 
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surgical/hospitalisation history), metformin therapy related information 
(metformin maintenance dose, duration of metformin therapy to onset of lactic 
acidosis, metformin plasma concentrations), laboratory measurements (arterial 
blood gases, estimates of renal function (any estimate of glomerular filtration 
rate (GFR), including CLcr or reported eGFR), and, plasma or serum 
concentrations of lactate, electrolytes (sodium, potassium, bicarbonate and 
chloride ions), creatinine, glucose and glycated haemoglobin (HbA1c), 
urea/blood urea nitrogen, concentrations of any concomitant intoxicants), 
identified risk factors for lactic acidosis, medical interventions and patient 
outcome.  
3.4.3.1. Independent risk factors for lactic acidosis 
Pre-existing risk factors that are reported to increase the risk of developing 
lactic acidosis, other than metformin therapy, were extracted from each of the 
published cases. The risk factors were categorised as; (i) acute 
(presenting/diagnosis on admission), (ii) chronic (diagnosis of condition prior 
to admission) or (iii) acute on chronic (exacerbation of a chronic condition) at 
presentation. The list of risk factors is presented in Appendix A1.2. 
3.4.3.2. Renal function metrics 
In the absence of reported data in the case reports about body surface area, 
weight or height pre-admission CLcr and eGFR were considered to be 
interchangeable. 
In the database the estimates of renal function were reported in: cc/min, 
L/week, mL/s, mL/min and mL/min/1.73m2. The units for the estimates of 
renal function were converted to mL/min and mL/min/1.73m2 as follows: 
• mL/s to mL/min: estimate of renal function multiplied by 60 
• cc/min was assumed to be equal to mL/min 
• L/week to mL/min: estimate of renal function multiplied by 0.099 
For cases that did not report pre-admission CLcr or eGFR, these metrics 
were calculated using the Cockcroft and Gault equation [80] and CKD-Epi 
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equation [83] respectively provided the publication reported the required 
demographic and laboratory data (e.g. pre-admission serum creatinine, weight, 
sex, age etc).  
3.4.4. Data Analysis 
3.4.4.1. Summary description of cases 
The demographics and clinical presentation of MALA cases identified from 
the database were summarised and tabulated.  
3.4.4.2. Completeness score 
A completeness score was developed to assess the quality and availability 
of data in each case history first introduced in this thesis in Chapter 2 (section 
2.4.4.3.). Each case history was assessed using the completeness score and 
assigned a score based on the availability of data for analysis. A maximum score 
of 31 was possible. The completeness score developed was an adaptation of the 
quality scoring tool published by Stades et al [108]. 
3.4.4.3. Causality assessment 
The role of metformin therapy in the development of lactic acidosis in the 
MALA cases with a history of chronic renal impairment was assessed using the 
World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) system 
for standardised case causality assessment [106] and the Naranjo adverse drug 
reaction (ADR) probability scale [107]. For the purposes of this study, the WHO-
UMC causality assessment was adapted with lactic acidosis specific diagnostic 
criterion to allow for the replicability of the results. The adapted WHO-UMC 
causality assessment tool is presented in Appendix A1.3. The Naranjo ADR 
probability scale was used verbatim reproduced in Appendix A1.4 (Table A1.9).  
A sensitivity analysis was performed to assess the influence of poor quality 
case histories on the causality assessment. Cases with a completeness score of 10 
or lower were excluded and the results of the causality assessment were re-
analysed and compared to the full cohort of cases. 
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3.4.4.4. Compliance to recommended renal dosing guidelines 
The metformin doses reported in the MALA cases with renal impairment 
were compared to current renal dosing guidelines from the European Medicines 
Agency (EMA) assessment report and the New Zealand datasheet (derived from 
Duong et al 2013) [15, 368]. Here, the New Zealand datasheet was selected to 
represent a local renal dosing guideline, whilst the EMA assessment report was 
selected to represent an international renal dosing guideline. In addition, the 
New Zealand datasheet was selected as it was the least conservative guideline at 
the lower end of renal function (down to a CLcr or 15 mL/min), whilst the EMA 
guideline was selected as it was the least conservative guideline at the upper end 
of renal function.  
3.4.4.5. Predicted pre-admission metformin plasma concentrations 
Pre-admission steady state plasma concentrations were not available for 
any cases in the MALA database, although several publications reported 
measured metformin plasma concentrations once the patient had been admitted 
to hospital. MALA is often accompanied by a rapidly developing acute kidney 
injury. Therefore, the metformin plasma concentrations measured at the time of 
admission may be elevated due to an acute decline in kidney function. The goal 
of the analysis conducted here is to understand whether steady-state plasma 
concentrations, prior to admission and the development of acute kidney injury, 
were elevated and therefore contributed to the risk of lactic acidosis. In other 
words, to predict what metformin plasma concentrations would have been when 
the patient was well.  
Pre-admission steady-state metformin plasma concentrations were 
predicted from a population pharmacokinetic model for metformin published 
by Duong et al [15]. Details of the model and the parameter estimates used for 
the simulations are summarised in Appendix A2.1. The model was implemented 
in MATLAB (R2016b, MathWorks, Natick, NA) and predictions were compared 
to the predicted plasma concentrations reported by Duong et al to ensure 
replicability.  
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Deterministic simulations to predict the steady-state trough (Cp,ss,trough), 
average (Cp,ss,ave) and peak (Cp,ss,max) concentration at day 20 were conducted for 
each MALA case with the following information available; the prescribed dose 
of metformin, the patients’ body weight, and the estimated pre-admission CLcr 
or eGFR. Missing body weight was imputed at the median for the MALA 






Equation 3.1 Formula to calculate Cp,ss,ave 
 
Here, 𝐷𝑜𝑠𝑒 represents the metformin dose used in the simulations, 𝐶𝐿 represents 
clearance of metformin in units of L/h, and, 𝐷𝐼 stands for dose interval and is 
the time difference between doses in hours. For cases that did not report 
information on metformin dosing frequency (i.e. only reported the total 
prescribed daily dose of metformin), each dose was assumed to be dosed twice 
or thrice daily based on reasonable division of the reported daily dose by 
available metformin tablet strengths. For example, a metformin dose of 2550 mg 
was divided into individual doses of 850 mg taken three times daily. The 
proportion of patients with steady state trough, average and peak concentrations 
prior to the development of MALA >5 mg/L (i.e. a concentration reported to be 
associated with increased risk of lactic acidosis) were determined [99, 369]. Cases 
were stratified into those with an estimated renal function of <60 mL/min and 
≥60 mL/min and a boxplot was drawn using R (version 3.3.3).  
  




3.5.1. Identified cases 
A total of 145 cases with a reported history of chronic renal impairment or 
CLcr/eGFR <60 mL/min (or 60 mL/min/1.73m2) were identified from the 
database.  
3.5.2. Description of metformin associated lactic acidosis cases with chronic 
renal impairment 
A description of the MALA cases with a history of chronic renal 
impairment is presented in Table 3.1. On admission 119 of the 145 (82%) cases 
presented with documented acute renal impairment. 
The median prescribed dose of metformin was 1700 mg. Metformin had 
been taken for a median of 4 months prior to admission for lactic acidosis. The 
median arterial pH on admission was 6.97 (range: 6-7.36), and, the median lactate 
concentration on admission was 13.5 mmol/L (range: 1.1-60.0).  
The median reported pre-admission estimates of renal function (CLcr or 
eGFR) were 32 in units of mL/min (range: 20-91 mL/min) and 43 
mL/min/1.73m2 (range: 8-92 mL/min/1.73m2). On admission, the median 
estimate of renal function was 36 mL/min (only 2 patients) and 8 
mL/min/1.73m2. 
A total of 64 cases reported metformin plasma concentrations. In all cases, 
the concentrations were measured on admission when many of the patients 
would be expected to be in acute renal failure. This is reflected in the data where 
a median concentration of 31 mg/L (range: 1.5-105 mg/L) was recorded. In some 
cases, repeated metformin plasma concentrations were measured during the 
course of the hospital admission to determine the impact of dialysis and other 
interventions. A plot of the reported time course of metformin plasma 
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Table 3.1 Demographics and clinical data for MALA cases with pre-existing chronic 
renal impairment 
  Cases with reported data (n = 145) 
Demographics   
     Gender (F:M) 90: 50 140 
     Age (years) 
71 [42 – 89] 
(65 - 76) 
143 
     Weight (kg) 
75.5 [46 – 94] 
(53.5 – 79.3) 
14 
     Height (m) 
1.62 [1.44 – 1.70] 
(1.51 – 1.67) 
10 
     BMI (kg/m2) 
29 [17 – 30] 
(28.3 – 30.0) 
5 
Metformin   
     Dose (mg/day) 
1700 [500 – 6000] 
(1500 - 2500) 
117 
     Therapy duration (months) 
4 [0.1 - 204] 
(0.5 – 48.0) 
19 
Key laboratory values pre-admissiona 
Renal function   
     in mL/min 
32 [20 – 91] 
(22.8 – 49.8) 
10 
     in mL/min/1.73m2 
43 [8 – 92] 
(33.8 – 50.5) 
40 
Creatinine (μmol/L) 
134 [56 – 1057] 
(108 – 173) 
93 
Key laboratory values after admission for lactic acidosisb 
Renal function   
     in mL/min 
36 [35 – 37] 
(35.5 – 36.5) 
2 
     in mL/min/1.73m2 
8 [3 – 38] 
(6 – 29.7) 
19 
     Creatinine (μmol/L) 
585 [90 – 1502] 
(327 – 761) 
133 
     Lactate concentration (mmol/L) 
13.5 [1.1 – 60.0] 
(9.2 – 20.0) 
131 
     pH 
6.97 [6.00 – 7.36] 
(6.8 – 7.14) 
130 
     Metformin (mg/L) 
31 [1.5 – 105] 
(15.3 – 45.3) 
64 
Data presented as median [range] (interquartile range) unless otherwise specified. Renal function 
is a mixture of CLcr and eGFR. aIn the case where there were multiple reported pre-admission 
values the most recent results were used. bThe on-admission values are the first laboratory results 
analysed when cases were admitted to a clinic and do not include repeated measures. CLcr/ GFR 
was not calculated for cases that did not report renal function but had reported serum creatinine 
as the cases commonly lacked other demographic data required for calculation (e.g. age, weight).  




Figure 3.1 Plasma metformin concentration from metformin associated lactic acidosis 
cases. The dots represent single measures of plasma metformin concentration and the 
lines link repeated measures data for a single case. 
3.5.3. Causality assessment 
In the published cases of MALA with chronic renal impairment, the WHO-
UMC system for standardised case causality assessment categorised metformin 
as a ‘certain’ cause of lactic acidosis in none of the cases, ‘probably/likely’ in 1 
case (0.7%), ‘possible’ in 130 cases (89.7%), ‘conditional/unclassified’ in 10 cases 
(6.9%) and ‘unassessable/unclassifiable’ in 4 cases (2.8%). Using the Naranjo 
ADR probability scale metformin was categorised as ‘probable’ in 2 cases (1.4%), 
‘possible’ in 143 cases (98.6%) and doubtful in none of the cases. Results from the 
sensitivity analysis showed no significant difference in the results when case 
histories with completeness scores of 10 or less were included in the causality 
assessment. A summary of the causality assessment results using the WHO-
UMC system and Naranjo ADR probability scale is presented in Table 3.2.  
Results from the completeness score are summarised in Appendix A2.2. 
 
Chapter 3: Chapter 1: Metformin therapy, renal impairment and lactic acidosis 
 90 
 
Table 3.2 Summary of the WHO-UMC system and Naranjo ADR scale causality 
assessment results 
Causality assessment Causality category 
Cases 
(n = 145) 
Sensitivity analysis 
(n = 125) 
WHO-UMC system 
Certain - - 
Probably/Likely 1 (0.7%) 1 (0.8%) 
Possible 130 (89.7%) 114 (91.2%) 
Unlikely - - 
Conditional/Unclassified 10 (6.9%) 8 (6.4%) 
Unassessable/Unclassifiable 4 (2.8%) 2 (1.6%) 
Naranjo ADR scale 
Definite - - 
Probable 2 (1.4%) 2 (1.6%) 
Possible 143 (98.6%) 123 (98.4%) 
Doubtful - - 
3.5.4. Compliance to recommended renal dosing guidelines 
Of 145 MALA cases with chronic renal impairment, only 50 included the 
prescribed metformin dose as well as an estimate of renal function (i.e. CLcr or 
eGFR) from prior to admission. Compliance of metformin prescribing to 
guidelines proposed by the EMA and Duong et al is presented in Table 3.3 [368, 
370]. All prescribed doses aligned with the renal dosing guidelines in cases 
whose estimated CLcr or eGFR was equal or greater than 60 mL/min. However, 
with increasing severity of renal insufficiency approximately 50% of the cases 
received doses that exceeded the recommended dose. The prescribed doses 
exceeded the recommended dose by a median of 1500 mg for the EMA guideline 
and 1000 mg according to the guideline proposed by Duong et al (Table 3.4). 
Please note that some of the MALA cases were included in the analysis despite 
having an eGFR >60 mL/min, as these cases had been included on the basis of 
having reported a history of CKD despite having an eGFR >60 mL/min. 
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Table 3.3 Compliance of prescribed metformin dose to renal dosing guidelines by EMA 
and Duong et al 










>59 3000 4 (8%) - 
45-59 2000 13 (26%) 6 (12%) 
30-45 1000 3 (6%) 12 (24%) 
<30 Contraindicated - 12 (24%) 
Duong et al 
90-120 3000 2 (4%) - 
60-90 2000 1 (2%) - 
30-60 1000 6 (12%) 29 (58%) 
15-30 500 - 10 (20%) 
<15 Contraindicated - 2 (4%) 
 
Table 3.4 Quantity of dose prescribed exceeding the renal dosing guidelines by EMA 
and Duong et al 
Amount of dose exceeding the 
renal dosing guidelines (mg) 
Guideline 
 EMA (n = 30) Duong et al (n = 41) 
0 – 500 3 7 
>500 – 1000 11 16 
>1000 – 2000 12 14 
>2000 – 3000 3 3 
>3000 1 1 
3.5.5. Predicted pre-admission steady-state metformin plasma 
concentrations 
Predictions from the metformin pharmacokinetic model aligned with the 
plots produced by Duong et al suggesting that the model was implemented 
correctly and replicated published predictions (details can be found in Appendix 
A2.3). 
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Pre-admission metformin steady state concentrations were predicted for 50 
cases, all with recorded metformin doses and estimates of pre-admission renal 
function available. The median age of the 50 cases was 72 years (range: 54-89) 
with two-thirds of the cases being female. Weight was not reported for 46 cases 
and hence was imputed as the median weight for the MALA cases. The results 
from the simulations are summarised in Table 3.5. 
Table 3.5 Summary of simulated metformin plasma concentration 
Metformin plasma concentration (mg/L) Median [range] 
Cp,ss,maxa 3.33 [1.41-8.77] 
Cp,ss,ave b 2.75 [0.64-8.20] 
Cp,ss,troughc 1.38 [0.17-6.49] 
aCp,ss,max: maximum plasma concentration at steady state, b Cp,ss,ave: steady state average plasma 
concentration, c Cp,ss,trough: trough plasma concentration at steady state 
 
The results from the simulations indicate that 94% of the MALA cases are 
predicted to have trough plasma metformin concentrations below 5 mg/L. 
Furthermore, it is predicted that 86% and 80% of cases would have steady state 
average and peak concentrations below 5 mg/L, respectively. 
The predicted pre-dose metformin plasma concentrations are shown in 
Figure 3.2. When stratifying cases based on their renal function, it can be seen 
that cases with an estimated renal function less than 60 mL/min had higher 
predicted steady-state pre-dose concentrations in comparison to cases with 
estimates of renal function greater than 60 mL/min whose plasma 
concentrations were all below 1 mg/L.   
 




Figure 3.2 Boxplot of simulated pre-admission plasma metformin concentrations for 50 
cases whom had their prescribed metformin dose and estimate of renal function from 
prior to admission available for analysis. Cases were stratified into two groups based on 
renal function: cases with an estimate of renal function of less than 60 mL/min and 
cases with an estimate greater than and equal to 60 mL/min. 
  




In this study, metformin was found to be a ‘possible’ cause of lactic acidosis 
in 90 percent of metformin associated lactic acidosis cases with chronic renal 
impairment. Interpretation of the causality term ‘possible’ is analogous for both 
causality algorithms, depicting a scenario where metformin played a possible 
role in the development of lactic acidosis however, there were other equally 
likely risk factors present in the cases that could have also led to the adverse 
event. In this study, almost all cases presented with acute renal impairment on 
admission, complicating any ability to assess the cause and effect relationship 
between metformin therapy, chronic renal impairment and lactic acidosis. 
However, in this study, it is worth noting that it is impossible to score 
‘doubtful’ when using the Naranjo ADR scale. This is because all MALA cases 
identified from the database would score positively on the questionnaire for 
firstly having taken the drug (i.e. metformin) and secondly, having objective 
evidence for lactic acidosis (e.g. pH and lactic acid concentrations). If the scores 
assigned for these two questions had been removed and the probability 
categories re-assigned it is likely that the finding that metformin played a 
‘possible’ role can be interpreted instead as ‘doubtful’. If consequently 
metformin was found to be a ‘doubtful’ cause, this would then be interpreted 
that the event of lactic acidosis was likely to be related to factors other than 
metformin. 
Comparison of the prescribed metformin dose relative to published renal 
dosing guidelines found that cases with moderate to normal renal function (i.e. 
>60 mL/min/1.73m2) received doses within the dosing guidelines whilst, in 
cases with impaired renal function (i.e. <60 mL/min/1.73m2), an increasing 
proportion received doses above the dosing guidelines. Based on the results 
from the simulations, the steady state pre-dose plasma metformin concentrations 
prior to admission would not have exceeded 5 mg/L in the majority of patients 
who developed lactic acidosis, however, it is worth noting that the predicted pre-
dose concentrations were about two times higher than reported in the literature 
[15, 45, 371]. When stratifying the predicted pre-dose, steady-state 
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concentrations by renal function, it can be seen that cases with good renal 
function (i.e. >60 mL/min) all had pre-dose metformin concentrations below 1 
mg/L, however, for cases with poor renal function (i.e. <60 mL/min) the pre-
dose steady-state concentrations were much higher. It is unknown what the 
reason is for this, but it could possibly be a result of the inappropriate renal 
dosing observed in this cohort. These findings suggest that if the recommended 
renal dose adjustments had been applied the predicted concentrations would lie 
within the proposed upper limit of 5 mg/L in the cases with poor renal function. 
In addition, it is worth noting that the results from our simulations are 5-10 
fold less than the metformin plasma concentrations observed in the cases 
reported to have stable chronic renal impairment on admission for lactic 
acidosis. This is suggestive that there may be other underlying processes 
simultaneously occurring in these cases that are yet to be explored. A possible 
explanation is that these cases had acute renal impairment on admission for 
lactic acidosis, however this was not reported in the case report. It is also possible 
that the simulations performed excluded cases with extremely low clearance and 
hence did not represent the MALA cases with chronic renal impairment.  
In patients with renal impairment on metformin therapy, it has been 
proposed that the initial trigger leading to lactic acidosis may be acute renal 
failure. This being the case, acute renal failure will result in the increase in 
metformin concentrations [372]. The upper end of the therapeutic range for 
metformin is usually considered to be 5 mg/L, although a recently revised upper 
limit of 2.5 mg/L has been proposed [45, 369]. The majority of published cases 
reviewed in this study reported plasma metformin concentrations that were 
much greater than 5 mg/L on admission with concomitant acute renal 
impairment. It is unclear if the excessive metformin plasma concentrations 
observed on admission led to the acute renal impairment, or the acute renal 
impairment led to metformin accumulation (or indeed a combination of both). 
In the former, unadjusted doses of metformin in patients with poor renal 
function might be implicated as the primary risk factor for lactic acidosis. The 
mechanism for this has been proposed to be due to metformin intoxication 
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leading to symptoms of gastroenteritis, dehydration and/or circulatory collapse, 
and, acute renal failure, respectively [18, 373]. In the latter, metformin is more 
likely to be an innocent bystander. Similar findings have been reported in the 
literature where many cases presenting with MALA had often presented with 
acute renal impairment on admission [272, 372, 374].  
Results from this study suggest that pre-admission plasma concentrations 
would be below the proposed upper limit of the therapeutic range of 5 mg/L 
and the revised upper limit of 2.5 mg/L in the majority of cases. This is despite 
the use of doses in excess of those recommended by current guidelines proposed 
by the EMA and Duong et al. The overarching impression is that metformin use 
in patients with renal impairment, even at doses 1000-1500 mg above the 
recommended doses, is not expected to produce excessive accumulation of pre-
dose concentrations and may therefore not be the primary cause of lactic acidosis 
in the published cases. This conjecture is supported by the causality assessment 
where most cases were found to have other risk factors for lactic acidosis (results 
shown in Chapter 2). Therefore, future work on quantifying an upper 
therapeutic limit for metformin is necessary to help guide renal drug dosing. 
Metformin has been shown to be tolerated in patients with severe renal 
impairment (i.e. CLcr of 20 mL/min) and in patients on dialysis [371, 375]. 
Current metformin renal dosing guidelines worldwide lack agreement and 
informative advice on how to safely dose metformin in renal impairment. Some 
guidelines state that metformin therapy should be contraindicated in renal 
impairment, whilst others advise to ‘review the dose’, ‘reassess the benefit to 
risk’, ‘caution’, ‘referral to a nephrologist’, a dose adjustment or no dose 
adjustment [23, 45, 60, 376, 377]. It has been reported that up to 19% of patients 
prescribed metformin have a renal contraindication to the drug [136, 213, 233, 
378-382]. Therefore, research to determine the safe dosing of metformin in renal 
impairment is warranted.  
  




Due to the retrospective nature of the data it is difficult to infer whether the 
cause of acute renal impairment in these cases was metformin-related (i.e. 
toxicity) or metformin-independent. To better investigate the relationship 
between metformin therapy and renal impairment, it would be ideal to have a 
temporal series of pre-admission and post-admission estimates of renal function, 
as this would provide an insight on whether the cases’ renal function were stable 
or deteriorating prior to admission; unfortunately, such information was rarely 
reported. In addition to this, it is important to note that the reported estimates of 
renal function in the case reports ranged from being measured several years to 
days prior to the development of lactic acidosis, and, in the majority of cases it 
was unknown when the estimate of renal function was estimated. Similarly, it is 
worth noting that the cases with reported estimates of renal function from prior 
to and on admission for lactic acidosis are not necessarily the same.  
Data reported in case reports is inconsistent and lacking. For instance, of 
the 145 MALA cases with CKD only 14 cases had reported weight. This was a 
limitation in the simulations performed to predict what pre-admission steady 
state plasma concentrations would have been prior to admission for lactic 
acidosis as weight had to be imputed for 46 cases.  
3.8. Conclusion 
Metformin played a possible role in 90% of the metformin associated lactic 
acidosis cases with renal impairment. Most cases presented with acute renal 
failure, confounding the relationship between metformin dose and plasma 
concentration. The prescribed metformin dose exceeded the dosing 
recommendations in more than 60% of cases with an eGFR of <60 mL/min by a 
median amount of 1000 mg/day. Despite this finding, the predicted pre-
admission metformin plasma concentrations measured pre-dose did not exceed 
the proposed upper limit of the therapeutic range of 5 mg/L in most cases, 
suggesting that chronic renal impairment is not the cause of metformin 
accumulating to high concentrations.  










Chapter 4:  The relationship between metformin 




















This chapter is based on the following peer-reviewed publication: 
Kuan IHS, Wright DFB, Duffull SB, Zhu X (2020). Understanding the association 
between metformin plasma concentrations and lactate. Br J Clin Pharmacol. doi: 
10.1111/bcp.14394. 
 




There is concern that patients with renal impairment who are prescribed 
metformin therapy may be at an increased risk of developing lactic acidosis. This 
is due to the fear that, if standard doses are used, the reduced metformin 
elimination in this patient group would lead to elevated plasma concentrations 
and an increased risk of lactic acidosis. In theory, dose reduction along with 
plasma metformin concentration monitoring to ensure that concentrations do 
not exceed a safe upper limit should help mitigate the risk of lactic acidosis in 
patients with renal impairment.  However, little is known about the relationship 
between metformin plasma concentrations and the risk of lactic acidosis. 
Metformin is recognised to cause lactic acidosis when taken in acute overdose 
[12, 63]. However, when used in therapeutic doses for type 2 diabetes there is a 
growing body of evidence to suggest that metformin may not be the primary 
cause of lactic acidosis [108, 353] - as was found in Chapter 2 and 3 of this thesis. 
Nonetheless, a better understanding of the relationship between plasma 
metformin concentrations and the risk of lactic acidosis will help guide dosing 
to mitigate the risk of lactic acidosis to patients prescribed metformin therapy. 
4.2. Objectives 
The aims of this work were to (i) determine the current consensus on the 
upper limit of safety for plasma metformin concentrations in the published 
literature and (ii) to quantitatively explore the relationship between plasma 
metformin concentrations and plasma lactate concentrations using data from 
published case reports. In this work, plasma lactate concentrations are used as a 
marker of lactic acidosis risk. This will be discussed further in the discussion. 
The metformin concentration associated with severe hyperlactatemia is assumed 
to define the upper limit of safety for metformin.  
  




4.3.1. Literature review to clarify the upper limit of safety for plasma 
metformin concentrations 
4.3.1.1. Data source 
A literature search was conducted to clarify the upper limit of safety for 
plasma metformin concentrations. The literature review was conducted using a 
static search performed in Ovid MEDLINE (1946 to March 2020) and Ovid 
EMBASE (1946 to March 2020). The search was performed in Ovid MEDLINE 
using the Medical Subject Heading (MeSH) terms; ‘Metformin’, ‘Acidosis, 
Lactic’, ‘Dose-Response Relationship, Drug’ and keywords ‘therapeutic 
concentration’, ‘therapeutic limit’ and ‘toxic concentration’. In Ovid EMBASE the 
search was performed using the MeSH terms; ‘Metformin’, ‘Lactic acidosis’, 
‘Dose response’ and keywords ‘upper limit’, ‘therapeutic concentration’, 
‘therapeutic limit’ and ‘toxic concentration’. The Boolean operators ‘AND’ and 
‘OR’ were used to search for relevant literature. Details of the static search 
strategy is shown in Appendix A3.1. The search was limited to studies conducted 
in humans and those published in the English language. Duplicate articles 
sourced from the databases were removed. 
The sourced articles were initially screened by study title and abstract for 
relevance to metformin and reference to an upper limit of safety for plasma 
metformin concentrations. Relevant screened articles were then eligible for a full 
text review and assessed for inclusion and exclusion. Studies were included if 
there was a reported upper limit of safety for plasma metformin concentrations. 
Studies were excluded if they: (i) were not human studies and (iii) were not 
written in the English language. 
4.3.1.2. Data extraction 
The following data were extracted from each article; publication details 
(author(s), year of publication), reported upper limit of safety for plasma 
metformin concentration, and, whether the study had defined the upper safety 
limit by means of a formal analysis (e.g. exposure-response study). 
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4.3.2. Quantitative analysis of metformin and lactate plasma concentrations 
from published reports 
4.3.2.1. Data source 
A retrospective analysis of plasma metformin and lactate concentrations 
extracted from published case reports and research studies was conducted. The 
data were derived from two primary sources: 
1. An observational study conducted by Duong et al [371] 
investigating the plasma concentrations of metformin and lactate in 
type 2 diabetic patients with chronic renal impairment who were 
taking therapeutic doses (i.e. between 250-2000 mg daily) of 
metformin. No patients in this cohort developed lactic acidosis. 
2. A database of metformin associated lactic acidosis (MALA) cases 
derived from case reports in Chapter 2 of this thesis. All patients in 
these case reports presented with or developed lactic acidosis. Only 
cases that had ingested an intentional overdose of metformin were 
extracted and included in the analysis. Non-overdose cases were 
excluded from the analysis to avoid the potential of other risk factors 
reported in the case reports (e.g. renal impairment and heart failure 
as identified in Chapter 2) being the cause of the elevated metformin 
and/or lactate concentrations.  
Note that the analysis was conducted using data from metformin overdose and 
non-overdose cases. 
4.3.2.2. Data selection 
All paired metformin and lactate concentrations from the observational 
study by Duong et al were included in the analysis. Concentration data from this 
cohort of patients represented the typical patient population taking metformin 
for therapeutic uses. 
Data extracted from cases in the published database were included if there 
were (i) paired metformin and lactate concentrations, (ii) no interventions (e.g. 
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renal replacement therapy) that could alter metformin and lactate concentrations 
prior to measurement, (iii) patient-level data (summary data was not analysed), 
(iv) the case had ingested an overdose of metformin, and, (v) metformin and 
lactate concentrations were measured on admission. Data from the database 
were excluded if the metformin and lactate concentrations did not have reported 
measurement units. 
4.3.2.3. Data extraction 
Metformin and lactate concentrations were extracted from cases in the 
published database that met the inclusion criteria. Data provided in graphical 
form were extracted using the MATLAB (R2016b, MathWorks, Natick, MA) 
script GRABIT. 
4.3.2.4. Data analysis 
Data sourced from the paper by Duong et al [371] and the published MALA 
database were combined, and, the data analysed by fitting a concentration-
response (𝐸𝑚𝑎𝑥) model with baseline. A sigmoidal 𝐸𝑚𝑎𝑥model with baseline was 
also tried. Here plasma metformin concentration was the independent variable 
and plasma lactate the response variable. The 𝐸𝑚𝑎𝑥 and sigmoidal 𝐸𝑚𝑎𝑥 models 
with baseline are shown in Equation 4.1 and Equation 4.2 respectively, as 
follows; 
 
𝐸 = 𝐸0 +
(𝐸𝑚𝑎𝑥 − 𝐸0) ∙ 𝐶
𝐸𝐶50 + 𝐶
 
Equation 4.1 The Emax  model with baseline 
 
𝐸 = 𝐸0 +





Equation 4.2 The sigmoidal Emax  model with baseline 
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where, 𝐸  represents lactate concentration (mmol/L), 𝐸0 is the basal lactate 
concentration in the absence of metformin (mmol/L), 𝐸𝑚𝑎𝑥  is the maximum 
lactate concentration (mmol/L), 𝐸𝐶50 is the concentration of metformin (mg/L) 
at which the drug produces half its maximum effect, 𝐶  is the observed 
concentration of metformin (mg/L) and 𝜆 is the Hill coefficient. Note that the 
basal lactate concentration was estimated in both the 𝐸𝑚𝑎𝑥 and sigmoidal 𝐸𝑚𝑎𝑥 
models with baseline. The 𝐸𝑚𝑎𝑥 and sigmoidal 𝐸𝑚𝑎𝑥 models with baseline were 
compared for fit based on: (i) visual inspection of the model fit to the data and 
(ii) the biological plausibility of parameter estimates.  
A naïve pooled analysis was conducted using NONMEM v7.4 (ICON 
Development Solutions, Hanover, MD, USA). In brief, a naïve pooled approach 
involves pooling all data available together as if the data were collected from a 
single individual or each observation were obtained from different individuals, 
refer to Chapter 1 (section 1.1.4.1.) for more information. Note a naïve pooled 
analysis was used to analyse the data because there were repeated paired 
metformin and lactate concentration data extracted from the publication by 
Duong et al that was not patient identifiable. The first-order (FO) estimation 
method was used. Pre- and post- processing was conducted using R (version 
3.5.3) to manipulate the data into a NONMEM readable form and for plotting 
graphs.  
For the purposes of this analysis it was assumed that blood lactate and 
plasma lactate concentrations were interchangeable. The difference between 
blood and plasma lactate concentrations have been shown to be negligibly 
different at rest (ratio 1:1) [383, 384]. 
The median and 95% confidence interval (CI) of plasma metformin 
concentrations associated with hyperlactatemia and severe hyperlactatemia 
were predicted from the models. Hyperlactatemia was defined as a lactate 
concentration of >2 mmol/L and severe hyperlactatemia was defined as a lactate 
concentration of >5 mmol/L (considered the lower limit for the diagnosis of 
associated acidosis). 
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4.3.3. Quantitative analysis of metformin and pH from published reports 
The concentration-response relationship between plasma metformin 
concentrations and pH was conducted using data extracted from the published 
database of MALA cases [385]. All paired metformin and pH concentrations 
were extracted from the database and included in the analysis if there was: (i) no 
intervention made that could affect the plasma metformin concentrations and 
pH, (ii) patient-level data, (iii) the case had ingested an acute overdose of 
metformin and (iv) the plasma metformin concentration and pH had been 
measured on admission. The extracted plasma metformin concentrations and 
pH data were analysed by fitting an 𝐸𝑚𝑎𝑥  and sigmoidal 𝐸𝑚𝑎𝑥  model with 
baseline (as described in section 4.3.2.4.). The median and 95% CI of plasma 
metformin concentrations associated with acidosis (i.e. pH <7.35) were predicted 
from the models.  
  




4.4.1. Literature review 
4.4.1.1. Identified literature 
The search identified a total of 173 articles. Duplicate articles were removed 
and a total of 161 articles were screened. Only 30 of the 161 screened articles were 
subject to a full-text analysis. Following the full-text analysis, 25 articles were 
excluded for the following reasons: no reference to an upper limit of safety for 
metformin (n=21) and article could not be accessed or located (n=4). Five articles 
met the inclusion criteria and were included in the literature review. A schematic 
of the workflow for the literature review is presented in Figure 4.1.  
 
 
Figure 4.1 Flow diagram for the literature review 
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4.4.1.2. Upper limit of safety for plasma metformin concentration 
A total of 5 articles reported an upper limit of safety for plasma metformin 
concentration (Table 4.1). The reported upper limit of safety for plasma 
metformin concentrations was reported to range from 2 to 5 mg/L [122, 386-389]. 
However, none of the identified articles conducted a formal analysis to support 
these values. It remains unclear how this safety limit had been defined.  
Table 4.1 Summary of reported upper safety limit for plasma metformin concentration 
in the published literature 
Author Year Ref 
Study conducted an 
analysis to define 
upper limit (Y/N) 
Upper safety limit for 
plasma metformin 
concentration (mg/L) 
Carland et al 2018 [386]  N 5 
Gil et al 2018 [387] N 5 
Goo et al 1996 [388] N 5 
Zoppellari et al 2013 [122] N 2 
Zoppellari et al 2019 [389] N 4 
4.4.2. Quantitative analysis of plasma metformin and lactate concentrations 
4.4.2.1. Data source 
Data were extracted from 24 patients in the publication by Duong et al and 
31 case histories were identified from the published MALA case report database. 
A flowchart of the inclusion and exclusion process for the cases in the database 
is shown in Figure 4.2. A total of 103 paired metformin and lactate concentrations 
were collected from 55 individuals (demographics shown in Table 4.2). 
 




Figure 4.2 Flow diagram for the inclusion and exclusion criteria of cases identified 
from the published database 
 
Table 4.2 Summary demographic and clinical characteristics of patients 
Demographics 
Duong et al [371] 
(n=24) 
Kuan et al [390] 
(n=31) 
Number of samples 72 31 
Age (years) 73 [51-86] 51 [15-74] 
Weight (kg) 87 [60-126] -b 
Metformin dose (mg/day) 1000 [250-2000] 60000 [12750-76500]c 
Lactate concentration (mmol/L)a 1.7 [0.8-5.5]d 14.5 [2.4-39.0] 
Metformin concentration (mg/L)a 1.5 [0.11-4.5] 66.0 [0.3-749.0] 
aLactate and metformin concentrations for cases extracted from the database were those 
measured on admission. bNo cases from the database reported weight. cThe ingested metformin 
dose was only available in 11 cases from the database. dNote that 18 lactate concentrations from 
the study by Duong et al met the criteria for hyperlactatemia (lactate >2 mmol/L). 
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4.4.2.2. Metformin and lactate concentration-response curve 
The 𝐸𝑚𝑎𝑥model provided a reasonable description of the metformin and 
lactate concentration-response curve (Figure 4.3). The model predicted that a 
median plasma metformin concentration of 1.57 mg/L (95% CI: 1.05-2.36 mg/L) 
and 7 mg/L (95% CI: 4.5-10.9 mg/L) was associated with hyperlactatemia and 
severe hyperlactatemia, respectively. Model parameter estimates and relative 
standard errors are presented in Table 4.3.  
The sigmoidal 𝐸𝑚𝑎𝑥 model was also trialled for fit to the metformin and 
lactate data (shown in Figure 4.4). In theory, the sigmoidal 𝐸𝑚𝑎𝑥 should provide 
a better fit to the data due to increased degrees of freedom, however, on visual 
inspection the sigmoidal 𝐸𝑚𝑎𝑥 does not appear to capture the data as well as the 
𝐸𝑚𝑎𝑥 model. The sigmoidal 𝐸𝑚𝑎𝑥  model predicted that a median plasma 
metformin concentration of 3.95 mg/L (95% CI: 2.57-6.08) and 5.6 mg/L (95% CI: 
4.6-6.8 mg/L) was associated with hyperlactatemia and severe hyperlactatemia, 
respectively. Model parameter estimates and relative standard errors for the 
sigmoidal 𝐸𝑚𝑎𝑥 model are shown in Table 4.4. 
The 𝐸𝑚𝑎𝑥 model estimated a reasonable basal plasma lactate concentration 
of 0.96 mmol/L (normal reference plasma lactate range: 0.5-1 mmol/L). 
However, the sigmoidal 𝐸𝑚𝑎𝑥  model estimated a basal plasma lactate 
concentration of 1.69 mmol/L, a value outside the normal plasma lactate 
concentration reference range. These results indicate that the 𝐸𝑚𝑎𝑥 model with 
baseline provided a more reasonable description. However, regardless of 
whether the 𝐸𝑚𝑎𝑥 or sigmoidal 𝐸𝑚𝑎𝑥 model with baseline was used to describe 
the data the lower bound of the 95% CI associated with severe hyperlactatemia 
was approximately 4.5 mg/L. 




Figure 4.3 The relationship between plasma metformin concentrations and lactate. The 
line of best fit from the Emax model is superimposed on the data. The circles and 
triangles in the plot represent data extracted from the study by Duong et al [371] and 
Kuan et al [390], respectively. The blue and red dashed line represents a lactate 
concentration of 2 and 5 mmol/L, respectively. 
 
Table 4.3 Model parameter estimates for the Emax model 
Parameters Definition Estimates [RSE%] 
𝐸𝑚𝑎𝑥 (𝑚𝑚𝑜𝑙/𝐿) Maximum lactate concentration 25.2 [16%] 
𝐸0(𝑚𝑚𝑜𝑙/𝐿) 
Basal lactate concentration in the 
absence of metformin 
0.96 [31%] 
𝐸𝐶50(𝑚𝑔/𝐿) 
Concentration of metformin at which 
it produces half its maximum effect 
34.7 [17%] 
RSE is relative standard error calculated as the standard error divided by the parameter estimate. 
 
 




Figure 4.4 The relationship between plasma metformin concentrations and lactate. The 
line of best fit from the sigmoidal Emax model is superimposed on the data. The circles 
and triangles in the plot represent data extracted from the study by Duong et al [371] 
and Kuan et al [390], respectively. The blue and red dashed line represents a lactate 
concentration of 2 and 5 mmol/L, respectively. 
 
Table 4.4 Model parameter estimates for the sigmoidal Emax model 
Parameters Definition Estimates [RSE%] 
𝐸𝑚𝑎𝑥 (𝑚𝑚𝑜𝑙/𝐿) Maximum lactate concentration 17.7 [10%] 
𝐸0(𝑚𝑚𝑜𝑙/𝐿) 
Basal lactate concentration in the 
absence of metformin 
1.69 [8%] 
𝐸𝐶50(𝑚𝑔/𝐿) 
Concentration of metformin at which 
it produces half its maximum effect 
6.64 [3%] 
𝐻𝑖𝑙𝑙 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡  7.66 [41%] 
RSE is relative standard error calculated as the standard error divided by the parameter estimate. 
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4.4.3. Quantitative analysis of plasma metformin concentrations and pH 
There was insufficient data in the published sources to conduct a 
meaningful analysis of the relationship between plasma metformin 
concentrations and pH. There were no paired metformin concentration and pH 
measurements in patients taking therapeutic doses of metformin. In addition, 
the range of reported pH data collected from metformin overdose cases was very 
narrow (i.e. pH of 6.05 to 7.39) making a meaningful analysis difficult. A raw 




Figure 4.5 Semi-log plot of paired plasma metformin concentration and pH measured 
on admission to a medical facility from cases whom had ingested an overdose of 
metformin from the published metformin associated lactic acidosis database. 
  




In this study, the relationship between plasma metformin concentrations 
and lactate was explored by quantitatively analysing the concentration-response 
relationship across a wide range of metformin doses, including intentional 
overdoses. This study found that metformin plasma concentrations greater than 
4.5 mg/L (the lower bound of the 95% confidence interval) are associated with 
severe hyperlactatemia and, based on the data analysed here, is proposed as the 
upper limit of safety. Dose adjustment to maintain metformin plasma 
concentrations below 4.5mg /L should mitigate the risk of lactic acidosis. In 
addition, no studies were found in the literature review to have explored the 
upper therapeutic limit for metformin using a safety endpoint. 
There has been little research focussed on establishing a therapeutic range 
for plasma metformin concentrations, although our findings are in agreement 
with the small number of studies in the published literature. In a systematic 
literature review of metformin studies, Kajbaf et al found that the majority of 
studies supported a therapeutic plasma metformin concentration range between 
0.1 and 4 mg/L [369]. This is supported by findings from a retrospective study 
that found that plasma metformin concentrations within 0.5±0.4 (standard 
deviation) mg/L were well tolerated in diabetic patients with normal renal 
function [391]. Similarly, in a study by Lalau et al, 798 plasma metformin 
concentrations were analysed from 467 patients [392]. Of these measured plasma 
concentrations only approximately 7% were found to be greater than 5 mg/L 
[392].  
4.6. Limitations 
The results of this study should be interpreted in light of the following 
limitations.  
It is assumed in this work that the association between metformin 
concentrations and the risk of lactic acidosis can be explored using lactate 
concentration as a marker of lactic acidosis risk in patients taking therapeutic 
and supra-therapeutic doses of metformin. While it is not necessarily implied 
Chapter 4: Metformin concentrations and lactic acidosis  
 114 
 
that metformin will cause lactate concentrations to increase directly, and that this 
in turn will cause lactic acidosis, it is assumed that lactic acidosis will cause a 
severe hyperlactatemia in many cases. Hence, while the association may exist, it 
does not imply cause and effect. In addition, lactate may be a fairly poor safety 
metric, since lactate concentrations may fluctuate significantly for many reasons, 
such as exercise and underlying pathology (e.g. chronic airway obstruction) 
[393].  
All cases extracted from the database had taken an acute overdose of 
metformin and were diagnosed with lactic acidosis in the case reports. These 
cases therefore all had increased lactate concentrations by definition. In the 
overdose cases included in this analysis it was assumed that the supra-
therapeutic dose of metformin was the dominant cause of lactic acidosis. None 
of the patients extracted from Duong et al had taken an intentional overdose and 
none experienced hyperlactataemia or acidosis [371]. Overall, the results from 
this chapter are only able to show an association between metformin and lactate 
concentrations. 
An assumption of this analysis was that there is no significant delay 
between elevated metformin concentrations resulting in an increased production 
of lactate as a consequence of lactic acidosis. However, four cases analysed in the 
study were noted to have on admission metformin concentrations greater than 
10 mg/L and lactate concentrations less than 5 mmol/L (as can be seen in Figure 
4.3 seen below the red dashed cut-off line). Upon closer investigation of these 
cases it was found that subsequent lactate concentrations that were measured 
post-admission to a medical facility were all greater than 5 mmol/L. This is a 
possible explanation why the 𝐸𝑚𝑎𝑥  model does not appear to provide a 
reasonable description for the paired concentration data for these cases. 
4.7. Conclusion 
In summary, the relationship between plasma metformin and lactate 
concentrations was explored quantitatively by analysing the concentration-
response relationship across a wide range of metformin doses. This study found 
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that plasma metformin concentrations >4.5 mg/L (the lower bound of the 95% 
CI) are associated with a risk of severe hyperlactatemia. Findings from this study 
suggest that dose adjustment to maintain plasma metformin concentrations to 
<4.5 mg/L should mitigate the risk of lactic acidosis. 
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5.1. Preamble to the chapter 
In Chapter 4 of this thesis plasma metformin concentrations greater than 
4.5 mg/L were found to be associated with an increased risk of lactic acidosis. 
Here, a better understanding of the pharmacokinetics of metformin in patients 
with reduced renal function will help guide dosing to maintain concentrations 
below this upper limit of safety. In this chapter a noncompartmental analysis 
was performed to explore the pharmacokinetics of metformin in renally 
impaired patients. 
5.2. Introduction 
Metformin is predominantly cleared from the body as unchanged drug by 
the kidneys [27, 29, 30]. It has been suggested that 80% of metformin is cleared 
via active tubular secretion by the kidneys and the remaining 20% by glomerular 
filtration [32]. Patients with renal impairment who are prescribed metformin 
therapy have been found to have reduced metformin clearance [394]. Metformin 
has traditionally been contraindicated in renally impaired patients due to the 
concern that accumulation of the drug will lead to an increased risk of lactic 
acidosis. Recent changes to dosing guidelines propose that metformin can be 
used in renally impaired patients provided that doses are reduced to account for 
reduced renal function [14, 24]. However, current dosing guidelines show little 
agreement and few appear to be evidence based, leaving prescribers with 
unclear messages about how to safely dose metformin in patients with renal 
impairment. 
The impact of reduced renal function on the handling of metformin may be 
more complex than previously assumed. According to first principles, dose 
reduction will normalise metformin exposure between patients with different 
levels of renal impairment and mitigate the risk of adverse effects. In theory, this 
could be achieved by reducing the dose in proportion to glomerular filtration 
rate (GFR), where it is assumed that metformin dosing requirements and GFR 
follow a simple linear relationship. However, it has been proposed that 
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compounds eliminated mainly by tubular secretion, like metformin, may display 
a non-linear relationship with GFR [395, 396]. It is therefore unclear if creatinine-
based equations used to estimate GFR (eGFR) or creatinine clearance (CLcr) in 
the clinical setting provide accurate predictions of metformin clearance. A 
quantitative analysis of metformin pharmacokinetics in patients with renal 
impairment is required to guide dosing.  
5.3. Objectives 
The aim of this chapter was to explore the pharmacokinetics of metformin 
in renal impairment to inform renal dosing. The specific objectives of this work 
were to: 
i. To conduct a pharmacokinetic analysis of metformin in subjects with 
different degrees of renal function  
ii. Compare the ability of different GFR equations used in the clinical 
setting to predict metformin clearance, and to determine which 
equation will provide the best guide for metformin dosing 
iii. Develop an empirical renal dosing equation for metformin using the 
Cockcroft and Gault equation, 4-variable Modification of Diet in 
Renal Disease equation and Chronic Kidney Disease Epidemiology 
Collaboration equation and determine the maintenance dose range 
for patients in different CKD groups to achieve a target steady-state 
plasma concentration of 1 mg/L.  
   





Data from an observation study conducted by the Nephrology Department 
at Dunedin Public Hospital (New Zealand) was available for analysis. The study 
was approved by the New Zealand Health and Disability Ethics Committee, 
application number: 14/STH/156/AM01. The study was registered with the 
Australian and New Zealand Clinical Trials Registry (ANZCTR), number: 
ACTRN12614001180616. All study subjects gave written and informed consent. 
A brief overview of the study procedures is provided however note that 
the collection of data was not part of this thesis. Thirty-four study participants 
with varying degrees of renal function were enrolled in the study. Participants 
were stratified into three groups based on their renal function: (i) those with 
stable eGFR ≥60 mL/min, (ii) those with stable eGFR 30-60 mL/min, and, (iii) 
those with stable eGFR <30 mL/min. Study participants fasted overnight prior 
to the first study day. On the first study day, a blood sample was taken for the 
measurement of baseline plasma metformin and creatinine concentrations. 
Subjects then received a single dose of metformin 500 mg orally. Metformin was 
administered with a minimum of 250 mL of filtered water and an intake of 100 
mL/h was maintained for the following four hours to ensure adequate urine 
output. Blood samples were collected at the following times post drug 
administration: 15-30 minutes, 30-60 minutes, 90-120 minutes, 3 hours, 5-6 hours, 
8-12 hours and 24 hours for the measurement of metformin and creatinine. An 
additional blood sample was collected at 30-36 hours for the measurement of 
metformin. Timed urine samples were collected at times 0-3 hours, 3-8 hours and 
8-24 hours post drug administration. The collected blood and urine samples 
were stored at -80oC. For a detailed overview of the study procedures refer to 
Appendix A4.1. 
A summary of the study participants’ demographics stratified by their 
enrolment groups is presented in Table 5.1.  
  
Chapter 5: Pharmacokinetics of metformin in renal impairment 
121  
 






































































































































Chapter 5: Pharmacokinetics of metformin in renal impairment 
 122 
 






































Data are presented as median [range] (interquartile range) unless otherwise specified. Group 1: 
participants with stable eGFR ≥60 mL/min. Group 2: participants with stable eGFR 30-60 
mL/min. Group 3 participants with stable eGFR <30 mL/min.aBMI is body mass index. bFFM is 
fat free mass calculated using the equation by Janmahasatian et al [397]. c𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine 
clearance estimated using the Cockcroft and Gault equation [80]. Note that ideal body weight 
[398] was used in the Cockcroft and Gault equation as a body size metric. d𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  is 
glomerular filtration rate estimated using the 4-variable Modification of Diet in Renal Disease 
equation [82]. e𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  is glomerular filtration rate estimated using the Chronic Kidney 
Disease Epidemiology Collaboration equation [83]. fNote that 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  (adjusted) and 
𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  (adjusted) were adjusted for the individual body surface area measurements for each 
subject calculated using the Du Bois Method [399].  
5.4.2. Pharmacokinetic analysis  
The pharmacokinetic analysis was performed in Microsoft® Excel® 2016 
and R (version 3.5.3) using the pk.nca function in the PKNCA package (v0.9.2). 
The R code is presented in Appendix A4.2.1. Unless stated, the metrics reported 
in section 5.5.1 were determined using Microsoft® Excel® 2016 (the outputs from 
R were used to quality assure the calculations). The following pharmacokinetic 
metrics for metformin were determined; (i) maximum plasma concentration 
achieved (𝐶𝑚𝑎𝑥) following a single oral dose, (ii) time when maximum plasma 
concentration was achieved (𝑇𝑚𝑎𝑥 ), (iii) terminal elimination slope (𝜆𝑧 ), (iv) 
terminal elimination half-life (𝑡1/2), (v) area under the curve (𝐴𝑈𝐶) from time 
zero to time of last observed concentration above the limit of quantification 
(𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡) and time zero to infinity (𝐴𝑈𝐶0−∞), (vi) apparent clearance (𝐶𝐿/𝐹), 
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and, (vii) renal clearance ( 𝐶𝐿𝑟𝑒𝑛𝑎𝑙 ). A description of how each of the 
pharmacokinetic metrics was determined is described as follows. 
 
𝑪𝒎𝒂𝒙 and 𝑻𝒎𝒂𝒙 . The 𝐶𝑚𝑎𝑥  achieved following a single dose of metformin was 
determined by identifying the maximum observed plasma metformin 
concentration. The 𝑇𝑚𝑎𝑥 for metformin was determined by identifying the time 
at which the maximum plasma metformin concentration was observed. The 
𝐶𝑚𝑎𝑥  and 𝑇𝑚𝑎𝑥  were determined in Microsoft® Excel® 2016 and the mean and 
standard deviation was calculated. 
 
Terminal elimination slope. To derive 𝜆𝑧 a linear regression was drawn through 
the last 2 observations on a semi-log plot of drug concentration versus time using 






Equation 5.1 Formula for the terminal elimination slope 
 
where, 𝐶𝑖 is the concentration (mg/L) taken at time 𝑖, 𝐶𝑖+1 is the concentration 
(mg/L) taken at time 𝑖 + 1 (in hours), and, Δ𝑡 is the time interval between the 
observations. Note that visual inspection of the data was performed prior to 
calculation of the terminal elimination slope. Based on the data available only 
the last 2 observations were used to determine the terminal elimination slope to 
avoid the use of the maximum observed plasma metformin concentration and to 
account for terminal phase samples being below the limit of quantification. 
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Terminal elimination half-life. The terminal elimination half-life was calculated 






Equation 5.2 Formula for terminal elimination half-life 
 
where, 𝑡1/2  is the terminal elimination half-life (h-1) and 𝜆𝑧  is the terminal 
elimination slope (described above). 
 
Area under the curve. The area under the curve was calculated using the 





 (𝑡𝑖+1 − 𝑡𝑖) 
Equation 5.3 Formula to calculate the area under the curve for each trapezoid 
 
where, 𝐴𝑈𝐶𝑖−𝑖+1 is the area under the curve (mg∙h/L) from time 𝑖 to time 𝑖 + 1, 
𝐶𝑖 is the concentration of the drug at time 𝑖, 𝐶𝑖+1 is the concentration of the drug 
at time 𝑖 + 1, 𝑡𝑖  is the time at 𝑖 and 𝑡𝑖+1 is the time at 𝑖 + 1. To calculate the 𝐴𝑈𝐶 
from time 0 to the first observed concentration it was assumed that the plasma 
concentration at time zero was equal to 0, under the assumption that drug 
absorption at time zero is negligible. The area under the curve from the time of 
last observed concentration above the limit of quantification to infinity 
(𝐴𝑈𝐶𝑙𝑎𝑠𝑡−∞) was calculated using the following equation; 
 







Equation 5.4 Formula to calculate the extrapolated area under the curve 
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where, 𝑡𝑙𝑎𝑠𝑡  is the time of last observed concentration above the limit of 
quantification, 𝐶  is the drug concentration, 𝐶𝑙𝑎𝑠𝑡  is the last observed 
concentration above the limit of quantification and 𝜆𝑧 is the terminal elimination 
slope. To calculate 𝐴𝑈𝐶0−∞ the interpolated trapezoid areas from  𝑡0 to 𝑡𝑙𝑎𝑠𝑡 and 
the extrapolated area from 𝑡𝑙𝑎𝑠𝑡 to 𝑡∞ were summated. 
 
Apparent clearance. Apparent clearance was determined using the following 
equation, 
 




Equation 5.5 Formula for area under the curve from time zero to infinity 
 
 where, 𝐶𝐿/𝐹 is apparent clearance, 𝑑𝑜𝑠𝑒 is the amount of drug administered (in 
mg) and 𝐴𝑈𝐶0−∞ is the area under the curve from time zero to infinity. 
 
Renal clearance. Renal clearance was calculated using plasma and urine 







Equation 5.6 Formula to calculate renal clearance 
 
where 𝑎𝑚𝑜𝑢𝑛𝑡 𝑒𝑥𝑐𝑟𝑒𝑡𝑒𝑑 is the product of the concentration of the drug in urine 
and volume of urine eliminated over a 24 hour period (in units of mg), and, 
𝐴𝑈𝐶0−24 is the area under the curve from time 0 to 24 hours (i.e. time of last 
observed urine collection). 
Study participants were stratified into their Chronic Kidney Disease (CKD) 
classification category, and, the mean and standard deviation of the estimated 
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pharmacokinetic metrics 𝐶𝑚𝑎𝑥 , 𝑇𝑚𝑎𝑥 , 𝜆𝑧 , 𝑡1/2 , 𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡 , 𝐴𝑈𝐶0−∞ , 𝐶𝐿/𝐹  and 
𝐶𝐿𝑟𝑒𝑛𝑎𝑙 for metformin were determined and tabulated.  
5.4.3. The relationship between eGFR/ CLcr and metformin clearance 
Creatinine clearance was estimated using the Cockcroft and Gault equation 
(𝐶𝐿𝑐𝑟𝐶𝐺) (as shown in Equation 5.7) [80]. Note that ideal body weight was used 
in place of total body weight in the Cockcroft and Gault equation as per usual 
practice in New Zealand. In the Cockcroft and Gault equation, 𝑎𝑔𝑒 is in years, 
𝐼𝐵𝑊  is ideal body weight [398] in kilograms, 𝑆𝑐𝑟  is serum creatinine in 
mg/100mL and 𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine clearance in units of mL/min. Serum 
creatinine was converted from units of μmol/L to mg/100mL by dividing by 
88.42. Creatinine clearance was estimated using the Cockcroft and Gault 
equation in R (version 3.5.3). The equation for ideal body weight (𝐼𝐵𝑊) is shown 




72 ∙  𝑆𝑐𝑟
 ∙ 0.85 (𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
Equation 5.7 Cockcroft and Gault equation 
 
𝐼𝑑𝑒𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑚𝑎𝑙𝑒) = 50𝑘𝑔 + 2.3𝑘𝑔 ∙ (ℎ𝑒𝑖𝑔ℎ𝑡 − 60) 
𝐼𝑑𝑒𝑎𝑙 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑓𝑒𝑚𝑎𝑙𝑒) = 45.5𝑘𝑔 + 2.3𝑘𝑔 ∙ (ℎ𝑒𝑖𝑔ℎ𝑡 − 60) 
Equation 5.8 Ideal body weight equation [398] 
 
Estimated glomerular filtration rate was determined using the 4-variable 
Modification of Diet in Renal Disease (MDRD) [82] and Chronic Kidney Disease 
Epidemiology Collaboration (CKD-Epi) [83] creatinine-based estimating 
equations. In this chapter estimated glomerular filtration calculated using the 4-
variable MDRD and CKD-Epi equations are referred to as 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  and 
𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 , respectively. The 4-variable MDRD equation used is shown in 
Equation 5.9. In the 4-variable MDRD equation, 𝑆𝑐𝑟 represents serum creatinine 
in mmol/L and 𝑎𝑔𝑒 is in years. The CKD-Epi equation is shown in Equation 5.10, 
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where, 𝑆𝑐𝑟 is serum creatinine in mg/dL, 𝑎𝑔𝑒 is age in years, 𝜅 is 0.7 for females 
and 0.9 for males, 𝛼 is -0.329 for females and -0.411 for males, 𝑚𝑖𝑛 indicates the 
minimum of 𝑆𝑐𝑟 𝜅⁄  or 1, and, 𝑚𝑎𝑥  indicates the maximum of 𝑆𝑐𝑟 𝜅⁄  or 1. The 
calculation of eGFR using the creatinine-based estimating equations was 
performed in R (version 3.5.3).  
 
𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 = 1.75 ∙  𝑆𝑐𝑟
−1.154  ∙ 𝑎𝑔𝑒−0.203  ∙ 0.742 (𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
Equation 5.9 4-variable Modification of Diet in Renal Disease equation 
 
𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 = 141 ∙ 𝑚𝑖𝑛(𝑆𝑐𝑟 𝜅, 1⁄ )
𝛼 ∙ 𝑚𝑎𝑥(𝑆𝑐𝑟 𝜅, 1⁄ )
−1.209 ∙ 0.993𝑎𝑔𝑒
∙ [1.018 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒] ∙ [1.159 𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
Equation 5.10 Chronic Kidney Disease Epidemiology Collaboration equation 
 
Metformin apparent clearance (𝐶𝐿/𝐹) and renal clearance (𝐶𝐿𝑟𝑒𝑛𝑎𝑙) were 
regressed against; (i) 𝐶𝐿𝑐𝑟𝐶𝐺 , (ii) 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 , and, (iii)  𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 . For the 
purposes of this analysis 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 were adjusted for by body 
surface area (i.e. 𝑒𝐺𝐹𝑅 was reported in units of mL/min instead of its standard 
units of mL/min/1.73m2). Total body weight was used to determine body 
surface area. 
A regression analysis was conducted in R (version 3.5.3). The R-squared 
values were determined and informally compared. 
5.4.4. Developing empirical renal dosing equations for metformin 
The regression equations were used to determine an empirical estimate of 
𝐶𝐿/𝐹 for an individual using individual estimates of eGFR/CLcr to guide the 
renal dosing of metformin using Equation 5.11. In Equation 5.11, 𝑀𝐷𝑅  is 
maintenance dosing rate (mg/day), 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑒(𝑡𝑎𝑟𝑔𝑒𝑡) is the target average steady-
state plasma drug concentration (mg/L) and 𝐶𝐿/𝐹 is apparent clearance (L/h). 
Note that the therapeutic range for metformin efficacy is poorly defined. Hence, 
an a priori 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑒(𝑡𝑎𝑟𝑔𝑒𝑡)of 1 mg/L was selected as a consensus value from 
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several studies where values of 0.1-2 mg/L have commonly been proposed [26, 
323, 369, 400]. The maintenance dose-rate range was predicted for the lower and 
upper bound of each CKD category. The predicted doses were rounded to the 
nearest pragmatic metformin dose based on available tablet strengths.  
 
𝑀𝐷𝑅 = 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑒(𝑡𝑎𝑟𝑔𝑒𝑡) ∙ 𝐶𝐿/𝐹 ∙ 24 
Equation 5.11 Formula to calculate the maintenance dosing rate 
  




A total of 257 plasma metformin concentrations and 102 timed urine 
samples from 34 study participants were available for analysis. Thirty-seven 
plasma concentrations were below the quantification limit and were excluded 
from the analysis. A graph of the plasma metformin concentrations versus time 
for study participants stratified by their CKD classification group is shown in 
Figure 5.1. 
5.5.1. Pharmacokinetics of metformin at different degrees of renal function 
The pharmacokinetic metrics of metformin in 34 study participants 
stratified by their CKD classification group is presented in Table 5.2. The 
maximum plasma metformin concentration achieved (i.e. 𝐶𝑚𝑎𝑥 ) was lowest in 
study participants with CKD 1 and 2 and was highest in study participants with 
CKD 5. The mean 𝐶𝑚𝑎𝑥 achieved in study participants with CKD 1, 2, 3, 4 and 5 
was 0.84, 0.84, 1.66, 2.34 and 2.36 mg/L, respectively. The time to achieve the 
maximum plasma concentration following a single dose of metformin was 
longer in study participants with CKD 3, 4 and 5. This was shown by the 𝑇𝑚𝑎𝑥 
for metformin in study participants with CKD 1 and 2 being approximately 2.4 
hours versus a 𝑇𝑚𝑎𝑥 of 2.92, 2.98 and 3.20 hours in study participants with CKD 
3, 4 and 5, respectively. The 𝑡1 2⁄  of metformin was higher in subjects with CKD 
3, 4 and 5. This is shown by the mean 𝑡1 2⁄  of metformin in CKD 1 and 2 being 
3.38 and 3.75 hours versus the 𝑡1 2⁄  of 6.19, 8.09 and 6.76 hours in CKD 3, 4 and 5, 
respectively. Metformin 𝐴𝑈𝐶0−∞ was higher in patients with increasingly severe 
renal impairment. This can be seen in Table 5.2 where both 𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡  and 
𝐴𝑈𝐶0−∞  increased from 3.81 and 4.44 mg ∙h/L in CKD 1 to 38.31 and 42.33 
mg ∙h/L in CKD 5, respectively. The apparent clearance (𝐶𝐿/𝐹 ) and renal 
clearance (𝐶𝐿𝑟𝑒𝑛𝑎𝑙) of metformin was shown to decrease from CKD 1 to CKD 4.  
Outputs from the pharmacokinetic analysis conducted in R are presented 
in Appendix A4.2.2. The pharmacokinetic metrics values determined in R were 
similar to the results obtained manually. Note a formal comparison was not 
conducted. 





Figure 5.1 Plasma metformin concentrations for study participants stratified by CKD 
renal group. The top is a Cartesian plot and the bottom is a semi-log plot. The dots 
represent single measures of plasma metformin concentration and the lines link 
repeated measures data for a single participant. In the plot, CKD 1 represents a 
glomerular filtration rate ≥90 mL/min, CKD 2 represents a glomerular filtration rate of 
60-89 mL/min, CKD 3 represents a glomerular filtration rate of 30-59 mL/min, CKD 4 
represents a glomerular filtration rate of 15-29 mL/min and CKD 5 represents a 
glomerular filtration rate <15 mL/min.  
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Table 5.2 Pharmacokinetic metrics for study participants stratified by their CKD classification group 
Parameter CKD 1 CKD 2 CKD 3 CKD 4 CKD 5 
Sample size (n) 7 10 5 6 6 
𝐶𝑚𝑎𝑥 (mg/L) 0.84±0.35 0.84±0.26 1.66±0.42 2.34±0.45 2.36±1.14 
𝑇𝑚𝑎𝑥 (h) 2.41±0.95 2.38±0.88 2.92±1.56 2.98±0.64 3.20±1.62 
𝜆𝑧 (h-1) 0.31±0.14 0.24±0.11 0.12±0.03 0.11±0.05 0.13±0.08 
𝑡1 2⁄  (h) 3.38±3.26 3.75±2.56 6.19±1.26 8.09±5.00 6.76±3.01 
𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡 (mg∙h/L) 3.81±1.75 4.67±2.36 16.55±7.19 32.17±10.84 38.31±18.42 
𝐴𝑈𝐶0−∞ (mg∙h/L) 4.44±2.11 5.51±2.13 18.47±6.20 37.13±18.80 42.33±21.73 
𝐶𝐿/𝐹 (L/h) 150.89±105.85 108.87±63.56 29.11±7.70 15.62±5.52 15.74±10.33 
𝐶𝐿𝑟𝑒𝑛𝑎𝑙 (L/h) 49.58±33.27 31.27±11.49 8.31±2.32 4.32±2.58 4.42±2.84 
Data are presented as mean ± standard deviation. CKD 1 represents a glomerular filtration rate ≥90 mL/min. CKD 2 represents a glomerular filtration rate of 
60-89 mL/min. CKD 3 represents a glomerular filtration rate of 30-59 mL/min. CKD 4 represents a glomerular filtration rate of 15-29 mL/min. CKD 5 represents 
a glomerular filtration rate of <15 mL/min. 
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5.5.2. The relationship between eGFR/CLcr and metformin clearance 
Plots of the apparent clearance for metformin versus different measures of 
renal function are presented in Figure 5.2. Note that in each of the plots there are 
three subjects with a particularly high apparent clearance but normal measure 
of renal function (presented as a red dot in each of the graphs). On inspection 
these subjects only had plasma metformin concentrations above the 
quantification limit within 8 hours post-drug administration (i.e. within 4 hours 
after 𝐶𝑚𝑎𝑥). It is speculated that only the distribution phase of metformin was 
observed in these subjects due to concentrations after 8 hours post-drug 
administration being below the quantification limit - resulting in a high apparent 
clearance. These data were excluded from the correlation analysis. A linear 
relationship was found between the apparent clearance of metformin and 𝐶𝐿𝑐𝑟𝐶𝐺 
estimated using the Cockcroft and Gault equation (R2=0.85), 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 
estimated using the 4-variable MDRD equation (R2=0.86) and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 
estimated using the CKD-Epi equation (R2=0.87).  
Plots of the renal clearance for metformin versus the different measures of 
renal function are presented in Figure 5.3. Similarly, a linear relationship was 
identified between the renal clearance of metformin and 𝐶𝐿𝑐𝑟𝐶𝐺  (R2=0.56), 
𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 (R2=0.53) and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 (R2=0. 54).  
  









Figure 5.2 Apparent clearance for metformin compared to different measures of renal 
function, including a CLcrCG (creatinine clearance estimated using the Cockcroft and 
Gault equation), b eGFRMDRD (glomerular filtration rate estimated using the 4-variable 
MDRD equation) and c eGFRCKDEPI (glomerular filtration rate estimating using the 
CKD-Epi equation). Each point represents a study participant. The line is a linear 
regression drawn through the data. The regression and R-squared value for each plot 
are reported. The red dots represent three outliers that were excluded from the 
correlation analysis. 
  









Figure 5.3 Renal clearance for metformin compared to different measures of renal 
function, including a CLcrCG (creatinine clearance estimated using the Cockcroft and 
Gault equation), b eGFRMDRD (glomerular filtration rate estimated using the MDRD 
equation) and c eGFRCKDEPI (glomerular filtration rate estimating using the CKD-Epi 
equation). Each point represents a study participant. The line is a linear regression 
drawn through the data. The regression and R-squared value for each plot are reported. 
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5.5.3. Empirical equations to guide the renal dosing of metformin 
The empirical equations developed to guide the renal dosing of metformin 
using 𝐶𝐿𝑐𝑟𝐶𝐺, 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 are given as follows; 
 
𝐷𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 = 𝐶𝑝(𝑡𝑎𝑟𝑔𝑒𝑡) ∙ (3.56 + 12.7 ∙ 𝐶𝐿𝑐𝑟𝐶𝐺) ∙ 24 
Equation 5.12 An empirical equation for the renal dosing of metformin using the 
Cockcroft and Gault equation 
 
𝐷𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 = 𝐶𝑝(𝑡𝑎𝑟𝑔𝑒𝑡) ∙ (−0.133 + 14.6 ∙ 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷) ∙ 24 
Equation 5.13 An empirical equation for the renal dosing of metformin using the 4-
variable MDRD equation 
 
𝐷𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 = 𝐶𝑝(𝑡𝑎𝑟𝑔𝑒𝑡) ∙ (1.39 + 13.1 ∙ 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼) ∙ 24 
Equation 5.14 An empirical equation for the renal dosing of metformin using the 
CKD-Epi equation 
 
where, 𝐷𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 is the daily dose of metformin required to achieve the target 
plasma metformin concentration in units of mg/day, 𝐶𝑝(𝑡𝑎𝑟𝑔𝑒𝑡)  is the target 
plasma metformin concentration in mg/L, 𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine clearance 
estimated using the Cockcroft and Gault equation in units of L/h, 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 is 
glomerular filtration rate estimated using the 4-variable MDRD equation in units 
of L/h adjusted for body surface area and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼 is glomerular filtration 
rate estimated using the CKD-Epi equation in units of L/h adjusted for body 
surface area. The predicted maximum daily metformin dose for each CKD 
eGFR/CLcr range using the developed empirical equations is presented in Table 
5.3. As shown in Table 5.3 the predicted doses for metformin are the same 
amongst the different empirical equations for CKD 3 to 5, but not for CKD 1 to 
2. 
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Table 5.3 Predicted maximum daily metformin doses using the developed empirical 
equations stratified by CKD group 








1 ≥90a 1700-2250 2000-2550 1700-2250 
2 60-89 1000-1700 1000-2000 1000-1700 
3 30-59 500-1000 500-1000 500-1000 
4 15-29 250-500 250-500 250-500 
5 <15 250 250 250 
𝐶𝐿𝑐𝑟𝐶𝐺  method represents using Equation 5.12 to predict metformin dose. 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  method 
represents using Equation 5.13 to predict metformin dose. 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  method represents using 
Equation 5.14 to predict metformin dose. aThe upper end of the GFR range CKD 1 was set as 120 
mL/min. 
  




In this study the pharmacokinetics of metformin in renal impairment was 
explored to understand the exposure metrics and how these related to covariates 
of interest. Whereby, the elimination curve of metformin was of particular 
interest given that metformin is recognised to exhibit flip-flop pharmacokinetics. 
The 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 𝑡1/2, 𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡 and 𝐴𝑈𝐶0−∞ of metformin were found to increase 
with poorer levels of renal function, whilst the 𝐶𝐿/𝐹 and 𝐶𝐿𝑟𝑒𝑛𝑎𝑙 of metformin 
were found to decrease with poorer levels of renal function. Findings from other 
published pharmacokinetic studies have collectively found the same trend in 
patients with renal impairment [30, 394]. 
A linear relationship was found between the apparent clearance of 
metformin and estimates of renal function calculated using the creatinine-based 
estimating equations (i.e. CLcr estimated using the Cockcroft and Gault equation 
and eGFR estimated using the 4-variable MDRD and CKD-Epi equations). 
Similarly, a linear relationship was found between the renal clearance of 
metformin and estimates of renal function calculated using the creatinine-based 
estimating equations. Based on these results it can be inferred that the commonly 
used creatinine-based estimating equations will provide a reasonable reflection 
of the apparent clearance of metformin. Thus, the commonly used creatinine-
based estimating equations can be used with ease to guide the dosing of 
metformin in the range of renal function explored in this analysis. 
As part of the analysis three empirical renal dosing equations were 
developed for metformin using the Cockcroft and Gault, 4-variable MDRD and 
CKD-Epi equations. Using the empirical renal dosing equations, a maximum 
metformin daily dose of 2250, 1700, 1000, 500 and 250 mg was recommended in 
patients with CKD 1, 2, 3, 4 and 5, respectively. The maximum daily dose 
determined for metformin from the empirical equations aligned with published 
renal dosing guidelines (as shown in Table 5.4). The maximum daily dose of 
metformin determined from the empirical equations lay within the 
recommendations published by the European Medicines Agency for each CKD 
category [368]. Relative to the dosing guidelines in the New Zealand Formulary, 
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the maximum daily dose of metformin calculated using the empirical equations 
were found to lie within the dosing recommendations for subjects with a 
creatinine clearance less than 30 mL/min, but were found to overestimate the 
maximum daily dose in those with a creatinine clearance above 30 mL/min [24]. 
Furthermore, the maximum daily dose of metformin calculated using the 
empirical equations was found to be higher than the recommendations provided 
in the Australian Medicines Handbook. 
Table 5.4 Summary of metformin renal dosing guidelines 
Guideline Ref Renal estimation method Renal dose adjustment 




Australian Medicines  
Handbook 




















Developed empirical equation 


































The results of this analysis should be viewed in light of the following 
limitations associated with noncompartmental pharmacokinetic analyses. A 
total of 37 plasma metformin concentrations were excluded in the analysis due 
to being below the limit of quantification; whereby, 33 of the 37 plasma 
concentrations below the limit of quantification were the final 24-hour and/or 
32-hour plasma concentrations collected from 20 study participants. Here, it is 
likely that only the distribution phase for metformin was observed in the study 
participants with both their 24 and 36 hour concentrations reported to being 
below the quantification limit because the elimination phase for metformin has 
been reported to only occur around 20 hours post metformin ingestion [18]. In 
these study participants it is likely that the estimates for 𝜆𝑧 (and pharmacokinetic 
statistics derived from 𝜆𝑧) will be overestimated. In addition, due to the 24- and 
32-hour plasma metformin concentrations being below the limit of quantification 
only 2 concentrations were used to calculate the 𝜆𝑧 in affected study participants. 
Here, the use of only the last two concentrations to determine the terminal 
elimination slope can result in biased results, particularly in the setting when at 
least one of the two samples was taken when drug distribution is not in 
equilibrium. In future pharmacokinetic metformin studies it is recommended 
that a higher dose of metformin is administered to patients with normal renal 
function to avoid terminal phase metformin data being below the limit of 
concentration. 
The dose predictions are limited by the assumption that a linear 
relationship exists between the apparent clearance for metformin and GFR. In 
addition, the dose predictions were based on a single covariate (i.e. an estimate 
of renal function). However, there are other factors that may determine 
metformin dose variability between patients, such as body weight or genetic 
variation in drug transporters. 
  




In this study the pharmacokinetics of metformin was explored in patients 
with varying levels of renal function. A linear relationship was found between 
the renal clearance of metformin and the widely used creatinine-based 
equations, suggesting that the creatinine-based equations can be used to guide 
the dosing of metformin in renal impairment. Furthermore, in this current piece 
of analysis an empirical equation to guide the renal dosing of metformin was 
developed. However, a clinical trial would be warranted to validate the 
empirical renal dosing equation prior to use in patients. 
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The pharmacokinetic profile of metformin is altered in patients with renal 
impairment. In Chapter 5 of this thesis, the maximum plasma metformin 
concentration achieved following a single dose (𝐶𝑚𝑎𝑥) and the time at which it 
occurred were found to be higher in individuals with renal impairment as 
opposed to those with normal renal function. Similarly, the elimination half-life 
(𝑡1/2), area under the curve from time zero to last observation (𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡), as well 
as the area under the curve from time zero to infinity (𝐴𝑈𝐶0−∞) for metformin 
were found to increase with poorer levels of renal function. Several hypotheses 
have been proposed to describe the possible physiological changes that occur in 
renal impairment that influence the pharmacokinetics of metformin. These 
proposed hypotheses include: (i) a decrease in renal clearance (𝐶𝐿𝑟𝑒𝑛𝑎𝑙) [27, 30], 
(ii) a decrease in volume of distribution ( 𝑉 ) [30, 34], (iii) a decrease in 
bioavailability (𝐹) and (iv) flip-flop pharmacokinetics [18, 27, 29, 30]. It is not 
clear whether one or more of the proposed hypotheses are possible mechanisms 
to describe the pharmacokinetic profile of metformin in renal impairment. 
Simulations provide a means of assessing each of the proposed mechanisms by 
testing to see which of the proposed hypotheses can recreate the metformin 
concentration time profiles seen in patients with varying degrees of renal 
impairment. 
6.2. Objectives 
The aim of this research was to test the hypotheses proposed to describe 
the pharmacokinetics of metformin in patients with renal impairment.  
  




The four hypotheses proposed to influence the pharmacokinetic profile of 
metformin in renal impairment (i.e. a reduction in 𝐶𝐿, a decrease in 𝑉, a decrease 
in 𝐹 and flip-flop pharmacokinetics) were implemented under a standard one-
compartment model (termed generic signature profile) and a published 
metformin pharmacokinetic model by Duong et al (termed metformin signature 
profile) [15]. Details of the simulations performed using a standard one-
compartment model and the published model by Duong et al are described, 
respectively, as follows;  
 
Generic signature profile. Deterministic simulations were performed under a 
standard one compartment model with first order absorption using MATLAB 
(R2016b, MathWorks, Natick, NA). A reference generic signature profile was 
simulated using the parameter values presented in Table 6.1 for comparison to 
the profiles simulated under the different proposed hypotheses. 
Table 6.1 Parameter and parameter values for the reference generic profile 
Parameters Values 
Dosing Dose number 1 
 Dose (𝑚𝑔) 100 
 Dose interval (ℎ) 24 
Pharmacokinetic 𝐹  1 
 𝐶𝐿 (𝐿 ∙ ℎ−1) 10 
 𝑘𝑎(ℎ
−1) 1 
 𝑉 (𝐿) 20 
Dose number: the number of doses administered; Dose interval: the time interval between 
administering individual doses. 𝐹  represents bioavailability, 𝐶𝐿  represents clearance, 𝑘𝑎 
represents absorption rate constant and 𝑉 represents the volume of distribution 
 
Deterministic simulations were performed with decreasing imputed values 
of 𝐶𝐿 (i.e. 10, 8, 6, 4 and 2 L/h) to explore the impact a reduction in 𝐶𝐿 would 
have on the pharmacokinetic profile. For the purposes of this analysis, the 
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remainder of parameter values in the model were kept the same as the reference 
generic signature profile (shown in Table 6.1). Similarly, decreasing values of 𝑉 
(i.e. 20, 16, 12, 8 and 4 L) and 𝐹 (i.e. 1.0, 0.8. 0.6, 0.4 and 0.2) were imputed into 
the one-compartment model, respectively. The influence of flip-flop on the 
pharmacokinetic profile of metformin was explored by simulating several 
scenarios describing flip-flop situations, which were: (i) constant elimination rate 
constant (𝑘) and changing absorption rate constant (𝑘𝑎), and, (ii) changing 𝑘 and 
constant 𝑘𝑎. 
 
Metformin signature profile. Deterministic simulations were performed under 
a published metformin population pharmacokinetic model by Duong et al in 
MATLAB (R2016b, MathWorks, Natick, NA) [15]. In brief, the metformin 
population pharmacokinetic model published by Duong et al was a two-
compartment model with first-order absorption and elimination processes (refer 
to Appendix 2.1 for a more detailed description of the model by Duong et al).  
 
A reference metformin signature profile using the model by Duong et al was 
simulated using the parameter values shown in Table 6.2. Deterministic 
simulations were performed to investigate the influence a reduction in 𝐶𝐿 would 
have on the pharmacokinetic profile by imputing the following creatinine 
clearance values into the model one at a time: 90, 60, 30 and 15 mL/min. The 
remainder of the parameter values were kept the same as the reference values 
presented in Table 6.2. Likewise, the influence a reduction in 𝑉  and 𝐹 would 
have on the concentration time profile for metformin was explored separately by 
individually imputing the following values of volume of distribution for the 
central compartment volume (20, 16, 12, 8 and 4 L) and 𝐹 ( 1, 0.8, 0.6, 0.4 and 0.2) 
into the model. The influence of flip-flop on the pharmacokinetic profile of 
metformin was performed by simulating the following two scenarios of flip-flop 
in the published model: (i) constant macro-constant describing the terminal 
decline in drug concentration (𝛽 ) and changing 𝑘𝑎 , and, (ii) changing 𝛽  and 
constant 𝑘𝑎.   
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Table 6.2 Parameter values for the reference metformin pharmacokinetic profile 
Parameters Values 
Dosing Dose number 1 
 Dose (𝑚𝑔) 500 
 Dose interval (ℎ) 24 
Pharmacokinetic Bioavailability 1 
 𝐶𝐿 (L/h) 72 
 𝑉𝑐 (L) 149 
 𝑄 (L/h) 203 
 𝑉𝑝 (L) 182 
 𝑘𝑎 (h-1) 0.35 
 𝑇𝐿𝑎𝑔 (h) 0.38 
Dose number: number of doses administered. Dose interval: time interval between administering 
individual doses. 𝐶𝐿  represents clearance, 𝑉𝑐  represents central compartment volume, 𝑄 
represents intercompartmental clearance, 𝑉𝑝  represents peripheral compartment volume, 𝑘𝑎 
represents absorption rate constant and 𝑇𝐿𝑎𝑔 corresponds to the time taken for a drug to appear 
in the systemic circulation following extravascular drug administration. 
  




The reference generic signature profile is shown in Figure 6.1. Simulated 
concentration time profiles exploring the influence of a reduction in clearance, 
volume of distribution and bioavailability are presented in Figure 6.2, 6.3 and 
6.4, respectively. Simulated concentration profiles exploring the influence of flip-
flop when (i) 𝑘 is constant and 𝑘𝑎  is changing and (ii) 𝑘 is changing and 𝑘𝑎  is 
constant are shown in Figure 6.5 and 6.6, respectively. 
 
 
Figure 6.1 Simulated reference generic signature profile of concentration versus time 
 







Figure 6.2 Simulated generic signature profile of concentration versus time exploring 
the influence of a reduction in clearance on a Cartesian plot (a) and semi-log plot (b) 







Figure 6.3 Simulated generic signature profile of concentration versus time exploring 
the influence of a reduction in volume of distribution on a Cartesian plot (a) and semi-
log plot (b) 







Figure 6.4 Simulated generic signature profile of concentration versus time exploring 
the influence of a reduction in bioavailability on a Cartesian plot (a) and semi-log plot 
(b) 







Figure 6.5 Simulated generic signature profile of concentration versus time exploring 
the influence of flip-flop where the rate of elimination (k) is kept constant and the rate of 
absorption (ka) is changing on a Cartesian plot (a) and semi-log plot (b) 







Figure 6.6 Simulated generic signature profile of concentration versus time exploring 
the influence of flip-flop where the rate of elimination (k) is changing and the rate of 
absorption (ka) is kept constant on a Cartesian plot (a) and semi-log plot (b) 
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The reference metformin signature profile simulated using the published 
model by Duong et al is shown in Figure 6.7. Simulated metformin concentration 
time profiles exploring the impact of a reduction in creatinine clearance, volume 
of distribution and bioavailability are shown in Figure 6.8, 6.9 and 6.10, 
respectively. The simulated flip-flop scenarios where (i) 𝛽 is constant and 𝑘𝑎 is 
changing and (ii) 𝛽 is changing and 𝑘𝑎 is constant is shown in Figure 6.11 and 
Figure 6.12, respectively.  
 
 
Figure 6.7 Simulated reference metformin signature profile for metformin 
concentration versus time 







Figure 6.8 Simulated metformin signature profile of concentration versus time 
exploring the influence of a reduction in creatinine clearance on a Cartesian plot (a) 
and semi-log plot (b) 







Figure 6.9 Simulated metformin signature profile of concentration versus time 
exploring the influence of a reduction in volume of distribution on a Cartesian plot (a) 
and semi-log plot (b) 







Figure 6.10 Simulated metformin signature profile of concentration versus time 
exploring the influence of a reduction in bioavailability on a Cartesian plot (a) and 
semi-log plot (b) 







Figure 6.11 Simulated metformin signature profile of concentration versus time 
exploring the influence of flip-flop where the macro-constant describing the terminal 
decline (β) is kept constant and the rate of absorption (ka) is changing on a Cartesian 
plot (a) and semi-log plot (b) 







Figure 6.12 Simulated metformin signature profile of concentration versus time 
exploring the influence of flip-flop where the macro-constant describing the terminal 
decline (β) is changing and the rate of absorption (ka) is kept constant on a Cartesian 
plot (a) and semi-log plot (b) 
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A description of the influence a reduction in clearance, reduction in volume 
of distribution, reduction in bioavailability, and, flip-flop had on the 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 
𝑡1/2 and 𝐴𝑈𝐶 is given as follows;  
 
Reduction in clearance. A reduction in clearance led to an increase in 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥 
and 𝐴𝑈𝐶 (as shown in Figure 6.2). In addition, as shown in Figure 6.2(b), the 
gradient of the terminal elimination slope became less steep with a decrease in 
clearance. On this basis it can be inferred that 𝑡1/2 increased with a reduction in 
clearance. 
 
Reduction in volume of distribution. A reduction in volume of distribution 
resulted in an increase in 𝐶𝑚𝑎𝑥, whilst, resulting in a decrease in 𝑇𝑚𝑎𝑥 and 𝑡1/2. A 
reduction in volume of distribution had negligible effects on 𝐴𝑈𝐶.  
 
Reduction in bioavailability. A reduction in bioavailability resulted in a drop 
in 𝐶𝑚𝑎𝑥 and 𝐴𝑈𝐶, whilst 𝑇𝑚𝑎𝑥and 𝑡1/2 were unchanged (Figure 6.4). 
 
Flip-flop. In the simulated flip-flop scenario where 𝑘 was kept the same and 𝑘𝑎 
was changing 𝐶𝑚𝑎𝑥 decreased with decreasing values of 𝑘𝑎whilst 𝑇𝑚𝑎𝑥increased 
with reduced 𝑘𝑎values. In the second flip-flop scenario where the value of 𝑘 
were changing and the 𝑘𝑎 was kept the same, both 𝐶𝑚𝑎𝑥and 𝑇𝑚𝑎𝑥decreased with 
increasing values of 𝑘. In both flip-flop scenarios the gradient of the terminal 
slope of decline was the same when the values of the 𝑘𝑎 were smaller than the 
values of 𝑘. However, when the values of 𝑘𝑎 were greater than 𝑘, the gradient of 
the terminal slope was different.  
  




Understanding the influence of renal impairment on the pharmacokinetics 
of metformin is important to guide dosing. Based on the results of this simulation 
study a reduction in clearance or flip-flop pharmacokinetics (where 𝑘  is 
changing and 𝑘𝑎  is constant) could possibly recreate the concentration time 
profile of metformin seen in renally impaired patients (Figure 5.1). This was on 
the basis of achieving the same trends seen in the pharmacokinetic metrics (i.e. 
𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 𝑡1/2, 𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡 and 𝐴𝑈𝐶0−∞) found in Chapter 5 (presented in bold). 
 
𝑪𝒎𝒂𝒙 was higher with increasing severity of renal impairment. This same trend 
was apparent in the simulated signature profiles exploring a reduction in 
clearance and flip-flop. A reduction in the volume of distribution had similarly 
resulted in an increase in 𝐶𝑚𝑎𝑥. However, from the simulated profiles exploring 
the influence of a reduction in volume of distribution, the concentration time 
curves cross over when the volume of distribution is reduced to a certain extent 
– a characteristic not evident in the observed metformin concentration time 
profiles. A reduction in bioavailability resulted in a decrease in 𝐶𝑚𝑎𝑥 , which is 
inverse of the trend seen in the pharmacokinetics of metformin in renal 
impairment. 
 
𝑻𝒎𝒂𝒙 was longer with poorer levels of renal function. From the deterministic 
simulations, this pharmacokinetic characteristic could only be recreated by a 
reduction in clearance or flip-flop kinetics. Whereby, neither a reduction in 
volume of distribution nor bioavailability could recreate the pharmacokinetic 
profile seen for metformin in study participants with varying degrees of renal 
impairment.  
 
𝒕𝟏/𝟐was longer with poorer levels of renal function. Based on the simulated 
signature profiles, both a reduction in clearance and the flip-flop kinetics 
hypotheses could recreate the increase in half-life with poorer levels of renal 
function. A reduction in the volume of distribution resulted in a decrease in half-
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life which is the inverse of the trend noted and a reduction in bioavailability did 
not influence the half-life.  
 
𝑨𝑼𝑪 increased with increasing severity of renal impairment. This characteristic 
of the concentration time curve could be recreated under the scenario where 
there was a reduction in clearance or flip-flop. A reduction in the volume of 
distribution had negligible effects on the area under the curve, whilst a reduction 
in bioavailability resulted in a reduction in the area under the curve. 
6.6. Conclusion 
In conclusion, the proposed hypothesis of a reduction in clearance and flip-
flop kinetics could recreate the concentration time profile of metformin in 
patients with renal impairment. 
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7.1. Preamble to the chapter 
In Chapter 5 an empirical dosing equation for metformin was developed 
and renal doses predicted. However, it is not known if the calculated doses will 
produce plasma metformin concentrations that remain within the upper limit of 
safety (i.e. 4.5 mg/L) defined in Chapter 4. In this chapter the development and 
evaluation of a population pharmacokinetic model for metformin in renal 
impairment is described. Simulations were performed to predict the plasma 
metformin concentration profile for metformin under the doses predicted in 
Chapter 5 and those published in the New Zealand Formulary to assess for 
safety. Note, that in this chapter, new data from a metformin study conducted at 
Middlemore Hospital (New Zealand) became available and was used in the 
model development along with the data from Chapter 5. 
7.2. Introduction 
Current renal dosing guidelines for metformin lack agreement and few 
appear to be evidence based. Some dosing guidelines state that metformin 
should not be used in patients with renal impairment, while others recommend 
caution, no dose adjustment, or a reduced dosage [5, 24, 47, 48, 51, 99]. This 
leaves prescribers with unclear messages on how to safely use and dose 
metformin in patients with chronic renal impairment. In theory, metformin 
therapy in renally impaired patients could be monitored for safety by measuring 
plasma metformin concentrations to ensure that they do not exceed the upper 
limit of safety defined in Chapter 4 (4.5 mg/L). However, this is not currently 
recommended in clinical practice.  
A nonlinear mixed effects population pharmacokinetic model presents a 
platform for which plasma metformin concentrations can be predicted across 
patient populations, including those with poor renal function, as a means of 
assessing safe dosing. Previous studies have described the pharmacokinetics of 
metformin in patients with moderate renal impairment (creatinine clearance 
(CLcr) 30-60 mL/min) [14, 15, 30, 370]. However, few studies have looked at the 
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pharmacokinetics of metformin in patients with severe renal impairment (CLcr 
<30 mL/min) (see [15] for an exception) – and only a handful of population 
analyses exist [14-16, 370, 401]. Only a few population pharmacokinetic studies 
have proposed dosing recommendations in patients with severe renal 
impairment (creatinine clearance <30 mL/min). Hence, the purpose of this study 
was to prove whether metformin could be used in patients with CKD 4 or CKD 
5 (creatinine clearance 15-29 mL/min). 
7.3. Objectives 
The specific objectives of this chapter were to (i) develop a population 
pharmacokinetic model for metformin in patients with varying degrees of renal 
function and (ii) simulate metformin concentration time profiles for patients 
with varying renal function under the empirical renal dosing recommendations 
developed in Chapter 5 and the published New Zealand Formulary renal dosing 
guidelines. The purpose of the simulations was to understand what percentage 
of patients would be expected to have plasma metformin concentrations above 
the upper limit of 4.5 mg/L (defined in Chapter 4). 
  





Data available for this analysis was collected from two sources: (i) a study 
conducted at the Dunedin Public Hospital (New Zealand) and (ii) a study 
conducted at Middlemore Hospital (New Zealand). The same data used in 
Chapter 5 from the Dunedin Public Hospital was used in this Chapter – refer to 
Chapter 5 (section 5.4.1.) for information about the data available from the 
Dunedin Public Hospital. The data from Middlemore Hospital was only made 
available after the completion of Chapter 5 and hence is firstly used and 
introduced in this chapter. A brief description of the new data from Middlemore 
Hospital is provided in the following section (section 7.4.1.1.). An overview of 
the data from the Dunedin Public Hospital and Middlemore Hospital is 
provided in this thesis, however, note that the collection of data was not part of 
this thesis.  
A summary of demographic data of study participants from the Dunedin 
Public Hospital and Middlemore Hospital is presented in Table 7.1. 
7.4.1.1. Middlemore Hospital 
Data from an open-label, prospective, phase I, safety study conducted at 
Middlemore Hospital (Auckland, New Zealand) was available for analysis [16]. 
The study was approved by the New Zealand Health and Disability Ethics 
Committees, reference number: NTX/11/12/112. All patients provided written 
and informed consent. 
Eighteen patients with type 2 diabetes mellitus and stable stage 4 chronic 
kidney disease (CKD) were enrolled in the study. Study volunteers were 
included in the study if they presented: between 30 and 75 years of age, had a 
diagnosis of type two diabetes for at least two years, an HbA1c level between 6% 
and 11% and stable stage 4 CKD. Stage 4 CKD was defined by a stable eGFR 
value between 15-30 mL/min/1.73m2 over the preceding three months. Study 
volunteers were excluded if they presented with: a history of metformin 
intolerance, pregnancy, breastfeeding, pre-existing metabolic acidosis or having 
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significant risk factors for metabolic acidosis. Significant risk factors for 
metabolic acidosis included: morbid obesity (>160 kg), unstable ischemic heart 
disease, a planned radiocontrast examination within the following six months 
and/or relevant medical comorbidities (e.g. severe chronic obstructive 
pulmonary disease, unstable congestive heart failure and significant liver 
disease). 
Study participants were randomised into one of three study arms to receive 
either 250, 500 or 1000 mg of metformin orally once daily for four weeks. 
Participants randomised to receive the lowest dose of metformin (i.e. 250 mg PO 
OD) were the first to complete the study. Participants in the second and third 
study arm then completed the study if metformin safety and tolerability were 
reported to be satisfactory, respectively. 
Study participants fasted overnight prior to the first study day. On the first 
study day, blood samples were collected to assess baseline fasting metabolic 
control profiles (glucose, insulin, lipids and HbA1c) and a safety profile (serum 
lactate, bicarbonate, venous pH, renal function, electrolytes, liver enzymes and 
a full blood count). A continuous capillary glucose monitoring system was used 
to assess glycaemic control over a 72 hour period. On study day four, study 
participants received a single daily dose of metformin followed by a standard 
breakfast. Blood samples were taken at 0 (baseline), 2, 4, 6, 8 and 24 hours after 
the first dose of metformin was administered. Study participants continued their 
daily metformin therapy for four weeks, returning to the clinic on a weekly basis 
to measure trough metformin concentrations, monitor their safety profiles and 
to assess for adverse events. The 72 hour continuous capillary glucose 
monitoring system was repeated on the last three days of the study and HbA1c 
was measured on the last day of the study. 
The same assay was used to determine plasma metformin concentrations 
in the Dunedin Public Hospital and Middlemore Hospital metformin studies. 
For more additional details regarding the assay used refer to Appendix A4.1.2. 
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Data presented as median [range] (interquartile range) unless otherwise specified. aBMI is body 
mass index. bFFM is fat free mass calculated using the equation by Janmahasatian et al [397]. 
c𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine clearance estimated using the Cockcroft and Gault equation [80]. Note that 
ideal body weight [398] was used in the Cockcroft and Gault equation as a body size metric. 
d𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 is glomerular filtration rate estimated using the 4-variable Modification of Diet in 
Disease in Renal Disease equation [82]. e𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  is glomerular filtration rate estimated using 
the Chronic Kidney Disease Epidemiology Collaboration equation [83]. fNote that 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  
(adjusted) and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  (adjusted) were adjusted the individual body surface area 
measurements for each subject calculated using the Du Bois Method [399]. 
7.4.2. General analytical approach and software 
A population analysis was conducted in NONMEM v7.3 using the first-
order conditional estimation method with interaction. The model runs were 
executed in Perl-speaks-NONMEM (v4.8.1). Pre- and post-processing was 
conducted in R (version 3.5.3) using the R packages xpose (version 0.4.4) and 
xpose4 (version 4.6.1). 
7.4.3. Data management 
Data were saved in an electronic spreadsheet and were converted into a 
NONMEM compatible format in R (version 3.5.3) using the tidyverse (version 
1.2.1) package.  
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7.4.3.1. Handling below the limit of quantification 
Data below the quantification limit (BQL) were handled differently based 
on the percentage of data below the quantification limit. If less than 5% of the 
observations in the study were BQL, the BQL data were ignored. If more than 5 
percent of the observations were BQL the M6 method described by Beal [402] 
was used where the first BQL observation was imputed as half of the lower limit 
of quantification and subsequent data discarded. If more than 10 percent of the 
observations were BQL then a likelihood-based method to determine the 
probability of the data being BQL was used (M3 method described by Beal [402]). 
7.4.3.2. Handling outliers 
A preliminary analysis of the data using an exploratory model in 
NONMEM was used to identify outliers. Outliers were identified by review of 
the conditional weighted residuals (CWRES). Absolute values >5 units were 
considered to be outliers. An influential outlier was defined as an outlier that 
resulted in a change in a parameter value of more than 10%. Influential outliers 
were excluded from the analysis. The developed final model was then used to 
reanalyse the full data set (i.e. including outliers), a sensitivity analysis was 
conducted and the difference in the results discussed. 
7.4.4. Model development 
7.4.4.1. Pharmacokinetic model 
A one-, two- and three-compartment structural model with first-order 
absorption and elimination were considered to describe the pharmacokinetics of 
metformin. Covariance between clearance and volume parameters was 
considered. The typical value for bioavailability was fixed to 0.55 in the models. 
Bioavailability was fixed to a consensus value of 0.55 on the basis of several 
studies proposing metformin bioavailability to range between 0.32 to 0.61 and, 
to allow for comparison of the results to other previously published population 
pharmacokinetic models for metformin that had also fixed the value for 
bioavailability to 0.55. 
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Statistical models were implemented to describe variability. The between 
subject variability (BSV) was modelled on an exponential scale to ensure 
population pharmacokinetic parameters were constrained to values greater than 
0. The parameter variability between individuals took the generic form; 
 
𝜃𝑖𝑝 = ?̂?𝑝 ∙ 𝑒𝑥𝑝
𝜂𝑖𝑝 
Equation 7.1 Model for between subject variability 
 
where, 𝜃𝑖𝑝 is the estimate of the 𝑝
𝑡ℎ parameter 𝜃 for the 𝑖𝑡ℎ individual, ?̂?𝑝 is the 
population estimate of the 𝑝𝑡ℎ  parameter, and, 𝜂𝑖𝑝  is the deviation of the 𝑝
𝑡ℎ 
parameter for the 𝑖𝑡ℎ individual from the population estimate. 𝜂 was assumed to 
be normally distributed with a mean of zero and a variance of 𝜔2.  
An additive, proportional and combined (i.e. additive and proportional) 
error model was tested to describe residual unexplained error. A description of 
an additive, proportional and combined residual error model is given as follows: 
• Additive error model. The additive error model describes variability that 
is constant at all concentrations. It can be given by the following equation; 
 
𝑌 = 𝐹 + 𝜀𝑎𝑑𝑑 
Equation 7.2 Additive error model 
 
where, 𝑌  represents observed dependent concentration, 𝐹  is the 
individual specific model prediction and 𝜀𝑎𝑑𝑑 is additive error. 
• Proportional error model. The proportional error model describes 
variability that is proportional to the magnitude of concentration. It is 
given by the following equation; 
 
𝑌 = 𝐹 ∙ (1 + 𝜀𝑝𝑟𝑜𝑝) 
Equation 7.3 Proportional error model  
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where, 𝜀𝑝𝑟𝑜𝑝 represents proportional error. 
• Combined error model. The combined error model is a combination of 
the additive and proportional error model (shown in Equation 7.4). 
 
𝑌 = 𝐹 ∙ (1 + 𝜀𝑝𝑟𝑜𝑝) + 𝜀𝑎𝑑𝑑 
Equation 7.4 Combined error model 
 
7.4.4.2. Covariate model and structure 
Covariates were considered in the model if there was a significant 
correlation between continuous covariates and the empirical Bayes estimates 
from the base model, or a significant p value from a t test for binary covariates. 
Covariates considered included age, sex, weight, fat free mass and creatinine 
clearance. Creatinine clearance was estimated using the Cockcroft and Gault 
equation [80]. Note that ideal body weight [398] was used in the Cockcroft and 
Gault equation. Fat free mass ( 𝐹𝐹𝑀 ) was determined using the formula 
developed by Janmahasatian et al presented in Equation 7.5 [397]; 
 
𝐹𝐹𝑀(𝑚𝑎𝑙𝑒) =
9.27 ∙ 103 ∙ 𝑇𝐵𝑊




9.27 ∙ 103 ∙ 𝑇𝐵𝑊
8.78 ∙ 103 + 244 ∙ 𝐵𝑀𝐼
 
Equation 7.5 Fat free mass equation developed by Janhamasatian et al [397] 
 
where, 𝑇𝐵𝑊 is total body weight in kilograms and 𝐵𝑀𝐼 is body mass index in 
units of kilograms per square metre. 
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7.4.4.3. Model selection 
Model selection was based on: (i) a reduction in objective function value 
(OFV) of 3.84 units (Chi-square [𝜒2], p < 0.05) for nested models with one degree 
of freedom, (ii) graphical goodness of fit plots (including visual predictive 
checks), (iii) a reduction in between subject variability, (iv) parameter precision 
(i.e. relative standard errors less than 50%) and (v) biological plausibility of the 
parameter estimates. 
7.4.4.4. Model building 
The model building process first involved the development of a base model 
– this included the structural components and statistical models for between 
subject variability and residual unexplained variability. Covariates were 
subsequently tested in the base model one at a time to evaluate fit to data. A 
likelihood ratio test was performed and statistically significant covariates that 
resulted in a reduction in objective function value (OFV) of 3.84 units (Chi-square 
[𝜒2], p < 0.05) were retained for further model building. Statistically significant 
covariates were sequentially added to the model in descending order of objective 
function value change from the base model (i.e. forward selection). The full 
covariate model was then subject to backwards deletion, which involved 
removing one covariate at a time to confirm statistical significance in the final 
model. Covariates that increased the objective function value by >6.6 units (Chi-
square [𝜒2], p < 0.01) following backwards deletion were retained in the final 
model.  
7.4.4.5. Model evaluation 
The final model was evaluated using standard diagnostic plots (i.e. 
dependent variable versus model predictions (DV v PRED), dependent variable 
versus individual predicted values (DV v IPRED), conditional weighted 
residuals versus model predictions (CWRES v PRED) and conditional weighted 
residuals versus time (CWRES v TIME)), a prediction corrected visual predictive 
check (pcVPC) and a non-parametric bootstrap. The median parameter values 
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and the 95% confidence intervals were determined from 1000 non-parametric 
bootstrap runs. The pcVPCs were produced in R (version 3.5.3) using the 
package xpose4 (version 4.6.1). A thousand datasets were simulated under the 
final model and the 5th, 50th and 95th percentiles were plotted against the same 
percentiles from the original dataset.  
7.4.5. Simulations 
Stochastic simulations were performed to predict the plasma metformin 
concentrations from the final population pharmacokinetic model for metformin. 
Plasma metformin concentrations were predicted for a one-week period under 
two guidelines; 
1. the doses predicted by the empirical dosing guideline developed in 
Chapter 5 (see Table 5.3) 
2. the doses recommended by the New Zealand Formulary (NZF) renal 
dosing guidelines (presented in Table 7.2).  
A summary of the simulated doses under the empirical renal dosing guideline 
and the NZF is presented in Table 7.2.  
 The simulations were implemented in R (version 3.5.3) using the R package 
RxODE (version 0.9.0-7). RxODE is a platform that facilitates simulation from 
models implemented with ordinary differential equation models in R that was 
designed for pharmacometric use. A total of 1000 virtual patients were simulated 
for each renal dosing band under each guideline. Creatinine clearance was 
generated from a uniform distribution based on the renal function range defined 
in the CKD categories defined in Chapter 5 and the NZF renal dosing guidelines. 
Weight was fixed to 70 kilograms. The probability of achieving a plasma 
metformin concentration exceeding the upper safety limit of 4.5 mg/L (as 
defined in Chapter 4) was determined. The simulation code is presented in 
Appendix A5.1.  
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Table 7.2 Simulated renal doses for the empirical renal dosing guideline (Chapter 5) and 










































































OD: once a day. BD: twice a day, TID: three times a day.  
  





A total of 321 plasma metformin concentrations from 52 study participants 
were available for analysis. A total of 77 plasma metformin concentrations 
collected from Middlemore Hospital were omitted from the analysis due to 
protocol violation. In the study protocol blood samples were to be collected 0, 2, 
4, 6, 8 and 24 hours post administration of the first metformin dose, with the 24 
hour blood sample to be measured prior to study participants receiving their 
second dose. However, in 5 study participants their 24 hour plasma metformin 
concentrations were greater than their 8 hour concentrations. Hence, these five 
aberrant concentrations were excluded from the analysis. It is likely that these 
participants ingested their second dose of metformin prior to the measurement 
of their 24 hour metformin trough concentration. In addition, in the protocol, 
weekly blood samples were to be collected from study participants prior to them 
ingesting their daily dose. However, in a large majority of the study participants 
their weekly trough concentrations measured were below the limit of 
quantification; this is likely to be due to issues surrounding patient compliance. 
For these reasons, data from unobserved doses were excluded from the analyses.  
Thirty-six plasma metformin concentrations were below the quantification 
limit. Data that were below the limit of quantification were accounted for using 
the M6 method described by Beal [402]. No data were identified as outliers. 
 A Cartesian and semi-log concentration time profile of the combined raw 
data is presented in Figure 7.1. 





Figure 7.1 Plasma metformin concentrations following a single oral dose of metformin 
on a Cartesian (top) and semi-log (bottom) plot. The dots represent single measures of 
plasma metformin concentration and the lines link repeated measures data for a single 
study participant. 
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7.5.2. Population pharmacokinetic model for metformin 
A two-compartment model with first-order absorption and elimination 
provided the best fit to the data. The final model to describe the 
pharmacokinetics of metformin is shown as follows;  
 
𝐶𝐿 =  𝜃𝐶𝐿 ∙ (𝐶𝐿𝑐𝑟𝐶𝐺 100⁄ )
𝐶𝐺_𝐸𝐹𝐹 
𝑉𝑐 = 𝜃𝑉𝑐 ∙ (𝑊𝑇𝐾𝐺 70⁄ )
𝑊𝑇𝐾𝐺_𝐸𝐹𝐹 
𝑄 = 𝜃𝑄 
𝑉𝑝 = 𝜃𝑉𝑝 
𝑘𝑎 = 𝜃𝑘𝑎 
𝐹 = 0.55 
Equation 7.6 Final pharmacokinetic model for metformin 
 
where 𝐶𝐿 is the clearance of metformin (L/h), 𝜃𝐶𝐿 is the mean population value 
for metformin clearance (L/h), 𝐶𝐿𝑐𝑟𝐶𝐺 is creatinine clearance calculated using the 
Cockcroft and Gault equation using ideal body weight as the body size metric, 
𝐶𝐺_𝐸𝐹𝐹  is the estimated exponent on the covariate effect for 𝐶𝐿𝑐𝑟𝐶𝐺 , 𝑉𝑐  is the 
central compartment volume (L), 𝜃𝑉𝑐  is the mean population value for the central 
compartment volume (L), 𝑊𝑇𝐾𝐺 is total body weight in kg, 𝑊𝑇𝐾𝐺_𝐸𝐹𝐹 is the 
exponent on the effect of 𝑊𝑇𝐾𝐺 on the central compartment volume that was 
fixed to 1, 𝑄 is intercompartmental clearance (L/h), 𝜃𝑄 is the mean population 
value for intercompartmental clearance (L/h), 𝑉𝑝 is the peripheral compartment 
volume (L), 𝜃𝑉𝑝  is the mean population value for the peripheral compartment 
volume (L), 𝑘𝑎 is the absorption rate constant (h-1), 𝜃𝑘𝑎  is the mean population 
value for the absorption rate constant (h-1) and 𝐹 is bioavailability that was fixed 
to 0.55. Between subject variability on the peripheral compartment volume (𝑉𝑝) 
and intercompartmental clearance (𝑄) were not supported under the current 
data and were not included in the final model. The parameter estimates and 
bootstrap results for the final population pharmacokinetic model for metformin 
are shown in Table 7.3.  
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Creatinine clearance and total body weight were found to be significant 
covariates on clearance and the central compartment volume, respectively. The 
addition of creatinine clearance as a covariate on clearance resulted in a 
reduction in BSV from 105% to 46% and the addition of total body weight on the 
central compartment volume resulted in a reduction in BSV from 37% to 30%. 
Subsequent removal of either of the covariates resulted in a poorer global fit. 
Diagnostic plots for the final model are presented in Figure 7.2. The 
conditional-weighted residual plots show no apparent bias for the model 
predictions. A pcVPC for the final metformin pharmacokinetic model is 
presented in Figure 7.3. The median, 5th and 95th percentiles of the population 
pharmacokinetic model predicted plasma metformin concentrations that follow 
the percentiles of the observed data well, suggesting a good model fit to the data. 
The non-parametric bootstrap results (shown in Table 7.3) are similar to the final 
model suggesting that the developed model is stable.  
The NONMEM control file for the final model is presented in Appendix 
A5.2. 
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[95% confidence interval] 
𝜃𝐶𝐿 (L/h) 90.5 (8) 89.6 [75.4-108.1] 
𝜃𝑉𝑐 (L/70kg) 147 (9) 143.8 [106.2-181.0] 
𝜃𝑄 (L/h) 3.7 (10) 3.6 [0.9-8.3] 
𝜃𝑉𝑝 (L) 57.2 (18) 53.6 [12.8-515.0] 
𝜃𝑘𝑎 (h
-1) 0.4 0.4 [0.3-0.5] 
𝜃𝐹  0.55 FIX 0.55 FIX 
𝜃𝐶𝐺_𝐸𝐹𝐹  0.8 (11) 0.8 [0.6-1.0] 
𝜃𝑊𝑇_𝐸𝐹𝐹  1 FIX 1 FIX 
Between subject variability 
𝜔𝐶𝐿 (CV%) 46.9 (12)  46.6 [35.0-61.0] 
𝜔𝑉𝑐 (CV%) 29.3 (18)  28.5 [12.5-39.1] 
𝜔𝑘𝑎 (CV%) 39.5 (24)  41.3 [18.2-60.0] 
Covariance 𝜔𝐶𝐿, 𝜔𝑉𝑐 0.0697 0.0605 [-0.0305-0.1513] 
Residual error 
𝜎𝑎𝑑𝑑 (mg/L) 0.0337 (42) 0.0316 [0.0069-0.1012] 
𝜎𝑝𝑟𝑜𝑝 (CV%) 24.1 (15) 24.0 [7.1-30.9] 
Shrinkage (%)   
𝜂-shrinkage (𝐶𝐿) 6  
𝜂-shrinkage (𝑉𝐶) 25  
𝜂-shrinkage (𝑘𝑎) 24  
𝜀-shrinkage 15  
 𝜃𝐶𝐿 mean population value for metformin clearance, 𝜃𝑉𝑐 mean population value for the central 
compartment volume, 𝜃𝑄  mean population value for intercompartmental clearance, 𝜃𝑉𝑝  mean 
population value for the peripheral compartment volume, 𝜃𝑘𝑎  mean population value for the 
absorption rate constant, 𝜃𝐹  mean population value for bioavailability, 𝜔𝐶𝐿  between subject 
variability for clearance, 𝜔𝑉𝑐  between subject variability for the central compartment volume, 
𝜔𝑘𝑎  between subject variability for the absorption rate constant, 𝜎𝑎𝑑𝑑  additive residual error, 
𝜎𝑝𝑟𝑜𝑝 proportional residual error. 
  











Figure 7.2 Goodness of fit plots for the final population pharmacokinetic model. a 
observed plasma metformin concentration data (DV) plotted against the population 
prediction for plasma metformin concentrations (PRED). b observed plasma metformin 
concentration data (DV) plotted against the individual prediction for plasma 
metformin concentrations. c conditional weighted residuals (CWRES) plotted against 
population predictions for plasma metformin concentrations. d conditional weighted 
residuals (CWRES) plotted against time. 
  




Figure 7.3 Prediction corrected visual predictive check for the final pharmacokinetic 
model. The plot shows the observed plasma metformin concentrations (open blue 
circles) and the 5th, 50th and 95th percentiles for the model-predicted plasma metformin 
concentration (red lines, dashed for the 5th and 95th percentiles and a solid red line for 
the 50th percentiles) with the 95% confidence interval around the percentiles. 
7.5.3. Simulations 
Simulations were performed using the parameter estimates shown in Table 
7.3. The simulated plasma metformin concentration profiles under the empirical 
renal dosing recommendations using the Cockcroft and Gault, 4-variable MDRD 
and CKD-Epi equations and, the NZF guidelines are presented in Figures 7.4, 
Figure 7.5, Figure 7.6 and Figure 7.7, respectively. The plasma metformin 
concentration was not found to exceed 4.5 mg/L under any of the simulated 
renal dosing guidelines. This finding is reflected in the simulated plasma 
metformin concentration profiles where the 95th percentiles all are all well within 
3 mg/L. 













Figure 7.4 Simulated plasma metformin concentration versus time profiles under the 
empirical CLcrCG method. a 750 mg metformin given thrice daily, creatinine clearance 
90-120 mL/min. b 850 mg metformin given twice daily, creatinine clearance 60-89 
mL/min. c 500 mg metformin given twice daily, creatinine clearance 30-59 mL/min. d 
500 mg metformin given once daily, creatinine clearance 15-29 mL/min. e 250 mg 
metformin given once daily, creatinine clearance <15 mL/min. The red dashed lines 
represent the 5th and 9th percentiles. The black line is the median percentile. 













Figure 7.5 Simulated plasma metformin concentration versus time profiles under the 
empirical eGFRMDRD method. a 750 mg metformin given thrice daily, creatinine 
clearance 90-120 mL/min. b 850 mg metformin given twice daily, creatinine clearance 
60-89 mL/min. c 500 mg metformin given twice daily, creatinine clearance 30-59 
mL/min. d 500 mg metformin given once daily, creatinine clearance 15-29 mL/min. e 
250 mg metformin given once daily, creatinine clearance <15 mL/min. The red dashed 
lines represent the 5th and 9th percentiles. The black line is the median percentile. 
 













Figure 7.6 Simulated plasma metformin concentration versus time profile under the 
empirical eGFRCKDEPI method. a 750 mg metformin given thrice daily, creatinine 
clearance 90-120 mL/min. b 850 mg metformin given twice daily, creatinine clearance 
60-89 mL/min. c 500 mg metformin given twice daily, creatinine clearance 30-59 
mL/min. d 500 mg metformin given once daily, creatinine clearance 15-29 mL/min. e 
250 mg metformin given once daily, creatinine clearance <15 mL/min. The red dashed 
lines represent the 5th and 9th percentiles. The black line is the median percentile. 
 









Figure 7.7 Simulated plasma metformin concentration versus time profiles under each 
renal dosing band in the New Zealand Formulary. a 1000 mg metformin given twice 
daily, creatinine clearance 60-120 mL/min. b 500 mg metformin given twice daily, 
creatinine clearance 30-60 mL/min. c 500 mg metformin given once daily, creatinine 
clearance 15-30 mL/min. The red dashed lines represent the 5th and 9th percentiles. The 
black line is the median percentile. 
   




In this study a population pharmacokinetic model for metformin was 
developed and evaluated. A two-compartment model with first-order 
absorption and elimination was found to best describe the pharmacokinetics of 
metformin in study participants with varying levels of renal function. Both 
creatinine clearance and total body weight were identified as significant 
covariates on the apparent clearance and the central compartment volume for 
metformin. Based on the simulations performed in this study it was predicted 
that under the doses predicted using the empirical equations developed in 
Chapter 5 and the current NZF renal dosing guidelines the plasma metformin 
concentration would not exceed the 4.5 mg/L upper limit of safety for metformin 
(defined in Chapter 4). 
Several published studies have described the pharmacokinetics of 
metformin in patients with normal and poor renal function [14-16, 370]. These 
published analyses have generally been designed to develop a renal dosing 
guideline for metformin in the clinic. However, only a few of these studies 
involved the development of a population pharmacokinetic model for 
metformin. Published population pharmacokinetic models have commonly 
found that a two-compartment structural model best described the absorption 
and disposition of metformin following an oral dose [15, 370, 403, 404]. The 
covariates identified in this study to predict the pharmacokinetics of metformin 
are similar to those in published studies [15, 404]. In a population 
pharmacokinetic model by Duong et al both creatinine clearance and total body 
weight were found to be significant covariates on the apparent clearance and 
central compartment volume for metformin, respectively, as identified in this 
study [15]. 
The intact nephron hypothesis provides a general model for renal 
impairment [405]. It assumes that each nephron is either fully functional (intact) 
or non-functional (lost), whereby changes in glomerular filtration are 
proportional to changes in tubular reabsorption and tubular secretion [405]. The 
implications of the intact nephron hypothesis for drug therapy are that only 
Chapter 7: Population pharmacokinetic model for metformin  
 186 
 
glomerular filtration rate is required to predict the impact of renal pathology on 
renal drug handling. Recent studies have suggested that the intact nephron 
hypothesis may not be a suitable general model for summarising renal drug 
handling, particularly in drugs that also undergo tubular secretion and/or 
reabsorption [406, 407]. However, for metformin, glomerular filtration and 
metformin renal clearance were shown to share a linear relationship (results 
from Chapter 5). This suggests that glomerular filtration rate (and creatinine 
clearance) can be used to sufficiently describe renal impairment and guide 
dosing and, is sufficient as a covariate on clearance for metformin. 
7.7. Limitation 
The results of this chapter should be viewed and interpreted in light of the 
influence flip-flop pharmacokinetics may have on nonlinear mixed effects 
modelling. As mentioned in Chapter 1 (section 1.2.4.4.) metformin has been 
reported to exhibit flip-flop pharmacokinetics. Noncompartmental analyses - 
such as those performed in Chapter 5 – are unaffected by flip-flop. However, it 
is unclear if flip-flop will present problems in population pharmacokinetic 
models due to issues of local identifiability. This warrants the need for further 
analyses to be performed to explore the influence of flip-flop in population 
pharmacokinetic models. 
7.8. Conclusion 
In this study a population pharmacokinetic model for metformin was 
developed and evaluated. A two-compartment structural model with first-order 
absorption and elimination provided the best fit to the metformin data from 
study participants with varying levels of renal impairment. Predictions from the 
model under the empirical renal dosing guideline (developed in Chapter 5) and 
the NZF renal dosing guidelines suggest that plasma metformin concentrations 
will not exceed the proposed upper limit of safety of 4.5 mg/L proposed in 
Chapter 4. This suggests that the empirical and NZF renal dosing guidelines can 
be used safely in patients with renal impairment.  
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8.1. Preamble to the chapter 
In Chapter 7 of this thesis a population pharmacokinetic model was 
developed for metformin using nonlinear mixed effects modelling techniques. 
Metformin is known to exhibit so called ‘flip-flop’ pharmacokinetics [27, 29]. 
Flip-flop is a pharmacokinetic phenomenon where the rate constant of 
absorption and elimination for extravascularly administered drugs can 
interchange. In compartmental nonlinear mixed effects models flip-flop presents 
a problem due to issues of local identifiability in the parameter estimates. This 
chapter explores the influence of flip-flop in population pharmacokinetic 
modelling using metformin as an example. 
8.2. Introduction 
The term ‘flip-flop’ is used to describe the scenario where the rate constant 
of absorption and rate constant of elimination for extravascularly administered 
drugs can swap over. Drugs that undergo absorption limited elimination (i.e. 
elimination rate constant (𝑘) > absorption rate constant (𝑘𝑎)) are often said to be 
‘flip-flop’ but in reality they are usually just ‘flip’ (𝑘 > 𝑘𝑎) or ‘flop’ (𝑘 < 𝑘𝑎). Of 
note, flip-flop can occur between patients for a drug with slow absorption from 
the gastrointestinal tract and with rapid and extensive renal clearance. In this 
setting, for patients with normal renal function the usual finding will be that 𝑘 > 
𝑘𝑎, however in patients with impaired renal function the finding may be 𝑘 < 𝑘𝑎. 
Flip-flop pharmacokinetics is in reality a permutation of the rank order of 
the parameter values and is therefore an issue of local identifiability in that there 
exists a finite set of parameter values (rather than a single set) that solves the 
problem. Any mammillary pharmacokinetic model that can be constructed from 
multiple exponential functions will also only be locally identifiable. The simplest 
example is a one-compartment model with first-order input and output which 
has two sets of permutations of parameter values that provide the same input-
output relationship. The possible permutations using a 𝐶𝐿, 𝑉, 𝑘𝑎  and 𝑘, 𝑉, 𝑘𝑎 
parameterisation are shown in Table 8.1 – where 𝐶𝐿 is clearance and 𝑉 is volume 
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of distribution. Here it can be seen that the 𝑘 , 𝑉 , 𝑘𝑎  parameterisation is a 
complete permutation of the parameters, whereby the values for 𝑘, 𝑉 and 𝑘𝑎 are 
completely different in permutation 1 and permutation 2. However, in Table 8.1 
it can be seen that the 𝐶𝐿, 𝑉, 𝑘𝑎 parameterisation is only a partial permutation, 
whereby 𝑉 becomes a function of 𝐶𝐿 and 𝑘𝑎, 𝑘𝑎 becomes a function of 𝐶𝐿 and 𝑉 
and, 𝐶𝐿  is invariant to flip-flop (i.e. 𝐶𝐿’  remains equal to 𝐶𝐿  in both possible 
permutations) where 𝐴𝑈𝐶 = 𝐷𝑜𝑠𝑒/𝐶𝐿 is irrespective of whether the system is in 
a state of ‘flip’ or ‘flop’ (i.e. 𝑘 > 𝑘𝑎 or 𝑘 < 𝑘𝑎). Note here that noncompartmental 
analyses are unaffected by a model being in either a ‘flip’ or a ‘flop’ state. Under 
this model, flip-flop can be considered a mathematical abstraction and a special 
case of local identifiability problem in that it is not just a finite set of parameter 
values but a partial permutation of the set. Refer to Appendix A6.1 for an 
extended discussion on the different sets of permutations of parameter values 
for pharmacokinetic compartmental models. 




𝑪𝑳, 𝑽, 𝒌𝒂 𝒌, 𝑽, 𝒌𝒂 
Permutation 1 
𝐶𝐿’ = 𝐶𝐿 
𝑉’ = 𝑉 
𝑘𝑎’ = 𝑘𝑎 
𝑘′ = 𝑘 
𝑉’ = 𝑉 
𝑘𝑎’ = 𝑘𝑎 
Permutation 2 
𝐶𝐿’ = 𝐶𝐿 
𝑉’ = 𝐶𝐿/𝑘𝑎 
𝑘𝑎’ = 𝐶𝐿/𝑉 
𝑘′ = 𝑘𝑎 
𝑉’ = (𝑉 ∙ 𝑘)/𝑘𝑎 
𝑘𝑎’ = 𝑘 
 
In theory, the issue of local identifiability (flip-flop behaviour) can be 
addressed by incorporating a mechanistic model of the absorption and 
elimination that accounts for the underlying processes. This is, however, 
generally not possible in a standard top-down estimation setting. A simpler 
alternative is to consider that there is a level of functioning of the elimination 
organ at which the absorption and elimination rate constants flip around and 
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that this can be estimated as a transition cut-off value. The model could then be 
stabilised into either its flip or flop state for any given individual and hence avoid 
flip-flop to yield a globally identifiable model. 
The concept of a transition cut-off was applied to pharmacokinetic data 
arising from metformin. Metformin is an antihyperglycaemic agent that is 
reported to exhibit absorption mediated elimination [27, 29]. In published 
human pharmacokinetic studies the terminal elimination phase of metformin 
was dissimilar following intravenous (IV) and oral (PO) administration, 
whereby there was an evident slower decline in metformin concentrations 
following PO administration [27, 29]. Whereby, the terminal plasma elimination 
half-life of metformin has been reported to be 1.74±0.11 and 8.41±0.58 hours 
(mean±standard error) following intravenous and oral administration, 
respectively [29]. The slower apparent elimination of metformin following PO 
administration has been suggested to be a result of the slow gastrointestinal 
absorption of the drug [29, 30]. This has led to speculation that the terminal slope 
of metformin following PO administration in patients with normal renal 
function is absorption rate limited, whilst in patients with poor renal function it 
is elimination rate limited. Metformin is predominantly renally eliminated as 
unchanged drug via tubular secretion [29]. However, it is not known if and at 
what level of renal impairment the terminal slope of metformin’s concentration 
profile changes from being absorption rate limited to elimination rate limited. 
8.3. Objectives 
The aim of this research was to explore the influence of flip-flop in 
population pharmacokinetic models using metformin as a motivating example. 
The specific objectives were: 
i. To determine whether it is possible to estimate the flip-flop 
transition point in order to parameterise a model that disallows flip-
flop  
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ii. To investigate the application of constraining parameters to address 
flip-flop 
iii. To investigate whether the inclusion of intravenous data addresses 
issues associated with flip-flop 
iv. To investigate the influence of flip-flop pharmacokinetics on 
covariate modelling 
  





8.4.1.1. Data source 
Data available for analysis arose from three sources: (i) Dunedin Public 
Hospital, (ii) Middlemore Hospital and (iii) a study by Pentikainen et al. The data 
sourced from Dunedin Public Hospital and Middlemore Hospital have 
previously been described in Chapter 5 (section 5.4.1.) and Chapter 7 (section 
7.4.1.1.) of this thesis, respectively. A description of the newly introduced data 
from the study by Pentikainen et al is provided in the following section. A 
summary of the demographic data of study participants from the three sources 
combined is shown in Table 8.2. 
8.4.1.1.1. Metformin pharmacokinetic study by Pentikainen et al 
Data was extracted from a study by Pentikainen et al [29]. In the study the 
pharmacokinetics of metformin following IV and PO administration in humans 
was investigated. The study included 5 healthy volunteers. Study volunteers 
fasted the night prior to the study. A single dose of metformin 500 mg was 
administered, either PO or IV, in the morning following the overnight fast. All 
study volunteers received an oral dose of metformin, with three of the volunteers 
receiving an additional IV bolus dose. The PO and IV doses were administered 
in random order and were given a minimum of three weeks apart. The oral dose 
of metformin was administered with 200 mL of water. Blood samples were 
collected at 0 (baseline), 5, 10, 20, 30, and 45 minutes, and, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 
12 and 24 hours post metformin PO and IV administration. Additional blood 
samples were collected following IV administration at the end of the injection 
and, 2 and 15 minutes post drug administration.  
Demographic, clinical and metformin pharmacokinetic data were extracted 
for the 3 study volunteers that had received both PO and IV doses of metformin. 
Demographic and clinical data extracted included: age, sex, height, weight and 
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serum creatinine. Data presented in the form of graphs was extracted using the 
MATLAB (R2016b, MathWorks, Natick, MA) code GRABIT. 
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Data presented as median [range] (interquartile range) unless otherwise specified. aBMI is body 
mass index. bFFM is fat free mass calculated using the equation by Janmahasatian et al [397]. 
c𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine clearance estimated using the Cockcroft and Gault equation [80]. Note that 
ideal body weight [398] was used in the Cockcroft and Gault equation as a body size metric. 
d𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷 is glomerular filtration rate estimated using the 4-variable Modification of Diet in 
Disease in Renal Disease equation [82]. e𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  is glomerular filtration rate estimated using 
the Chronic Kidney Disease Epidemiology Collaboration equation [83]. fNote that 𝑒𝐺𝐹𝑅𝑀𝐷𝑅𝐷  
(adjusted) and 𝑒𝐺𝐹𝑅𝐶𝐾𝐷𝐸𝑃𝐼  (adjusted) were adjusted the individual body surface area 
measurements for each subject calculated using the Du Bois Method [399]. 
8.4.1.2. Data management 
Data were handled as previously described in Chapter 7 (section 7.4.3.). 
8.4.2. Models for examining flip-flop with metformin 
For the purposes of this analysis a simplified one-compartment 
pharmacokinetic model was used to examine flip-flop with metformin. A 
simplified model was used as this work is illustrative for any drug rather than 
definitive for metformin and the issue of local identifiability becomes more 
complicated when the number of mammillary-compartments (𝑛)  increases; 
whereby, the possible number of permutations of parameter values that provide 
the same input-output relationship for a given compartmental model is 𝑛 + 1 
(counting only disposition compartments). 
In order to accommodate the effects of flip-flop, three levels of parameter 
constraints were considered (i) no constraints (i.e. flip-flop was allowed) termed 
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an unconstrained model, (ii) constraints at the population level to avoid flip-flop 
at the population parameter level (termed a partially constrained model) and (iii) 
constraints at the individual level to avoid flip-flop at the individual parameter 
level (termed a fully constrained model). The models were parameterised using 
either 𝐶𝐿 , 𝑉 , 𝑘𝑎 or 𝑘 , 𝑉 , 𝑘𝑎 . The parameter constraints, when applied, were 
applied to force the model into either its ‘flip’ or ‘flop’ state. The transition point 
(when 𝐶𝐿/𝑉 = 𝑘𝑎) was attempted to be estimated. The constraints were applied 
such that: (i) 𝑘 > 𝑘𝑎  in subjects with a creatinine clearance (𝐶𝐿𝑐𝑟𝐶𝐺) calculated 
using the Cockcroft and Gault equation greater than the flip-flop transition 
point, and, (ii) 𝑘 < 𝑘𝑎 in subjects with a 𝐶𝐿𝑐𝑟𝐶𝐺less than the transition point. In 
this setting 𝑘  was either the primary parameter or a secondary parameter 
(calculated from 𝐶𝐿 and 𝑉). The model constrained designs parameterised using 
𝐶𝐿, 𝑉, 𝑘𝑎and 𝑘, 𝑉, 𝑘𝑎 is shown as follows; 
 




, 𝐶𝐿𝑐𝑟𝐶𝐺 ≥ 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡
(𝐶𝐿/𝑉) ∙ (1 + 𝑘𝑎
∗), 𝐶𝐿𝑐𝑟𝐶𝐺 < 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡
 
 
𝒌, 𝑽, 𝒌𝒂 parameterisation 
𝑘 = {
𝑘𝑎 ∙ (1 + 𝑘
∗), 𝐶𝐿𝑐𝑟𝐶𝐺 ≥ 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡
𝑘𝑎
1 + 𝑘∗
, 𝐶𝐿𝑐𝑟𝐶𝐺 < 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡
 
 
where, 𝐶𝐿𝑐𝑟𝐶𝐺is creatinine clearance determined using the Cockcroft and Gault 
equation [80], 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡 is an estimated value of creatinine clearance at 
which 𝐶𝐿/𝑉 is believed to equal 𝑘𝑎. In the 𝐶𝐿, 𝑉, 𝑘𝑎 parameterisation, 𝐶𝐿, 𝑉 and 
𝑘𝑎
∗  are estimated parameters, and, 𝑘𝑎  is a calculated parameter. In the 𝑘, 𝑉, 𝑘𝑎 
parameterisation 𝑘𝑎 , 𝑉  and 𝑘
∗  are estimated parameters and 𝑘  is a calculated 
parameter. Note that the values of 𝑘𝑎 and 𝑘
∗ were constrained to values greater 
than 0.  
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Between subject variability was modelled using an exponential model to 
ensure individual pharmacokinetic parameters were constrained to values 
greater than 0. Covariance was considered for each parameterisation separately. 
A combined error model was used to describe residual unexplained variability 
(as described in Chapter 7 section 7.4.4.1.). 
The pharmacokinetic models were run with PO and IV concentration data 
combined and, also PO data only. Two sets of initial parameter estimates were 
used for the unconstrained models where 𝑘 < 𝑘𝑎 or 𝑘 > 𝑘𝑎 (shown in Table 8.3).  
Table 8.3 Initial estimates used for the unconstrained models 
Parameter values 𝒌 <  𝒌𝒂 𝒌 >  𝒌𝒂 
𝐶𝐿 (L/h) 25 25 
𝑉 (L) 100 50 
𝑘𝑎 (h-1) 0.5 0.25 
𝑘 (h-1) 0.25 0.5 
8.4.3. Performance of model constrained designs 
The performance of the model constrained designs were assessed by 
calculating the percentage of cases whose empirical Bayesian estimates (EBE) 
were as anticipated (i.e. 𝑘 > 𝑘𝑎 in subjects with 𝐶𝐿𝑐𝑟𝐶𝐺 > 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡 and 𝑘 
< 𝑘𝑎 in subjects with a 𝐶𝐿𝑐𝑟𝐶𝐺 < 𝑡𝑟𝑎𝑛𝑠𝑖𝑡𝑖𝑜𝑛 𝑝𝑜𝑖𝑛𝑡).  
8.4.4. Assessing flip-flop in covariate modelling 
A covariate analysis was conducted for each of the unconstrained models 
to assess the influence of flip-flop. In the unconstrained models parameterised 
using 𝐶𝐿, 𝑉 , 𝑘𝑎  creatinine clearance calculated using the Cockcroft and Gault 
equation (𝐶𝐿𝑐𝑟𝐶𝐺) was added as a covariate to (i) only 𝑘𝑎, (ii) only 𝐶𝐿 and (iii) 
both 𝑘𝑎 and CL. Similarly, 𝐶𝐿𝑐𝑟𝐶𝐺 was added as a covariate to (i) 𝑘𝑎, (ii)  𝑘 and 
(iii) both 𝑘𝑎 and 𝑘 in the unconstrained models parameterised using 𝑘, 𝑉, 𝑘𝑎. A 
significant reduction in the objective function value (i.e. 3.84 units Chi-square 
[𝜒2], p≤0.05) was used to test for significance. 
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8.4.5. Model evaluation 
A prediction corrected visual predictive check (pcVPC) was produced to 
assess whether a one-compartment model provided a reasonable fit to the data. 
Models were evaluated using standard diagnostic plots (described in Chapter 7 
section 7.4.4.5.) and pcVPCs. For the pcVPCs 1000 datasets were simulated under 
the models and the 5th, 50th and 95th percentiles were plotted against the same 
percentiles from the original dataset. The standard diagnostic plots and pcVPCs 
were produced using R (version 3.5.3). 
8.4.6. Modelling software 
The models were implemented using NONMEM v7.3 (ICON Development 
Solutions, Ellicott City, MD, USA) using the first-order conditional estimation 
method with interaction for parameter estimation. Pre- and post- processing was 
conducted using Perl-speaks-NONMEM (version 4.9.0) and R (version 3.5.3). 
The convergence criterion for estimation was set to 3 significant digits.  
  





The data analysed included a total of 426 plasma metformin concentrations 
available from 55 study participants. Cartesian and semi log plots of the plasma 
concentration time curves for the combined data are shown in Figure 8.1. Plots 




Figure 8.1 Plasma metformin concentrations following a single oral dose of metformin 
on a Cartesian (top) and semi-log (bottom) plot. The dots represent single measures of 
plasma metformin concentrations and the lines link repeated measures data for a single 
study participant. The red, green and blue lines reresent the metformin studies 
conducted by Dunedin Public Hospital, Middlemore Hospital and Pentikainen et al, 
respectively. 
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Seventy-seven plasma metformin concentrations collected from 
Middlemore Hospital were omitted from the analysis due to protocol violation 
(refer to Chapter 7 section 7.5.1. for additional details). Overall, eight percent of 
the plasma concentrations were below the quantification limit and were 
accounted for using the M6 method described by Beal [402]. 
Seventeen study participants had normal renal function (i.e. chronic kidney 
disease (CKD) category 1), and, 7, 16, 14 and 1 participant(s) had CKD 2, 3, 4 and 
5, respectively. Refer to Chapter 1 section 1.3.3. for more information about CKD 
categories. A histogram of the range of renal functions in the study population 
is shown in Figure 8.2.  
 
Figure 8.2 Histogram of the range of renal function represented by creatinine clearance 
in the combined dataset 
8.5.2. Models exploring flip-flop 
Sixteen models with different constrained designs, parameterisations and 
initial estimates were run with and without IV metformin concentration data. In 
all cases a one-compartment model with first-order input and output provided 
a reasonable description of the data. A pcVPC of the base model and goodness 
of fit plots for the sixteen models are presented in Appendix A6.3. Parameter 
estimates for the models run with concentration data following PO 
administration only and those following PO and IV administration are shown in 
Table 8.4 and Table 8.5, respectively. Examples of the NONMEM control files for 
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the unconstrained, partially constrained and fully constrained models 
parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎 are presented in Appendix A6.4. 
The parameter estimate for clearance was similar within each model 
parameterisation (i.e. 𝐶𝐿, 𝑉, 𝑘𝑎  and 𝑘, 𝑉, 𝑘𝑎) across the unconstrained models. 
This is shown in Table 8.4 and 8.5 where the model estimates for clearance were 
approximately 24 L/h under the 𝐶𝐿, 𝑉, 𝑘𝑎parameterisation, whilst the estimates 
of clearance determined by taking the product of 𝑘  and 𝑉  in the models 
parameterised using 𝑘, 𝑉, 𝑘𝑎 also appear to be approximately the same with a 
calculated value of approximately 44 L/h. The results from both tables suggest 
that the parameter estimates for clearance in the unconstrained models were not 
affected by the initial estimates used for 𝑘 and 𝑘𝑎 . It is worth noting that the 
estimates of clearance are similar across the partially and fully constrained 
designs. However, it appears that the remaining estimated parameters - 𝑘, 𝑉 and 
𝑘𝑎- were dissimilar across the different model designs. 
A comparison of the variance of the EBEs (𝑣𝑎𝑟𝜂) and their relative estimated 
variance (Ω) is shown in Table 8.6 (models run with PO data only) and Table 8.7 
(models run with PO and IV data). From both tables there is evidence of Ω 
shrinkage (i.e. 𝑣𝑎𝑟𝜂 >  Ω ) and Ω  inflation ( 𝑣𝑎𝑟𝜂 <  Ω ). It is only possible to 
describe the relative characteristics of Ω  and 𝑣𝑎𝑟𝜂 and, it is possible that Ω 
shrinkage may be due to 𝜂  inflation. It is assumed that 𝜂  follows a normal 
distribution. However, in the setting of flip-flop, it is possible that some subjects 
are estimated to be in ‘flip’ whilst others in are in ‘flop’ (i.e. some subjects are 
estimated to exhibit absorption mediated elimination whilst others exhibit 
elimination mediated elimination). This may lead to a bimodal distribution for 
𝜂, hence violating the assumption of normality on which Ω is predicated and 
causing Ω to be significantly inflated.  
The variance for 𝑘𝑎 appears to be larger under the constrained designs, and 
even more so under the fully constrained design (as shown in Table 8.6 and Table 
8.7). This is shown in the Table 8.6 and Table 8.7 where the variance for 𝑘𝑎 in the 
unconstrained models ranged between 0.08 to 0.43, whilst the variance for 𝑘𝑎 in 
the partially and fully constrained models range from 0.44 to 0.81 and 0.21 to 
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2.34, respectively. In the fully constrained design the variance for 𝑘𝑎 is likely to 
be larger as the constrained design forces the value for 𝑘𝑎 to either be in a ‘flip’ 
or ‘flop’ state based on the relative relationship between a study participants’ 
creatinine clearance and the transition point. Consequently, due to flip-flop, the 
distribution of Ω may have high skewness (i.e. heavy tail) and thus violate the 
normality assumption that predicates the use of the variance ( Ω ) to be a 
descriptor of dispersion. This can be seen in the histogram of the EBEs for 𝑘𝑎 
from the fully constrained models presented in Figure 8.3. 
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Table 8.4 Parameter estimates for models developed using metformin concentrations 








CL, V, ka k, V, ka 
CL, V, ka k, V, ka CL, V, ka k, V, ka 
Rank order of model initial estimates 
used for k and ka 
k < ka k > ka k < ka k > ka 
θCL 24.03 27.27   44.64  42.26  
θk   0.17 0.57     
θk(SMALL)      0.79  1.48 
θk(BIG)      0.43  7.14E-5 
θV 134.44 67.00 259.78 74.44 157.40 133.42 172.92 172.06 
θ𝑘𝑎  0.54 0.23 0.61 0.17  0.29  0.38 
θk𝑎(SMALL)     1.32E-4  9.97E-6  
θk𝑎(BIG)     0.360  0.694  
Between subject variability 
ωCL (CV%) 102.1 85.6   104.4  113.2  
ωk (CV%)   78.0 78.3  36.5  127.4 
ωV (CV%) 46.5 102.4 53.5 115.1 50.5 68.6 43.9 40.2 
ωk𝑎  (CV%) 68.6 50.6 50.7 61.2 100 101.9 237.1 51.7 
corrCL,V 0.797 0.519   0.565  0.795  
corrCL,k𝑎 0.078 0.260   0.185  -0.707  
corrk,V   0.009 -0.498  -0.014  -0.100 
corrk,k𝑎    -0.428 -0.251  -0.489  0.891 
corrV,k𝑎 0.447 0.900 0.637 0.865 0.900 0.879 0.052 0.362 
Residual error 
σadd   0.033 0.031 0.018 0.011 0.018 0.046 0.049 0.116 
σprop 0.264 0.251 0.263 0.265 0.258 0.222 0.219 0.098 
OFV -610.78 -606.58 -618.84 -619.00 -620.79 -623.84 -607.18 -608.96 
𝜃𝐶𝐿 is the mean population value for clearance (L/h). 𝜃𝐾 is the mean population value for the 
elimination rate constant (h-1). 𝜃𝑘(𝑆𝑀𝐴𝐿𝐿)  is an adjusting factor used to constrain 𝑘<𝑘𝑎  in the 
partially and fully constrained models. 𝜃𝑘(𝐵𝐼𝐺) is an adjusting factor used to constrain 𝑘>𝑘𝑎 in the 
partially and fully constrained models. 𝜃𝑉  is the mean population value for the volume of 
distribution (L). 𝜃k𝑎  is the mean population value for the absorption rate constant (h
-1). 𝜃k𝑎(𝑆𝑀𝐴𝐿𝐿) 
is an adjusting factor used to constrain 𝑘>𝑘𝑎  in the partially and fully constrained models. 
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𝜃k𝑎(𝐵𝐼𝐺)  is an adjusting factor used to constrain 𝑘<𝑘𝑎  in the partially and fully constrained 
models. ωCL is between subject variability for clearance, ωk is between subject variability for the 
elimination rate constant. ωV is between subject variability for the volume of distribution. ωk𝑎  is 
between subject variability for the absorption rate constant. σadd  is additive residual error 
(mg/L). σprop is proportional residual error (CV%). 𝑐𝑜𝑟𝑟 stands for correlation. OFV stands for 
objective function value. 
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Table 8.5 Parameter estimates for models developed using metformin concentrations 








CL, V, ka k, V, ka 
CL, V, ka k, V, ka CL, V, ka k, V, ka 
Rank order of model initial estimates 
used for k and ka 
k < ka k > ka k < ka k > ka 
𝜃𝐶𝐿 24.37 24.17   42.84  42.19  
𝜃𝑘   0.19 0.65     
𝜃𝑘(𝑆𝑀𝐴𝐿𝐿)      0.47  9.61E-5 
𝜃𝑘(𝐵𝐼𝐺)      1.50  2.46 
𝜃𝑉 128.01 37.27 227.04 66.79 148.62 104.11 172.96 83.64 
𝜃𝑘𝑎  0.54 0.16 0.51 0.16  0.24  0.19 
𝜃𝑘𝑎(𝑆𝑀𝐴𝐿𝐿)     9.95E-5  5.13E-6  
𝜃𝑘𝑎(𝐵𝐼𝐺)     0.22  0.51  
Between subject variability 
𝜔𝐶𝐿  (CV%) 100.4 98.2   101.6  100  
𝜔𝑘 (CV%)   98.6 10.5  39.1  97.9 
𝜔𝑉 (CV%) 68.3 102.4 86.0 109.7 113.7 108.8 63.5 79.2 
𝜔𝑘𝑎  (CV%) 50.9 72.8 75.2 73.4 111.4 99.9 569.6 59.1 
𝑐𝑜𝑟𝑟𝐶𝐿,𝑉 0.372 0.989   0.537  0.712  
𝑐𝑜𝑟𝑟𝐶𝐿,𝑘𝑎  -0.038 0.835   0.340  -0.147  
𝑐𝑜𝑟𝑟𝑘,𝑉   -0.426 -0.558  -0.571  -0.750 
𝑐𝑜𝑟𝑟𝑘,𝑘𝑎    -0.567 -0.442  -0.697  -0.998 
𝑐𝑜𝑟𝑟𝑉,𝑘𝑎  0.637 0.828 0.737 0.836 0.820 0.897 0.590 0.790 
Residual error 
𝜎𝑎𝑑𝑑  0.331 0.025 0.020 0.022 0.024 0.023 0.014 0.022 
𝜎𝑝𝑟𝑜𝑝 0.027 0.342 0.379 0.384 0.371 0.377 0.453 0.395 
OFV -507.92 -524.40 -416.76 -449.68 -410.73 -446.57 -303.87 -434.13 
𝜃𝐶𝐿 is the mean population value for clearance (L/h). 𝜃𝐾 is the mean population value for the 
elimination rate constant (h-1). 𝜃𝑘(𝑆𝑀𝐴𝐿𝐿)  is an adjusting factor used to constrain 𝑘<𝑘𝑎  in the 
partially and fully constrained models. 𝜃𝑘(𝐵𝐼𝐺) is an adjusting factor used to constrain 𝑘>𝑘𝑎 in the 
partially and fully constrained models. 𝜃𝑉  is the mean population value for the volume of 
distribution (L). 𝜃k𝑎  is the mean population value for the absorption rate constant (h
-1). 𝜃k𝑎(𝑆𝑀𝐴𝐿𝐿) 
is an adjusting factor used to constrain 𝑘>𝑘𝑎  in the partially and fully constrained models. 
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𝜃k𝑎(𝐵𝐼𝐺)  is an adjusting factor used to constrain 𝑘<𝑘𝑎  in the partially and fully constrained 
models. ωCL is between subject variability for clearance, ωk is between subject variability for the 
elimination rate constant. ωV is between subject variability for the volume of distribution. ωk𝑎  is 
between subject variability for the absorption rate constant. σadd  is additive residual error 
(mg/L). σprop is proportional residual error (CV%). 𝑐𝑜𝑟𝑟 stands for correlation. OFV stands for 
objective function value. 
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Table 8.6 Variance of empirical Bayesian estimates and their relative estimated variance values for models developed using metformin 
concentrations following oral metformin administration only 
Parameters 
Model constraint design 
Unconstrained Partially constrained Fully constrained 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 Rank order of model initial estimates used for 𝑘 and 𝑘𝑎 
𝑘 < 𝑘𝑎 𝑘 > 𝑘𝑎 𝑘 < 𝑘𝑎 𝑘 > 𝑘𝑎 
𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 
𝐶𝐿 0.70 0.71 0.70 0.55     0.71 0.74   0.71 0.73   
𝑘     0.36 0.48 0.30 0.48   0.24 0.13   0.83 0.96 
𝑉 0.15 0.20 0.94 0.72 0.19 0.25 0.64 0.84 0.19 0.23 0.25 0.39 0.18 0.21 0.14 0.15 
𝑘𝑎 0.26 0.39 0.30 0.23 0.10 0.23 0.24 0.32 0.57 0.69 0.60 0.71 1.36 1.63 0.21 0.24 
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Table 8.7 Variance of empirical Bayesian estimates and their relative estimated variance values for models developed using metformin 
concentrations following oral and intravenous administered metformin 
Parameters 
Model constraint design 
Unconstrained Partially constrained Fully constrained 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 𝐶𝐿, 𝑉, 𝑘𝑎 𝑘, 𝑉, 𝑘𝑎 Rank order of model initial estimates used for 𝑘 and 𝑘𝑎  
𝑘 < 𝑘𝑎 𝑘 > 𝑘𝑎 𝑘 < 𝑘𝑎 𝑘 > 𝑘𝑎 
𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 𝑣𝑎𝑟𝜂 Ω 
𝐶𝐿 0.65 0.70 0.64 0.68     0.67 0.71   0.66 0.71   
𝑘     0.45 0.68 0.002 0.01   0.05 0.14   0.56 0.67 
𝑉 0.28 0.38 0.66 0.72 0.43 0.55 0.73 0.79 0.40 0.83 0.63 0.78 0.37 0.78 0.44 0.49 
𝑘𝑎 0.08 0.23 0.37 0.43 0.20 0.45 0.37 0.43 0.44 0.81 0.53 0.69 1.24 2.34 0.25 0.3 
𝑣𝑎𝑟𝜂: represents the variance of the empirical Bayes estimates, Ω: represents the model estimated variance 
 











Figure 8.3 Histogram of empirical Bayesian estimates for ka from the fully constrained 
models. a is the fully constrained model parameterised using CL, V, ka run using oral 
data. b is the fully constrained model parameterised using CL, V, ka run using oral and 
intravenous data. c is the fully constrained model parameterised using k, V, ka run 
using oral data. d is the fully constrained model parameterised using k, V, ka run using 
oral and intravenous data 
 
8.5.2.1. Determining a flip-flop transition point 
A flip-flop transition point could not be estimated from the data available 
for analysis. A sensitivity analysis was performed by fixing the flip-flop 
transition point to 𝐶𝐿𝑐𝑟𝐶𝐺values of 10 to 100 mL/min in 10 mL/min increments, 
but the modelling results were not sensitive to the changes. Instead, a flip-flop 
transition point of 𝐶𝐿𝑐𝑟𝐶𝐺  30 mL/min was selected based on theoretical 
considerations (discussed in Appendix A6.5).  
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8.5.2.2. Performance of constrained designs  
Initial estimates were found to influence the model parameter estimates in 
the unconstrained models. This was demonstrated by the model parameter 
estimates sharing the same rank order as the model initial estimates used. The 
percentage of subjects with 𝑘  values less than or greater than 𝑘𝑎  when using 
different rank orders for 𝑘 and 𝑘𝑎 as the initial estimates is shown in Table 8.8. 
Table 8.8 Percentage of subjects with empirical Bayes estimates of k less than or greater 
than ka when using different initial estimates of k and ka in the unconstrained model 
Model description 
𝒌 > 𝒌𝒂 
(% of subjects) 
𝒌 < 𝒌𝒂 
(% of subjects) Parameterisation 
Rank order of initial 
estimates 
Models run using oral metformin concentration data only 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘 < 𝑘𝑎 5.8% 94.2% 
 𝑘 > 𝑘𝑎 80.8% 19.2% 
𝑉, 𝑘𝑎 , 𝑘 𝑘 <  𝑘𝑎 0.0% 100.0% 
 𝑘 > 𝑘𝑎 96.2% 3.8% 
Models run using oral and intravenous concentration data 
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘 < 𝑘𝑎 10.9% 89.0% 
 𝑘 > 𝑘𝑎 98.2% 1.8% 
𝑉, 𝑘𝑎 , 𝑘 𝑘 <  𝑘𝑎 7.3% 92.7% 
 𝑘 > 𝑘𝑎 98.2% 1.8% 
 
A summary of the performance of the parameter constrained designs is 
shown in Table 8.9. The fully constrained model performed the best at 
constraining the rank order of model parameters. This was demonstrated by the 
rank order of EBEs (as shown in Table 8.9) always being as theoretically 
anticipated when using the fully constrained model. 
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Table 8.9 Percentage of cases with output EBEs theoretically anticipated based on the 
transition point (creatinine clearance of 30 mL/min) 
Models description 
CLcr >30 mL/min 
𝒌 > 𝒌𝒂 (%true) 
CLcr ≤30 mL/min 
𝒌 < 𝒌𝒂 (% true) 
Constrain design 
Rank order of 
initial estimates 
PO IV & PO PO IV & PO 
Unconstrained      
𝐶𝐿, 𝑉, 𝑘𝑎 𝑘 < 𝑘𝑎 8.1 15 100 100 
 𝑘 > 𝑘𝑎 75.7 97.5 6.7 0 
𝑉, 𝑘𝑎 , 𝑘 𝑘 <  𝑘𝑎 0 10 100 100 
 𝑘 > 𝑘𝑎 94.6 97.5 0 0 
Partially constrained      
𝐶𝐿, 𝑉, 𝑘𝑎  48.6 62.5 86.7 93.3 
𝑉, 𝑘𝑎 , 𝑘  59.5 95 93.3 86.7 
Fully constrained      
𝐶𝐿, 𝑉, 𝑘𝑎  100 100 100 100 
𝑉, 𝑘𝑎 , 𝑘  100 100 100 100 
8.5.2.3. Accounting for important covariates 
In the unconstrained models parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎 the univariate 
addition of 𝐶𝐿𝑐𝑟𝐶𝐺  to either 𝐶𝐿  or 𝑘𝑎  was found to be significant on each 
parameter – with the exception of the addition of 𝐶𝐿𝑐𝑟𝐶𝐺  to 𝑘𝑎  in the 
unconstrained model run with PO and IV data with initial estimates of 𝑘 > 𝑘𝑎. In 
the unconstrained models parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎 the greatest reduction 
in objective function value followed the univariate addition of 𝐶𝐿𝑐𝑟𝐶𝐺  as a 
covariate on 𝐶𝐿.  
The univariate addition of 𝐶𝐿𝑐𝑟𝐶𝐺  to 𝑘  was found significant in all 
unconstrained models parameterised using 𝑘 , 𝑉 , 𝑘𝑎 . However, the univariate 
addition of 𝐶𝐿𝑐𝑟𝐶𝐺 to 𝑘𝑎 was only found significant in the unconstrained model 
parameterised using 𝑘, 𝑉, 𝑘𝑎 with initial estimates of 𝑘 < 𝑘𝑎 run with PO and IV 
data. As was found in the unconstrained models parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎, 
the greatest reduction in objective function value in the unconstrained models 
parameterised using 𝑘, 𝑉, 𝑘𝑎 followed the univariate addition of  𝐶𝐿𝑐𝑟𝐶𝐺 to 𝑘.  
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Furthermore, in the unconstrained models, the order 𝐶𝐿𝑐𝑟𝐶𝐺was added as 
a covariate on 𝐶𝐿  (or 𝑘) or 𝑘𝑎  and then both 𝐶𝐿  (or 𝑘) and 𝑘𝑎  were found to 
influence model findings. When 𝐶𝐿𝑐𝑟𝐶𝐺was first added as a covariate on 𝐶𝐿 (or 
𝑘 ), the further addition of 𝐶𝐿𝑐𝑟𝐶𝐺  on 𝑘𝑎  did not result in any further 
improvement in global fit (shown in Table 8.10). However, when 𝐶𝐿𝑐𝑟𝐶𝐺was first 
added as a covariate on 𝑘𝑎, the further addition of 𝐶𝐿𝑐𝑟𝐶𝐺on 𝐶𝐿 improved the 
global fit. 
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Table 8.10 Objective function value for unconstrained base and covariate models 
Model description OFV 
Data 
Rank order of 
initial estimates 
Model 𝐶𝐿, 𝑉, 𝑘𝑎 𝑉, 𝑘𝑎, 𝑘 
PO 𝑘 < 𝑘𝑎 Base model -610.777 -618.839 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎 -619.756 -613.612 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝐶𝐿 (or 𝑘) -664.627 -664.544 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎and 𝐶𝐿 (or 𝑘) -664.576 -668.277 
 𝑘 > 𝑘𝑎 Base model -606.575 -619.003 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎 -618.988 -612.479 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝐶𝐿 (or 𝑘) -664.076 -658.409 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎and 𝐶𝐿 (or 𝑘) -665.584 -657.125 
PO & IV 𝑘 < 𝑘𝑎 Base model -507.917 -416.763 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎 -524.710 -450.193 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝐶𝐿 (or 𝑘) -566.119 -472.453 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎and 𝐶𝐿 (or 𝑘) -565.131 -470.012 
 𝑘 > 𝑘𝑎 Base model -524.404 -449.678 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎 -524.710 -450.193 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝐶𝐿 (or 𝑘) -566.119 -473.763 
  𝐶𝐿𝑐𝑟𝐶𝐺on 𝑘𝑎and 𝐶𝐿 (or 𝑘) -560.991 -471.527 
OFV represents objective function value 
  




In this study the influence of issues associated with flip-flop in population 
pharmacokinetic modelling was explored and an approach to solve flip-flop was 
proposed. The following five inferences can be made from this work; 
 
Inference 1. Clearance is invariant to flip-flop 
Clearance is not affected by flip-flop. For instance, in a one-compartment model 
with first-order input and output parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎 there are two 
sets of permutations of parameter values that will provide the same input-output 
relationship. In both permutations clearance remains the same and is 
independent of other parameters (shown in Table 8.1) and also it is seen 
theoretically when permuting the parameter values for the 𝐶𝐿 , 𝑉 , 𝑘𝑎 
parameterisation.  
 
The product of 𝑘  and 𝑉  (under the 𝑘 , 𝑉 , 𝑘𝑎 ) parameterisation also remains 
unaffected by flip-flop although their respective values are affected. 
 
Inference 2. Unconstrained models require a covariate on clearance  
If an unconstrained model is used to model a drug with flip-flop 
pharmacokinetics, a covariate on clearance describing the elimination process is 
required if there is no paired oral and intravenous data. A strong covariate 
relationship should be able address issues of local identifiability due to flip-flop 
and hence, stabilise the model. Note that inference 2 would not apply to a 
covariate that also influences other processes, such as absorption. This is because 
the covariate would be confounded by the absorption and elimination processes 
and hence, would no longer be able to address issues of local identifiability. 
 
Inference 3. A fully constrained design is needed if there is no IV data and no covariate 
on clearance 
A fully constrained model should be used to model drugs with flip-flop 
pharmacokinetics if there is no paired IV and PO data and, no covariate available 
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to describe clearance. The fully constrained design should be used if the volume 
of distribution and absorption rate constant are parameters of interest. 
 
Inference 4. The k, V, ka parameterisation should not be used when investigating flip-
flop 
The 𝑘, 𝑉, 𝑘𝑎 parameterisation should not be used to model drugs with flip-flop 
pharmacokinetics as all parameters in this parameterisation set are influenced 
by flip-flop (shown in Table 8.1). However, it is worth noting that the product of 
𝑘 and 𝑉 (i.e. 𝐶𝐿) is not affected. Instead, the 𝐶𝐿, 𝑉, 𝑘𝑎 parameterisation should be 
used when dealing with drugs exhibiting flip-flop pharmacokinetics. 
 
Inference 5. Flip-flop may result in spurious relationships being found if important 
covariates are not accounted for 
A relationship was identified between 𝐶𝐿𝑐𝑟𝐶𝐺 and 𝑘𝑎  for the unconstrained 
model when the relationship 𝐶𝐿𝑐𝑟𝐶𝐺 and 𝐶𝐿 (or 𝑘) had not been accounted for. 
This relationship between 𝐶𝐿𝑐𝑟𝐶𝐺and 𝑘𝑎 is likely to be spurious. 
 
In Chapter 7 of this thesis, a population pharmacokinetic model for 
metformin was developed. The findings from this chapter indicate that the 
developed model would not be affected by flip-flop. This is for two reasons. The 
first is because the model was parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎; hence, the estimate 
of 𝐶𝐿 would not be affected and can reasonably be used in simulations exploring 
the renal dosing of metformin. Secondly, the developed model was an 
unconstrained model but had a covariate (i.e. 𝐶𝐿𝑐𝑟𝐶𝐺) on clearance, and hence, 
would stabilise the model into ‘flip’ or ’flop’ by preventing it from ‘flip-flop’. 
There are very few published compartmental population pharmacokinetic 
models where flip-flop pharmacokinetics were observed that also explain how 
the data were analysed. In these studies flip-flop pharmacokinetics was 
commonly exhibited in drugs that were either in a modified drug release 
formulation or had been administered via a zero order process (e.g. continuous 
infusion) [408-410]. The methodology used to solve the issues of local 
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identifiability due to flip-flop pharmacokinetics in population pharmacokinetic 
modelling ranged from methods that simply ignored flip-flop to studies that had 
applied constraints in the structural model [408-410]. In addition, only one study 
was identified that explicitly stated how constraints were applied to maintain a 
certain rank order amongst model parameters [408]. 
8.7. Limitations 
An important limitation for extrapolation of these study results is the 
dependence of the inferences on metformin data. While it is reasonable that some 
of the concepts could be generalised to other drugs that are predicted to exhibit 
‘flip-flop’ we cannot state the degree of certainty or power of such analyses. 
Future work would need to be performed to explore the truth behind these 
findings, such as a stochastic simulation estimation method.  
8.8. Conclusions 
In this study, the influence of the ‘flip-flop’ problem in modelling was 
explored and approaches to solve the ‘flip-flop’ problem in population 
pharmacokinetic modelling were proposed. In the absence of IV data a fully 
constrained design is needed. The 𝐶𝐿, 𝑉 , 𝑘𝑎  parameterisation should be used 
when dealing with drugs with flip-flop pharmacokinetics.  
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9.1. Synopsis of this thesis 
In this thesis different approaches were used to explore the safe use of 
metformin and to create a renal dosing guideline to mitigate the risk of lactic 
acidosis. 
In Chapter 2 a systematic literature review was performed to identify 
published case reports of metformin associated lactic acidosis (MALA) and the 
association between metformin therapy and lactic acidosis was formally 
evaluated in the published case reports using the World Health Organisation-
Uppsala Monitoring Centre system for case causality assessment (WHO-UMC) 
and the Naranjo Adverse Drug Reaction (ADR) Probability Scale [106, 107]. As 
part of this work a database of MALA case reports identified from the systematic 
literature review was developed and is available to other researchers in the 
figshare repository; https://figshare.com/s/4a1129faa048322cfa0c.  
In Chapter 3 a subgroup analysis was performed to explore the relationship 
between metformin dose, plasma metformin concentrations and lactic acidosis 
in published MALA cases with chronic renal impairment to assess whether 
metformin therapy could safely be used in patients with renal impairment. 
In Chapter 4 a pragmatic literature search was performed to clarify the 
upper limit of safety for metformin. This was complimented by a quantitative 
analysis that identified an upper limit of safety for metformin by fitting a 
concentration response curve to plasma metformin and lactate concentrations. 
In Chapter 5 a pharmacokinetic analysis was performed to explore the 
pharmacokinetics of metformin in renal impairment to inform dosing and, from 
which an empirical renal dosing guideline for metformin was developed.  
In Chapter 6 simulations were performed to explore the concentration time 
profile of metformin in patients with renal impairment. 
In Chapter 7 a population pharmacokinetic model for metformin was 
developed and evaluated. Simulations were performed from the model to assess 
the safety of the dose recommendations from the empirical renal dosing 
guideline and the New Zealand Formulary (NZF)[24].  
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Lastly, in Chapter 8, an analysis was performed to explore the influence of 
flip-flop pharmacokinetics in population pharmacokinetic models.  
9.2. Synopsis of the thesis findings 
9.2.1. Metformin therapy and lactic acidosis 
The causal association between therapeutic doses of metformin and lactic 
acidosis is well-debated. In this thesis, metformin was found to play only a 
possible role in the development of lactic acidosis at therapeutic doses in the 
published cases of MALA according to analyses using the WHO-UMC and 
Naranjo causality assessments [106, 107]. Almost all identified cases presented 
with risk factors, other than metformin, that could on their own have led to lactic 
acidosis. These findings support the growing argument in literature that 
therapeutic doses of metformin may not be a primary cause of lactic acidosis. 
Rather, that metformin may play a contributory role in the development of lactic 
acidosis alongside other risk factors. Published work by other authors have 
collectively reported that the majority of MALA cases had presented with other 
risk factors for lactic acidosis that could better explain the development of lactic 
acidosis (e.g. septic shock) [100, 213, 260], and thus, has led to the notion that the 
presence of metformin in these cases is coincidental and that it may merely be an 
innocent bystander. Overall, these results support the notion that metformin can 
safely be used in patients at therapeutic doses. 
9.2.1.1. Metformin therapy and lactic acidosis in renal impairment 
In a subgroup analysis looking at MALA cases with a history of chronic 
renal impairment, metformin was similarly found to play only a possible role in 
the development of lactic acidosis when using the WHO-UMC and Naranjo 
causality assessments. Most of the cases with a history of chronic renal 
impairment presented with acute renal failure on admission, which confounded 
the relationship between metformin dose and plasma concentrations. However, 
it is worth noting that the prescribed metformin dose was found to exceed 
published renal dosing guidelines in over 60% of cases with an eGFR less than 
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60 mL/min by a median of 1000 mg/day. However, despite this, simulations 
performed using a published pharmacokinetic model for metformin predicted 
that pre-admission plasma metformin concentrations measured pre-dose were 
not expected to exceed the proposed upper limit of the therapeutic range of 5 
mg/L in most cases. These findings suggest that chronic renal impairment is 
unlikely to be the primary cause of the highly elevated plasma metformin 
concentrations seen in MALA cases presenting with concomitant acute renal 
failure. Here, these findings reinforce the idea that metformin can be used safely 
for the treatment of type 2 diabetes mellitus in patients with or without chronic 
renal impairment provided that plasma metformin concentrations are 
maintained within a safe therapeutic range. 
9.2.2. Metformin dosing in renal impairment 
9.2.2.1. An upper limit of safety for metformin 
To date, the upper limit of safety for metformin is not well established. In 
a pragmatic literature search no studies were identified to have reported an 
upper limit of safety for metformin that was defined by means of a formal 
exposure response analysis. Historically, a plasma metformin concentration of 5 
mg/L has been nominated as the upper limit of safety for metformin. However, 
the origin of this proposed upper safety limit for metformin is unclear and has 
been questioned [45, 386]. Findings from an exploration of the concentration 
response relationship between plasma metformin and lactate concentrations 
suggested that plasma metformin concentrations greater than 4.5 mg/L were 
associated with severe hyperlactatemia – a value in the same ballpark as the 
nominated upper limit of safety for metformin of 5 mg/L.  
Overall, the proposed upper limit of 4.5 mg/L provides a metric that can 
be used to guide the safe dosing of metformin, particularly in renal impairment. 
The findings suggest that metformin doses should be adjusted to maintain 
plasma metformin concentrations below 4.5 mg/L to mitigate the risk of lactic 
acidosis. The proposed upper limit of safety for metformin was used in Chapter 
7 to assess the safety of renal dosing guidelines for metformin.  
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9.2.2.2. Pharmacokinetics of metformin in renal impairment 
The pharmacokinetic profile of metformin was found to be influenced by 
renal impairment. Patients with poorer renal function were found to have lower 
apparent and renal clearances for metformin. In a correlation analysis, the 
decrease in the apparent and renal clearance for metformin in patients with 
varying levels of renal impairment could reasonably be predicted by estimates 
of renal function determined using the Cockcroft and Gault, 4-variable 
Modification Diet in Renal Disease (MDRD) and Chronic Kidney Disease 
Epidemiology Collaboration (CKD-Epi) equations [80, 82, 83]. These findings 
highlight the idea that metformin can continued to be used in renal impairment 
provided doses are reduced in proportion to renal function to maintain plasma 
concentration within a safe therapeutic range. In addition, the results suggest 
that the Cockcroft and Gault, 4-variable MDRD and CKD-Epi equations can be 
used to interchangeably to inform the renal dosing of metformin [80, 82, 83]. 
Furthermore, a simulation study found that a reduction in clearance and/or flip-
flop kinetics could recreate the concentration time profile of metformin seen in 
patients with renal impairment. 
A population pharmacokinetic model for metformin was developed in 
healthy subjects and patients with severe renal impairment. The covariate 
analysis found that renal function and total body weight could describe patient 
differences in metformin apparent clearance and volume of distribution, 
respectively. The addition of creatinine clearance as a covariate on the apparent 
clearance of metformin resulted in a reduction in between subject variability 
from 105% to 46%. Similarly, the addition of total body weight as a covariate on 
the central compartment volume was found to reduce between subject 
variability from 37% to 30%. Here, it is worth noting, that the model structure, 
parameter estimates and covariates of the final developed population 
pharmacokinetic model for metformin were similar to published models of 
metformin developed in subjects with and without renal impairment [15, 370]. 
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9.2.2.3. Dosing metformin in patients with stable chronic renal impairment 
An empirical renal dosing guideline for metformin using the Cockcroft and 
Gault, 4-variable MDRD and CKD-Epi equations was developed, and, the 
maintenance dose range was determined for patients in different CKD category 
groups. In simulations performed using the developed population 
pharmacokinetic model under the dose predictions from the empirical equations 
and the NZF guidelines it was predicted that plasma concentrations would not 
exceed the proposed upper limit of safety of 4.5 mg/L.  
To date, there are a number of published renal dosing guidelines for 
metformin, though few appear to be evidence based. Here, it is worth noting that 
the published metformin renal dosing guidelines recommended the use of doses 
around the same magnitude as the doses predicted from the empirical equations. 
This suggests, that on this basis, it can be inferred that the plasma metformin 
concentrations in the published renal dosing guidelines are also unlikely to 
exceed the upper limit of safety of 4.5 mg/L, and thus, furthermore suggests that 
the published renal dosing guidelines do provide reasonable dose 
recommendations that will maintain plasma concentrations within a safe range.  
9.2.3. Flip-flop pharmacokinetics in population pharmacokinetic models 
The influence of flip-flop pharmacokinetics in population pharmacokinetic 
models was explored and an approach to solve problems due to flip-flop was 
proposed. In the absence of paired intravenous (IV) and oral (PO) concentration 
data, it was found that a covariate on clearance is required in an unconstrained 
model to avoid issues of local identifiability due to flip-flop. However, in the 
absence of paired IV and PO data as well as a covariate on clearance, a fully 
constrained model is required. Published population pharmacokinetic models 
dealing with flip-flop commonly addressed flip-flop in the context of 
compounds delivered using controlled release dosage forms (i.e. the elimination 
rate constant (𝑘) is larger than the absorption rate constant (𝑘𝑎)) [408]. However, 
in this thesis, novel approaches to address issues of local identifiability when 𝑘 
< 𝑘𝑎 and 𝑘 < 𝑘𝑎 can occur in a single dataset are proposed.   
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9.3. Thesis limitations 
The findings presented in this thesis should be interpreted in light of the 
following limitations. 
An important limitation of the causality assessment work was that the 
Naranjo Adverse Drug Reaction Probability Scale was not designed to assess 
causality retrospectively. Rather, the Naranjo causality assessment was designed 
for use in the clinic where clinicians could request for laboratory tests to be 
performed. Therefore, the Naranjo causality assessment was used beyond its 
original intention. Despite this, the results from the Naranjo causality assessment 
supported the results from the WHO-UMC causality assessment which was 
designed to assess causality using retrospective data presented in case reports. 
In addition, the association between metformin therapy and lactic acidosis 
was assessed using retrospective data from case reports. From an 
epidemiological stance, case reports are commonly recognised to be poor in 
quality and incomplete in terms of data reported. Furthermore, due to the 
retrospective nature of the data presented in the case reports the causation of 
metformin in the development of lactic acidosis could not be proven [411]. 
Rather the published case reports could only be used to provide evidence for and 
to show the strength of an association between metformin therapy and lactic 
acidosis [411]. Only by means of a randomised controlled trial could the 
causation of metformin therapy in the development of lactic acidosis be 
established. 
The use of the empirical renal dosing equations should viewed in light of 
the following limitations. Previous literature has suggested that the 
bioavailability of metformin decreases with increasing dose [27, 31]. However, 
the data from which metformin concentrations were sampled from came from 
study participants that were all given a single oral 500 mg dose of metformin. 
However, here, the dose predictions from the empirical equation assumes that 
bioavailability is the same between the different doses. In addition, the 
developed empirical equation only had a single covariate (i.e. renal function) to 
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describe patient variability. Though, it is possible that there are other patient 
characteristics that may also help inform dosing. 
Although it was not addressed in this thesis it is important to consider the 
impact of obesity on the estimation of renal function. In obese patients, the 
impact of obesity may result in overestimated values for clearance and renal 
function, which may lead to higher doses of a drug being prescribed than truly 
required. This is particularly evident in the Cockcroft and Gault equation (shown 
in Equation 1.1) as the formula uses weight to predict creatinine clearance. 
Hence, in obese patients, it is commonly recommended that an alternate body 
size descriptor is used (e.g. lean body weight) instead of total body weight when 
using a renal function estimating equation that relies on body weight. 
9.4. Future prospects 
In Chapter 2 and 3 the use of the WHO-UMC and Naranjo causality 
assessments may have produced biased results in this study. It was noted that 
both the causality assessments frequently assigned causality to the “possible” 
category – a finding raised by other authors in the literature [362, 363]. Future 
work investigating the reason for the noted bias in the causality criteria could 
guide areas where the current published causality assessments could be 
modified and improved. 
In this thesis metformin doses were assessed for safety by predicting 
whether plasma metformin concentrations would exceed the identified upper 
limit of safety. However, as this thesis did not explore the pharmacodynamics of 
metformin, it is not known whether the doses recommended are efficacious. A 
study is needed to define the therapeutic range (i.e. both upper and lower limits 
for safety and efficacy) for metformin. The identification of a therapeutic range 
for metformin would help inform the dosing of metformin to provide a dose that 
is both safe and efficacious.  
In Chapter 5 a dose banding approach was used to guide the renal dosing 
of metformin when using the empirical renal dosing guidelines. However, it is 
unclear whether patients at the upper end of a dose band cut-off are more 
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susceptible to treatment failure and whether patients at the lower end of the dose 
band cut-off are more susceptible to drug toxicity due to increased drug 
exposure. Future work to explore the impact of being near the renal function cut-
offs on treatment failure and drug toxicity would provide resolution on whether 
dose banding is an appropriate method to guide dosing or whether other 
methods are warranted. 
Future work could involve the development of a model-based dose 
banding guideline from the developed population pharmacokinetic model in 
Chapter 7. Here, the empirical renal dosing guideline and model-based dosing 
guidelines could be compared using a clinical trial simulation design involving 
stochastic simulations to identify the best dosing approach. This work could then 
be followed by a randomised controlled trial to assess the proposed renal dosing 
guideline in patients with type 2 diabetes mellitus patients. 
In Chapter 8 the influence of flip-flop pharmacokinetics in population 
pharmacokinetic models was explored using metformin data. Thus, the findings 
in this setting are true for metformin but not all concepts are necessarily 
generalisable to other drugs. Here, a future stochastic simulation estimation 
study to explore the influence of flip-flop pharmacokinetics in population 
pharmacokinetic models could be conducted to evaluate these findings and their 
relevance to other drugs. 
9.5. Conclusion 
Metformin was found to play only a possible role in the majority of 
published MALA cases with and without renal impairment at therapeutic doses. 
Almost all cases presented with risk factors other than metformin that could on 
their own have caused to lactic acidosis.  
The concentration-response relationship between plasma metformin and 
lactate concentrations was explored across a wide range of metformin doses. 
Plasma metformin concentrations >4.5 mg/L were found to be associated with 
an increased risk of severe hyperlactatemia. This suggests that dose adjustment 
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to maintain plasma metformin concentrations to <4.5 mg/L should mitigate the 
risk of lactic acidosis. 
A pharmacokinetic analysis was performed to explore the exposure metrics 
of metformin in patients with renal impairment. The results suggest that 
metformin exposure in renal impairment is influenced by a reduction in 
clearance and/or flip-flop. The creatinine-based equations for estimating renal 
function were found to provide reasonable predictions of the renal clearance of 
metformin and can be used interchangeably to inform the dosing.  
An empirical renal dosing guideline was developed for metformin. A 
population pharmacokinetic model for metformin was developed and was used 
to assess the safety of the developed empirical renal dosing guideline for 
metformin and the current NZF renal dosing guidelines. Based on the simulation 
results plasma concentrations of metformin were predicted to not exceed the 
upper safety limit of 4.5 mg/L. This suggests that both the empirical and NZF 
renal dosing guidelines can be used safely in patients with renal impairment. 
The influence of the flip-flop in modelling was explored and approaches to 
solve the ‘flip-flop’ problem in population pharmacokinetic modelling were 
proposed. 
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A1.1. Systematic literature review search strategy  
In this section the search strategies used to perform the systematic literature 
review are presented. The search strategies are divided into the following two 
sections: 
• Appendix A1.1.1 Static search strategy 
• Appendix A1.1.2 Learning based approach search strategy 
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A1.1.1. Static search strategy 
The static search strategies conducted in Ovid EMBASE, Ovid MEDLINE, 
Google Scholar and SCOPUS are presented in Table A1.1, A1.2, A1.3 and A1.4, 
respectively. 
Table A1.1 Ovid EMBASE static search strategy 
Source Search strategy 
Ovid EMBASE 
Covering period 1946 to 
July 2017 
1. exp Metformin/ or Biguanide derivative/ or Oral 
antidiabetic agent/ 
2. exp biguanide 
 3. Antidiabetic agent/ 
 4. Antihyperglycemic.mp 
 5. 1 or 2 or 3 or 4 
 6. exp Lactic acidosis 
 7. exp Acidosis 
 8. exp Lactic acid 
 9. exp Hyperlactatemia 
 10. 6 or 7 or 8 or 9 
 11. Case report/ 
 12. exp Case study/ 
 13. Case.mp 
 14. 11 or 12 or 14 
 15. 5 and 10 and 14 
 Results: 1025 
 16. Limit 15 to (English language and human) 
 Results: 835 
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Table A1.2 Ovid MEDLINE static search strategy 
Source Search strategy 
Ovid MEDLINE 
Covering period 1946 to 
July 2017 
1. exp Metformin 
2. Biguanides 
3. Antidiabetic agent.mp 
4. Antihyperglycemic.mp 
5. 1 or 2 or 3 or 4 
6. exp Acidosis, Lactic/ 
7. exp Acidosis/ 
8. exp Lactic Acid/ 
9. exp Hyperlactatemia/ 
10. 6 or 7 or 8 or 9 
11. exp Case reports/ 
12. Case series.mp 
13. Case.mp 
14. 11 or 12 or 13 
15. 5 and 10 and 14 
Results: 306 
16. Limit 15 to (English language and humans) 
Results: 219 
 
Table A1.3 Google Scholar static search strategy 
Source Search strategy 
Google Scholar 
Search was conducted 
using the software 
Harzing’s Publish and 
Perish 
All of the words:  
metformin, lactic acidosis, case, patient, lactate, pH 
Any of the words:  
metformin, lactic acidosis 
The phrase:  
metformin associated lactic acidosis 
 Results: 765 
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Table A1.4 SCOPUS static search strategy 
Source Search strategy 
SCOPUS 
1. exp Metformin 
2.  Lactic acidosis 
3. Case 
Results: 609 
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A1.1.2. Learning based approach search strategy 
Two searches using the learning based approach were conducted in Ovid 
MEDLINE. The first was a general search of metformin associated lactic acidosis 
case reports (Table A1.5) and the second was a search to identify case reports of 
metformin associated lactic acidosis following metformin overdose (Table A1.6).  
Table A1.5 General learning based approach search strategy 
Source Iterations Medical subject headings 
Ovid MEDLINE 
Covering period 
1946 to July 2017 
1 
1. exp Acidosis 
2. exp Biguanides 
3. exp Buformin 
4. exp Diabetes Complications 
5. exp Diabetes Mellitus 
6. exp Hypoglycaemic Agents 
7. exp Lactates 
8. exp Metformin 
9. Phenformin 
 Results: 1473 
2 
10. exp Diabetes Mellitus 
11. exp Hypoglycaemic Agents 
12. exp Metformin 
13. exp Acidosis, Lactic 
14. exp Cohort Studies 
15. exp Hyperlactatemia 
16. exp Case-control Studies 
17. exp Pharmacovigilance 
18. exp Drug-related side effects 
19. exp Biguanides 
20. exp Patients 
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Table A1.5 cont General learning based approach search strategy 
Source Iterations Medical subject headings 
 
 1 OR 2 
 Results: 2557 
 Limit to English language 
 Results: 2128 
 Limit to Humans 
 Results: 2036 
 
Table A1.6 Overdose learning based approach search strategy 
Source Iterations Medical subject headings 
Ovid MEDLINE 
Covering period 
1946 to July 2017 
1 
1. exp Acidosis 
2. exp Biguanides 
3. exp Buformin 
4. exp Diabetes Complications 
5. exp Diabetes Mellitus 
6. exp Hypoglycaemic Agents 
7. exp Lactates 
8. exp Metformin 
9. exp Phenformin 
 Results: 1473 
2 
10. exp Diabetes Mellitus 
11. exp Hypoglycaemic Agents 
12. exp Metformin 
13. exp Acidosis, Lactic 
 14. exp Lactates 
 15. exp Cohort Studies 
 16. exp Hyperlactatemia 
 17. exp Case-Control Studies 
 18. exp Inappropriate Prescribing 
 
19. exp Adverse Drug Reaction Reporting 
Systems 
 20. exp Pharmacovigilance 
 21. exp Biguanides 
 22. exp Patients 
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Table A1.6 cont Overdose learning based approach search strategy 
Source Iterations Medical subject headings 
 
 
1. exp Suicide 
 2. exp Drug Overdose 
 3. exp Drug Dosage Calculations 
  Results: 1714 
 
3 
4. exp Hypoglycaemic Agents 
 5. exp Metformin 
 6. exp Case-Control Studies 
 7. exp Diabetes Mellitus 
 8. exp Acidosis, Lactic 
 9. exp Cohort Studies 
 10. exp Hyperlactatemia 
 11. exp Lactates 
 12. exp Drug Dosage Calculations 
 13. exp Biguanides 
 14. exp Drug Overdose 
 15. exp Inappropriate Prescribing 
 16. exp Patients 
 
17. exp Adverse Drug Reaction Reporting 
Systems 
 18. exp Pharmacovigilance 
 19. exp Suicide 
 20. exp Medication Errors 
  Results: 1766 
  1 or 2 or 3 
  Results: 2648 
  Limit to English language 
  Results: 2217 
  Limit to Humans 
  Results: 2122 
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A1.2. List of pre-existing risk factors for lactic acidosis  
Presented in this section is a table of known risk factors for lactic acidosis. 
Table A1.7 List of risk factors for lactic acidosis 
Risk factors for lactic acidosis 
Type Aa 
Anaerobic muscle activity 
Seizures 
Post-cardiac arrest 

























Systemic inflammatory response syndrome 
Human immunodeficiency virus 
 
Appendix 1: Appendices to Chapter 2 
 236 
 
Table A1.7 cont List of risk factors for lactic acidosis 
Risk factors for lactic acidosis 























Type B3 (lactic acidosis due to inborn errors of metabolism) 
Glucose-6-phosphatase deficiency (von Gierke’s disease) 
Fructose-1,6-diphosphatase deficiency 
Pyruvate carboxylase deficiency 
Pyruvate dehydrogenase deficiency 
Oxidative Phosphorylation defects 
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Table A1.7 cont List of risk factors for lactic acidosis 






aThe Cohen and Woods classification was used to categorise the risk factors into Type A (clinical evidence 
of tissue hypoxia) and Type B (no evidence of tissue hypoxia) lactic acidosis. bEthanol is known to increase 
the risk of lactic acidosis when taken alongside other risk factors for lactic acidosis. cThese drugs and/or 
toxins are recognised to cause lactic acidosis when taken in toxic concentrations.  
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A1.3. WHO-UMC system for standardised case causality assessment  
The adapted WHO-UMC causality assessment annotated with lactic 
acidosis specific diagnostic criterion under each causality category is presented 
in Table A1.8.  
Table A1.8 Adapted WHO-UMC causality assessment 
Causality term Assessment criteria 
Certain 
Event or laboratory test abnormality, with plausible time relationship to 
drug intake 
• Involves metformin ingestion prior to lactic acidosis 
Cannot be explained by disease or other drugs 
• Patient presents with no independent comorbidities, concomitant 
medications or risk factors for lactic acidosisa 
Response to withdrawal plausible (pharmacologically, pathologically) 
• Metformin withdrawal results in resolution of lactic acidosis symptoms 
Event definitive pharmacologically or phenomenologically (i.e. an objective 
and specific medical disorder or a recognised pharmacological 
phenomenon) 
• Diagnosis of lactic acidosis: 
o Lactate plasma concentration >5 mmol/L 
o pH <7.35 
Rechallenge satisfactory, if necessary 
• Metformin rechallenge results in lactic acidosis 
Probably/ 
Likely 
Event or laboratory test abnormality, with reasonable time relationship to 
drug intake 
• Involves metformin ingestion prior to lactic acidosis 
• Diagnosis of lactic acidosis: 
o Lactate plasma concentration >5 mmol/L 
o pH <7.35 
Unlikely to be attributed to disease or other drugs 
• Patient presents with independent comorbidities, concomitant medications 
and other risk factors for lactic acidosisa that are unlikely to be a causative 
agent or none of these 
Response to withdrawal clinically reasonable 
• Metformin withdrawal results in resolution of lactic acidosis 
Rechallenge not required 
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Table A1.8 cont Adapted WHO-UMC causality assessment 
Causality term Assessment criteria 
Possible 
Event or laboratory test abnormality, with reasonable time relationship to 
drug intake 
• Involves metformin ingestion prior to lactic acidosis 
• Diagnosis of lactic acidosis: 
o Lactate plasma concentration >5 mmol/L 
o pH <7.35 
Could also be explained by disease or other drugs 
• Patient presents with comorbidities and/or concomitant medications that 
are risk factors for lactic acidosisa and could explain the adverse event 
Information on drug withdrawal may be lacking or unclear 
• If available: outcome of metformin withdrawal is unclear or lacking 
Unlikely 
Event or laboratory test abnormality, with a time to drug intake that makes 
a relationship improbable (but not impossible) 
• Involves metformin ingestion prior to lactic acidosis 
• Diagnosis of lactic acidosis: 
o Lactate plasma concentration >5 mmol/L 
o pH <7.35 
Disease or other drugs provide plausible explanations 
• Patient presents with comorbidities and/or concomitant medications that 




Event or laboratory test abnormality 
• Event involves history of metformin ingestion with no time restraint 
More data for proper assessment needed, or additional data under 
examination 
• Uncertain diagnosis of lactic acidosis 
• Lacking/unavailable clinical information required to support diagnosis 
Unasssessable/ 
Unclassifiable 
Reported suggesting an adverse reaction 
• Medical report suggests lactic acidosis diagnosis in patient 
Cannot be judged because information is insufficient or contradictory 
• Insufficient and/or contraindicatory information to diagnose lactic acidosis 
Data cannot be supplemented or verified 
Annotations of lactic acidosis specific diagnostic criteria are presented in italics. aRisk factors 
were defined using the list of risk factors for lactic acidosis summarised in Table A1.7.  
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A1.4. Naranjo adverse drug reaction probability scale 
Presented in this section is the Naranjo adverse drug reaction probability 
scale that was used to assess the association between metformin therapy and 
lactic acidosis in Chapter 2. The Naranjo adverse drug reaction probability scale 
questionnaire is shown in Table A1.9 and interpretation of the Naranjo adverse 
drug reaction probability categories is shown in Table A1.10. 
 
Table A1.9 Naranjo adverse reaction probability scale 
To assess the drug reaction, please answer the following questionnaire and give the 
pertinent score 
  Yes No Do not know Score 
1 
Are there previous conclusive reports on this 
reaction? 
+1 0 0  
2 
Did the adverse event appear after the suspected 
drug was administered? 
+2 -1 0  
3 
Did the adverse reaction improve when the drug 
was discontinued or a specific antagonist was 
administered? 
+1 0 0  
4 
Did the adverse reaction reappear when the drug 
was readministered? 
+2 -1 0  
5 
Are there alternative causes (other than the drug) 
that could on their own have caused the reaction? 
-1 +2 0  
6 
Did the reaction reappear when a placebo was 
given? 
-1 +1 0  
7 
Was the drug detected in the blood (or other fluids) 
in concentrations known to be toxic? 
+1 0 0  
8 
Was the reaction more severe when the dose was 
increased, or less when the dose was decreased? 
+1 0 0  
9 
Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
+1 0 0  
10 
Was the adverse event confirmed by any objective 
evidence? 
+1 0 0  
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• Followed a reasonable temporal sequence after a drug or in 
which a toxic drug level had been established in body fluids 
or tissues 
• Followed a recognised response to the suspected drug 
• Confirmed by improvement on withdrawing the drug and 
reappeared on re-exposure 
Probable 5-8 
• Followed a reasonable temporal sequence after a drug 
• Followed a recognised response to the suspected drug 
• Confirmed by withdrawal but not by exposure to the drug 
• Could not be reasonably explained by the known 
characteristics of the patient’s clinical state 
Possible 1-4 
• Followed a temporal sequence after a drug 
• Possibly followed a recognised pattern to the suspected 
drug 
• Could be explained by characteristics of patient’s disease 
Doubtful ≤0 • Likely related to factors other than a drug 
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A1.5. Completeness scores for identified metformin associated lactic 
acidosis case reports 
A summary of the completeness score results for the identified metformin 
associated lactic acidosis case reports is shown below in Table A1.11. 
  
Table A1.11 Completeness scores for each metformin associated lactic acidosis case 
report 
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A1.6. Gastrointestinal illness and metformin associated lactic acidosis  
In patients on metformin therapy it has been proposed that gastrointestinal 
illness may be an independent risk factor for lactic acidosis. Several hypotheses 
have been proposed that describe the series of events linking acute 
gastrointestinal illness to lactic acidosis in patients on metformin therapy [18, 
373]. However, it is unknown whether the hypothesised scenarios, if any, are a 
true representation of the series of events that cases of metformin associated 
lactic acidosis present with. Knowledge of whether gastrointestinal illness does 
play a role in the development of lactic acidosis would allow for preventative 
measures to be implemented to safeguard the use of metformin. 
Three of the proposed scenarios postulated to describe the series of events 
from acute gastrointestinal illness to lactic acidosis in patients on metformin 
therapy are described as follows: 
• Scenario one.  
Acute gastroenteritis leads to dehydration which then leads to acute 
renal failure and consequently lactic acidosis 
• Scenario two 
Acute gastrointestinal illness leads to dehydration followed by acute 
renal failure, resulting in metformin accumulation and lactic 
acidosis, respectively.  
• Scenario three 
Metformin toxicity leads to symptoms of gastroenteritis which lead 
to acute renal failure and ultimately, lactic acidosis. 
  




The aims of this study were to investigate the role of gastrointestinal illness 
in the development of metformin associated lactic acidosis from published case 
reports in the literature. The specific objectives of this study were: 
i. To determine the prevalence of gastrointestinal illness in published 
case reports of metformin associated lactic acidosis 
ii. To describe the clinical and demographic features of the cases 
presenting with gastrointestinal illness 
iii. To test each hypothesised scenario linking gastrointestinal illness to 
metformin associated lactic acidosis 
  




A1.6.2.1. Data source 
The database of published metformin associated lactic acidosis case reports 
identified in the systematic literature in Chapter 2 were used to address the 
research question. For the purposes of this analysis only case histories that had 
ingested a therapeutic dose of metformin (identified from the database) were 
included in the analysis.  
A1.6.2.2. Data analysis 
Description and clinical presentation. A summary of the demographic and 
clinical presentation of metformin associated lactic acidosis cases with reported 
gastrointestinal illness was described. Data analysis and graphing was 
conducted using R (version 3.3.3). 
Postulated scenario hypothesis testing. The three scenarios hypothesised to 
link gastrointestinal illness to lactic acidosis in patients on metformin therapy 
were tested for feasibility using available data extracted from case reports. Each 
of the hypotheses were tested and were deemed feasible if all of the components 
of the series of events were present in the cases.  
Metformin concentrations were extracted from the database, if available, 
for each case history. Metformin accumulation was defined as plasma metformin 
concentrations that exceeded 5 mg/L at any time throughout the case’s 
admission to a medical facility.  
  




Description of cases identified 
A total of 186 metformin associated lactic acidosis cases were identified to 
have reported symptoms of gastrointestinal illness. A summary of the 
demographics for these cases is presented in Table A1.12.  
The duration of gastrointestinal illness in these cases varied greatly. On 
presentation, 184 of the 186 (98.9%) cases presented with acute gastrointestinal 
symptoms that were present for less than a month. The remainder two cases 
presented with gastrointestinal symptoms that lasted for 3 and 12 months. The 
most common identifiable causes for the gastrointestinal symptoms were 
gastrointestinal infection, recent use of antibiotics, post-op nausea and recent 
bowel preparation for colonoscopy.  
Acute renal impairment was noted in 154 cases. Forty-four cases of those 
with acute renal impairment had pre-existing chronic renal impairment. 
Twenty-two cases presented in a clinical state of dehydration.  
Table A1.12 Demographics of cases with reported gastrointestinal illness 
Demographics  Cases with reported data (n = 186) 
Gender (F: M) 118:68 186 
Age (years) 69 [20 – 90] 186 
Weight (kg) 68.5 [27 – 117] 12 
Height (m) 1.631.53 – 1.65] 9 
Data presented as median[range] unless otherwise specified 
 
Postulated scenario hypothesis testing 
Only a total of 21, 5 and 42 cases fulfilled the series of events described in 
scenario one, two and three, respectively. 
  




The presence of acute gastrointestinal illness, leading to vomiting, 
diarrhoea and dehydration, has been proposed to increase the risk of MALA. 
While vomiting and diarrhoea are recognised side effects of metformin it is 
anticipated that these side effects are minimal in most patients already stabilised 
on metformin therapy [99]. The causal relationship between gastrointestinal 
illness and lactic acidosis involving a combination of gastrointestinal illness, 
dehydration, acute kidney injury and metformin accumulation, is hard to 
determine in the published cases reviewed here due to limitations arising from 
the retrospective nature of the data.  
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A2.1. Description of population pharmacokinetic model for metformin by 
Duong et al  
In the metformin population pharmacokinetic study by Duong et al, 
metformin was described by a two compartment model with first order 
absorption for immediate release formulations and zero-order absorption for 
extended release formulations (a schematic of the published model by Duong et 
al is presented in Figure A2.1). In the model Duong et al, creatinine clearance 
and total body weight were found to be significant covariates on metformin 
𝐶𝐿 𝐹⁄  and 𝑉1 𝐹⁄ , respectively. The published equations for 𝐶𝐿 𝐹⁄  and 𝑉1 𝐹⁄ are as 
follows: 
 
𝐶𝐿 𝐹⁄ = (𝜃𝐶𝐿 𝐹⁄  × (𝐶𝐿𝐶𝑅 6⁄ )) × 𝑒
𝑃𝑃𝑉𝐶𝐿 
𝑉1 𝐹⁄ = (𝜃𝑉1 𝐹⁄  × (𝑇𝐵𝑊 70⁄ )) × 𝑒
𝑃𝑃𝑉𝑉1 
 
where 𝜃𝐶𝐿 𝐹⁄  is the mean population value for 𝐶𝐿 𝐹⁄ , 𝜃𝑉1 is the mean population 
value for 𝑉1 𝐹⁄ , 𝑃𝑃𝑉𝐶𝐿  is the sum of inter-individual variability and inter-
occasion variability for 𝐶𝐿 𝐹⁄ , 𝑃𝑃𝑉𝑉1  is the sum of the inter-individual 
variability and inter-occasion variability for 𝑉1 𝐹⁄ , 𝐶𝐿𝐶𝑅  is creatinine clearance 
estimated using the Cockcroft Gault equation using lean body weight, and, 𝑇𝐵𝑊 
is total body weight.  
The simulations performed using the published model by Duong et al were 
deterministic. Case specific characteristics (i.e. metformin dose, weight and pre-
admission estimate of renal function) were entered into the model for each case 
where the data was available. The median weight for the cohort of metformin 
associated lactic acidosis cases was imputed if weight was not reported. The 
parameter values used in the simulation were the same as the published model 
by Duong et al and are presented in Table A2.1. Parameter values for between 
subject or between occasion variability and residual unexplained variance were 
not used in the simulations so are not reported in Table A2.1 below 
 









Figure A2.1 Schematic of published population pharmacokinetic model for metformin 
by Duong et al. CL is clearance, F is bioavailability, ka is the absorption rate constant, 
Q is intercompartmental clearance, TLAG is lag time for absorption, V1 is the central 
compartment volume and V2 is the peripheral compartment volume. 
 
Table A2.1 Parameter values in the published model by Duong et al to predict pre-
admission plasma concentration for metformin associated lactic acidosis patients 
Parameter Values 
𝜃𝐶𝐿 𝐹⁄  (mL/min) 72 
𝜃𝑉1 𝐹⁄  (L)b 149 
𝜃𝑄 𝐹⁄  (mL/min) 203 
𝜃𝑉2 𝐹⁄  (L) 182 
𝜃𝑘𝑎 (h
-1) 0.35 
𝜃𝑇𝐿𝐴𝐺  (h-1) 0.38 
The final covariate model for metformin clearance was 𝐶𝐿 𝐹⁄ = (𝜃𝐶𝐿 𝐹⁄ ∙ (𝐶𝐿𝑐𝑟𝐶𝐺 6⁄ )) ∙ 𝑒
𝑃𝑃𝑉𝐶𝐿 , 
where 𝜃𝐶𝐿 𝐹⁄  is the population estimate for metformin clearance, 𝐶𝐿𝑐𝑟𝐶𝐺  is creatinine clearance 
calculated using the Cockcroft and Gault equation [80] and 𝑃𝑃𝑉𝐶𝐿  is the sum of the 
interindividual and interoccassion variability for 𝐶𝐿. The final covariate model for metformin 
central compartment volume was 𝑉1 𝐹⁄ = (𝜃𝑉1 𝐹⁄ ∙ (𝑇𝐵𝑊 70⁄ )) ∙ 𝑒
𝑃𝑃𝑉𝑉1 , where 𝜃𝑉1 𝐹⁄  is the 
population estimate for the central compartment volume for metformin, 𝑇𝐵𝑊  is total body 
weight and 𝑃𝑃𝑉𝑉1 is the sum of the inter-individual and inter-occassion variability for 𝑉1. 𝜃𝑄 𝐹⁄  
is population estimate for intercompartmental clearance. 𝜃𝑉2 𝐹⁄  is the population estimate for the 
peripheral compartment volume. 𝜃𝑘𝑎  is the population estimate for the absorption rate constant. 
𝜃𝑇𝐿𝐴𝐺 is the population estimate for the lag time for absorption. 𝜃𝐹 is the population estimate for 
bioavailability that was fixed to a value of 1 for the purposes of the simulations.   
Appendix 2: Appendices to Chapter 3  
 252 
 
A2.2. Completeness score results 
A completeness score was developed to assess the availability and quality 
of data provided in each case history. Below is a table summarising the results 
from the completeness score. A maximum score of 31 could be obtained. 
 
Table A2.2 Summary results for completeness scores allocated to MALA cases with a 
history of chronic renal impairment from the database 
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A2.3. Implementation of the metformin population pharmacokinetic model 
by Duong et al  
The simulated metformin plasma concentration time profiles in the 
publication by Duong et al were replicated to ensure the model was correctly 
implemented for the purposes of analysis. Stochastic simulations were 
performed as described in the publication by Duong et al by using the maximum 
doses for patients with varying levels of renal impairment (shown in Table A2.2). 
The median weight (i.e. 65 kg) for the study population in the publication by 
Duong et al was imputed as the weight for the simulations. Each simulation was 
replicated 1000 times to day 25 (i.e. steady state). The simulations were 
performed in MATLAB (R2016b, MathWorks, Natick, NA) and the 5th, 50th and 
95th percentiles of the simulated concentrations were plotted.  
Table A2.3 Dosing regimen used for the stochastic simulations 





The replicated stochastic simulations performed under the different renal 
dosing regimens are presented side by side with the published original plots by 
Duong et al in Figure A2.2. The replicated predictions from the metformin 
pharmacokinetic model are similar to the published plots produced by Duong et 
al for the scenarios with a creatinine clearance of 15, 30 and 120 mL/min. 
However, in the simulations where creatinine clearance is equal to 60 mL/min 
the 5th, 50th and 95th percentiles appear to overestimate the metformin 
concentrations relative to the published plots. In addition, in all the plots the 50th 
percentiles of the simulated data appear higher than the measured values. In the 
publication by Duong et al the dosing frequency for each scenario was not 
reported. Hence, it was assumed that metformin was given as a single dose. This 
could be a potential reason for deviation seen in each of the plots. 








Figure A2.2 Original plots by Duong et al  (left) and replicated (right) stochastic 
simulations of plasma metformin concentrations at the maximum recommended dose 
for patients with varying levels of renal impairment. The 5th, 50th and 95th percentiles of 
the predicted concentrations are shown in the plot.  
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A3.1. Literature review search strategy  
The static search strategy performed in Ovid MEDLINE and Ovid EMBASE 
are presented in Table A3.1 and A3.2, respectively.  
Table A3.1 Ovid MEDLINE static search strategy 
Source Search strategy 
Ovid MEDLINE 
Covering period 1946 to 
March 2020 
17. Metformin 
18. Acidosis, Lactic 
19. upper limit.mp 
20. therapeutic concentration.mp 
21. therapeutic limit.mp 
22. toxic concentration.mp 
23. Dose-Response Relationship, Drug 
24. 3 or 4 or 5 or 6 or 7 
25. 1 and 2 and 8 
26. Limit 9 to humans 
27. Limit 10 to English language 
Results: 21 
 
Table A3.2 Ovid EMBASE static search strategy 
Source Search strategy 
Ovid EMBASE 
Covering period 1946 to 
March 2020 
1. Metformin 
2. Lactic acidosis 
3. upper limit.mp 
4. therapeutic concentration.mp 
5. therapeutic limit.mp 
6. toxic concentration 
7. dose response  
8. 3 or 4 or 5 or 6 or 7 
9. 1 and 2 and 8 
10. Limit 9 to humans 
11. Limit 10 to English language 
Results: 152 
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A4.1. Details of the study procedure for data available from the Dunedin 
Public Hospital  
Additional details of the study procedures for the metformin study 
conducted at the Dunedin Public Hospital is described in this section. 
A4.1.1. Study participant inclusion/exclusion criteria 
Study participants were excluded if they presented with: inability to give 
written informed consent, type 2 diabetes or were currently taking metformin, 
had evidence of >25% change in eGFR in the past month, pregnancy, known 
allergy to medications used in the study (i.e. biguanides or aminoglycosides), or, 
were taking drugs known or suspected to interact with the renal tubular 
transport of metformin or creatinine (i.e. antibiotics, atenolol, calcium channel 
blockers, antiarrhythmic drugs, histamine (H2) antagonists, thiazide diuretics, 
antituberculosis drugs and probenecid). During the eligibility screening process 
baseline information, including study participant demographics and 
concomitant medications were recorded. 
A4.1.2. Metformin assay 
A high-performance liquid chromatography (HPLC) assay was used to 
determine plasma metformin concentrations. The assay used has been described 
and validated by Zhang et al [412]. The standard curve of metformin were found 
to be linear over the concentration range of 0.02-4 mg/L. The assay lower limit 
of quantification was reported to be around 0.02 mg/L. The intra- and inter-day 
coefficients of variation were reported to be less than 9.0%. 
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A4.2. Pharmacokinetic analysis conducted in R  
In this section the R code and outputs from the pharmacokinetic analysis 
are presented in section A4.2.1. and A4.2.2., respectively.  














metforminstudy <- read.csv("metformin.csv") 
 
initialconc <- metforminstudy %>% 
  filter(study == 1) %>% 
  select(id) %>% 
  distinct %>% 
  mutate(time = 0, 
         dv = 0) 
 
metforminconc <- metforminstudy %>% 
  filter(study == 1) %>% 
  filter(cmt == 2) %>% 
  filter(mdv == 0) %>% 
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  mutate(dv = as.numeric(as.character(dv))) %>% 
  select(id, time, dv) %>% 
  full_join(initialconc, by = c("id", "time", "dv")) %>% 
  arrange(id, time) %>% 
  rename(conc = dv) 
 
metformindose <- metforminstudy %>% 
  filter(study == 1) %>% 
  filter(evid == 1) %>% 
  select(id, time, amt) %>% 
  rename(dose = amt) 
 
#------------------------------------------------------------------- 
# DATA VISUALIATION 
#------------------------------------------------------------------- 
 
met.obs1 <- metforminconc %>% 
  mutate(id = as.factor(id)) %>% 
  ggplot(mapping = aes(x = time,  
                                          y = as.numeric(conc),  
                                          group = id,  
                                          colour = id)) + 
  geom_line() +  
  geom_point() +  
  ylab("Metformin concentration (mg/L)") +  
  xlab("Time (h)") +  
  theme(panel.grid.major = element_blank(), 
              panel.grid.minor = element_blank(),  
              panel.background = element_blank(), 
              axis.line = element_line(colour = "black")) + 
  ggtitle("Metformin plasma concentrations versus time") 





met.obs2 <- metforminconc %>% 
  mutate(id = as.factor(id)) %>% 
  ggplot(mapping = aes(x = time,  
                                          y = as.numeric(conc))) + 
  geom_line() + geom_point() + 
  facet_wrap(~id, nrow = 5) +  
  geom_line() +  
  geom_point() +  
  ylab("Metformin concentration (mg/L)") +  
  xlab("Time (h)") +  
  theme(panel.grid.major = element_blank(),  
              panel.grid.minor = element_blank(),  
              panel.background = element_blank(), 
              axis.line = element_line(colour = "black")) + 




# NCA ANALYSIS 
#------------------------------------------------------------------- 
PKNCA.options() 
conc <- PKNCAconc(data = metforminconc, formula = conc~time|id) 
dose <- PKNCAdose(metformindose, dose~time|id) 
data <- PKNCAdata(conc, dose) 
 
my.results <- pk.nca(data) 
summary(my.results) 
raw <- my.results$result 
 




results <- raw %>% 
  select(id, PPTESTCD, PPORRES) %>% 
  spread(PPTESTCD, PPORRES) 
 
metformin.urine <- metforminstudy %>% 
  mutate(dv = as.numeric(as.character(dv)), 
         amt = as.numeric(as.character(amt)), 
         mdv = as.numeric(as.character(mdv)), 
         uvol = as.numeric(as.character(uvol))) %>% 
  filter(mdv == 0 & cmt == 4) %>% 
  mutate(amt = 500) %>% 
  rename(dose = amt, 
                 conc = dv, 
                 volume = uvol) %>% 
  mutate(AE = conc*volume) %>% 
  group_by(id) %>% 
  summarise(ae = sum(AE)) %>% 
  ungroup 
 
table <- results %>% 
  left_join(metformin.urine, by = ("id")) %>% 
  mutate(fe=ae/500,  
                cl.last = 500/auclast,  
               cl.obs = 500/ aucinf.obs,  
               vz.obs=cl.obs/lambda.z, 
               vd.obs=500/(aucinf.obs*lambda.z),  
               clr.last=ae/auclast,  
               clr.obs=ae/aucinf.obs) 
 
units <- (setNames((c("UNITS", "", "mg/L.h", "mg/L.h", 
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                                       "mg/L", "mg/L", "mg/L", "h", "1/h", "",  
                                       "h", "", "", "h", "h", "mg", "", "L/h", "L/h", 
                                       "L", "L", "L/h", "L/h")), 
                                     c(colnames(table)))) 
n <- table %>%  
        summarise_all(funs(round(sum(!is.na(.)),0))) %>%  
        mutate(id="n") 
mean <- table %>%  
                summarise_all(funs(round(mean(., na.rm=T))),2) %>% 
                mutate(id="MEAN") 
sd <- table %>%  
          summarise_all(funs(round(sd(., na.rm=T))),2) %>%  
          mutate(id="SD") 
colnames(table) 
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A4.2.2. Output from noncompartmental analysis conducted in R 
Presented in this section of the appendix is the pharmacokinetic metric output from the PKNCA R package. 
Table A4.1 Pharmacokinetic metric estimates for study participants stratified by their CKD classification group 
Parameter CKD 1 CKD 2 CKD 3 CKD 4 CKD 5 
Sample size (n) 7 10 5 6 6 
𝐶𝑚𝑎𝑥 (mg/L) 0.84±0.35 0.84±0.26 1.66±0.42 2.34±0.45 2.36±1.14 
𝑇𝑚𝑎𝑥 (h) 2.41±0.95 2.38±0.88 2.92±1.56 2.98±0.64 3.20±1.62 
𝜆𝑧 (h-1) 0.28±0.19 0.25±0.14 0.13±0.03 0.11±0.05 0.13±0.08 
𝑡1 2⁄  (h) 4.21±4.10 4.25±3.48 5.69±1.40 8.01±4.62 6.71±2.83 
𝐴𝑈𝐶0−𝑙𝑎𝑠𝑡 (mg∙h/L) 2.91±2.19 4.15±0.73 13.51±5.88 15.81±5.31 20.66±18.31 
𝐴𝑈𝐶0−∞ (mg∙h/L) 3.30±2.60 5.06±1.13 16.52±5.97 33.71±19.52 38.18±20.88 
𝐶𝐿/𝐹 (L/h) 225.27±152.69 103.95±29.49 32.85±9.21 17.99±7.29 19.05±15.04 
𝐶𝐿𝑟𝑒𝑛𝑎𝑙 (L/h) 68.63±55.39 35.56±4.59 11.87±4.08 9.69±5.49 8.97±6.08 
Data are presented as mean ± standard deviation 
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A5.1. Simulation code  
Presented in this section is the code used to simulate plasma metformin 
concentration profiles as described in Chapter 7 (section 7.4.5.).  
 





set.seed <- 123456 
 
#------------------------------------------------------------------- 
# Define model 
#------------------------------------------------------------------- 
 
ode <- " 
C2 = centr/V2; 
C3 = peri/V3; 
d/dt(depot) = -KA*depot; 
d/dt(centr) =  F1*KA*depot - CL*C2 - Q*C2 + Q*C3 
d/dt(peri)  =                        Q*C2 - Q*C3;  
" 
# Compile model 
mod001 <- RxODE(model = ode, modName = "mod001") 
 
#------------------------------------------------------------------- 
# Create virtual patients 
#------------------------------------------------------------------- 
# number of subjects 
nsub <- 1000 




# Creatinine Clearance (Cockcroft-Gault Equation) 
CG <- runif(nsub, min = [minimum value of creatinine clearance] , 
                                max = [maximum value of creatinine clearance]) 
WT <- 70 
 
# eta1: CL, eta2: V2, eta3: KA 
omega <- matrix(c(0.199,   0.0697,   0, 
                  0.0697,  0.118,    0, 
                  0,       0,        0.145),3,3) 
 
eta    <- mvrnorm(n=nsub, rep(0,3), omega) 
 
# Population typical parameter values 
CG_EFF      <- 0.797 
WT_EFF      <- 1 
F1          <- 0.55 
 
TVCL        <- 90.5*(CG/100)^CG_EFF 
TVV2        <- 147*(WT/70)^WT_EFF 
TVQ         <- 3.74 
TVV3        <- 57.2 
TVKA        <- 0.4 
prop_err_ed <- 0.241 
add_err_ed  <- 0.0337 
 
# Individual parameter values 
virtual_patients <- data.frame(ID = 1:nsub,  
                               CG = CG,  
                               F1 = F1) %>% 
  mutate(ETA1 = eta[,1], 
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         ETA2 = eta[,2], 
         ETA3 = eta[,3]) %>% 
  mutate(CL = TVCL*exp(ETA1), 
         V2 = TVV2*exp(ETA2), 
         Q  = TVQ, 
         V3 = TVV3, 
         KA = TVKA*exp(ETA3), 
         F1 = F1) 
  
params.all <- cbind(CL = virtual_patients$CL, 
                    V2 = virtual_patients$V2, 
                    Q  = virtual_patients$Q, 
                    V3 = virtual_patients$V3, 
                    KA = virtual_patients$KA, 
                    F1 = virtual_patients$F1) 
 
#------------------------------------------------------------------- 
# Simulate a single dose 
#------------------------------------------------------------------- 
 
# Initialize event table 
ev <- eventTable() 
 
# Specify dose 
ev$add.dosing(dosing.to="depot",dose = [insert dose], nbr.doses = [insert 
number doses], dosing.interval= [insert dosing interval]) 
 
# Specify sampling 
ev$add.sampling(0:168) 
 
# Initial conditions 
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inits <- c(0,0,0) 
 
res <- NULL #Create an empty matrix for storing results 
 
# Loop through each row of parameter values and simulate 
for (i in 1:nsub)  { 
  params <- params.all[i,] 
  temp <- mod001$run(params, ev, inits = inits) 
  res <- cbind(res,temp[,"C2"]) 
} 
 
#The same can be achieved more efficiently by replacing the above for-loop 
with: 
res <- apply(params.all, 1, function(params) mod001$run(params, ev, 
inits)[, "C2"]) 
 
# Plot results 
par(mfrow = c(2), mar = c(4,4,1,1)) 
matplot(res, type = "l",  ylab = "Concentration", xlab = "Time (h)") 
 
# Calculate and plot quantiles 
res.q.t <- apply(res, 1, quantile, prob = c(.05, .5, .95)) 
matplot(t(res.q.t), type = "l", lty = c(2,1,2), col = c(2,1,2),  
        ylab = "Plasma metformin concentration (mg/L)", xlab = "Time (h)", 
ylim=c(0,2)) 
legend("topright", lty = c(1,2), col = c("black","red"), cex = .8) 
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A5.2. NONMEM control file for the final population pharmacokinetic 
model for metformin  
$PROBLEM METFORMIN PK 
 
$INPUT C STUDY ID STUDYID TIME DV AMT CMT1=CMT CMT2 CMT3 
 EVID DVID MDV BLQ RATE FORM OCC AGE SEX HTCM WTKG BMI  
FFM IBW GENTCL CR CG CGIBW MDRD CKDEPI DWTKG BLACT  
BBICAR DSTART DSTOP DRETURN BFR DFR SA DIAL 
 
$DATA metformin.csv 
      IGNORE = C 
      IGNORE = (BLQ.EQ.1) 
      IGNORE = (STUDY.EQ.3) 
      IGNORE = (STUDY.EQ.4) 
      IGNORE = (STUDY.EQ.5) 
      IGNORE = (STUDY.EQ.6) 
      IGNORE = (STUDY.EQ.7) 
      IGNORE = (STUDY.EQ.8) 
      IGNORE = (STUDY.EQ.9) 
      IGNORE = (STUDY.EQ.10) 
      IGNORE = (STUDY.EQ.11) 
      IGNORE = (CMT1.EQ.3) 
      IGNORE = (CMT1.EQ.-3) 
      IGNORE = (FORM.EQ.2) 
 


































; SCALE CONCENTRATIONS 
S2 = V2 
 
$DES 
DADT(1) = -KA*A(1) 
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DADT(2) = KA*A(1)-(K23+K20)*A(2)+K32*A(3) 
DADT(3) = K23*A(2)-K32*A(3) 
 
$ERROR 
IPRED = F 
    W = SQRT(THETA(9)**2*IPRED**2 + THETA(10)**2) 
    Y = IPRED + W*EPS(1) 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA 
(0, 98)          ; CL 
(0, 181)         ; V2 
(0, 4.2)         ; Q 
(0, 47)          ; V3 
(0, 0.38)        ; KA 
0.55 FIX         ; F1 
(0, 1)           ; CG_EFF 
1 FIX            ; WT_EFF 
(0, 0.258)       ; Prop 
(0, 0.02)        ; Add 
 
$OMEGA BLOCK(2) 
0.1              ; IIV CL 
0.01     0.1     ; IIV V2 
 
$OMEGA 
0 FIX            ; IIV Q 
0 FIX            ; IIV V3 
(0.20)           ; IIV KA 
 




1 FIX ; Proportional PK S1 
 






$TABLE STUDY ID TIME DV MDV EVID CMT1 CMT2 CMT3 BLQ IPRED  
IWRES CWRES ONEHEADER NOPRINT FILE=sdtab56 
$TABLE STUDY ID CL V2 Q V3 KA ETA1 ETA2 ETA3 ETA4 ETA5 
 ONEHEADER NOPRINT FILE=patab56 
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A6.1. Extended theoretical consideration  
In this section, all possible permutations of parameter values for a one-, 
two- and three-compartment mamillary pharmacokinetic model are explicitly 
shown. The pharmacokinetic mathematical models for a one-, two- and three-




𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐(𝑘𝑎 − 𝑘)






















𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝑘𝑎 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝑘𝑎 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝑘𝑎 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝛽)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡
(𝛼 − 𝑘𝑎)(𝛽 − 𝑘𝑎)(𝛾 − 𝑘𝑎)
)] 
 
Here, 𝐶  represents concentration, 𝐹  is bioavailability, 𝐷  is the dose, 𝑘𝑎  is the 
absorption rate constant, 𝑘  is the elimination rate constant, 𝑉𝑐  is the central 
compartment volume, 𝑡 is time, and, both 𝑘21 and 𝑘31 are the first-order transfer 
rate constants of a drug from the peripheral compartment volume to the central 
compartment volume. In the two- and three-compartment models 𝛼 is a macro-
constant that describes the initial decline in drug concentrations. In a two-
compartment model 𝛽 is a macro-constant that describes the terminal decline in 
drug concentrations. In the three-compartment model 𝛽  and 𝛾  are macro-
constants that describe the intermediate and terminal decline in drug 
concentrations, respectively.  
Appendix 6: Appendices to Chapter 8  
277  
 
There are two possible permutations of parameter values that provide the 
same input and output relationship in a one-compartment mamillary model. The 
two possible permutations are: 
 
Permutation 1: 
𝑘𝑎 = 𝑘𝑎 
𝑘 = 𝑘 
𝑉𝑐 = 𝑉𝑐 
Permutation 2: 
𝑘𝑎
′ = 𝑘 







As shown in Permutation 2, the volume of distribution (𝑉𝑐
′) becomes a function 
of the absorption rate constant (𝑘𝑎) and the elimination rate constant (𝑘). If the 
parameter values for Permutation 2 are substituted in the one-compartment 
model and simplified the same input-output relationship can be obtained as 
Permutation 1. The substitution and simplification of Permutation 2 into the one-




′ = 𝑘 







Substituted into a one-compartment model  
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐(𝑘𝑎 − 𝑘)
 (𝑒−𝑘∙𝑡 − 𝑒−𝑘𝑎∙𝑡) 
 
𝐶 =










𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐 (𝑘𝑎 − 𝑘)
(𝑒−𝑘∙𝑡−𝑒−𝑘𝑎∙𝑡) 
 
For a two-compartment pharmacokinetic model there are three possible 
permutations of parameter values that can give the same input-output 
relationship. The three possible permutations of sets of parameter values are: 
  
Permutation 1: 
𝛼 = 𝛼 
𝛽 = 𝛽 
𝑘𝑎 = 𝑘𝑎 
𝑉𝑐 = 𝑉𝑐 
Permutation 2: 
𝛼′ = 𝑘𝑎 
𝛽′ = 𝛽 
𝑘𝑎







𝛼′ = 𝛼 
𝛽′ = 𝑘𝑎 
𝑘𝑎







Here, Permutation 2 and 3 can be substituted into the two-compartment model 
and provide the same answer as Permutation 1. The mathematical substitution 
of Permutation 2 and 3 into a two-compartment model followed by 








𝛼′ = 𝑘𝑎 
𝛽′ = 𝛽 
𝑘𝑎







Substituted into the two-compartment model: 
C =





















































𝛼′ = 𝛼 
𝛽′ = 𝑘𝑎 
𝑘𝑎







Substituted into the two-compartment model: 
C =































(𝛼 − 𝛽)(𝑘𝑎 − 𝛽)
)] 
 


















(𝛼 − 𝑘𝑎)(𝛽 − 𝑘𝑎)
)] 
 
For a three-compartment model the four possible permutations are: 
 
Permutation 1: 
𝛼 = 𝛼 
𝛽 = 𝛽 
𝛾 = 𝛾 
𝑘𝑎 = 𝑘𝑎 
𝑉𝑐 = 𝑉𝑐 
Permutation 2: 
𝛼′ = 𝑘𝑎 
𝛽′ = 𝛽 
𝛾′ = 𝛾 
𝑘𝑎







𝛼′ = 𝛼 
𝛽′ = 𝑘𝑎 
𝛾′ = 𝛾 
𝑘𝑎







𝛼′ = 𝛼 
𝛽′ =  𝛽 
𝛾′ = 𝑘𝑎 
𝑘𝑎
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As previously shown for the two-compartment model, Permutations 2, 3 and 4 
can be substituted into the three-compartment model to provide the same input-
output relationship as Permutation 1. The mathematical substitution and 
simplification is given as follows: 
 
Permutation 2 
𝛼′ = 𝑘𝑎 
𝛽′ = 𝛽 
𝛾′ = 𝛾 
𝑘𝑎







Substituted into the three-compartment model: 
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝑘𝑎 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝑘𝑎 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝑘𝑎 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝛽)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡








(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡
( 𝛼 − 𝑘𝑎)(𝑘𝑎 − 𝛽)(𝑘𝑎 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
( 𝛼 − 𝛽)(𝛽 − 𝑘𝑎)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
( 𝛼 − 𝛾)(𝛾 − 𝑘𝑎)(𝛾 − 𝛽)
) + (
(𝑘21 −  𝛼)(𝑘31 −  𝛼)𝑒𝑥𝑝
− 𝛼∙𝑡





𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 −  𝛼)(𝑘31 −  𝛼)𝑒𝑥𝑝
− 𝛼∙𝑡
(𝑘𝑎 −  𝛼)(𝛽 −  𝛼)(𝛾 −  𝛼)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
( 𝛼 − 𝛽)(𝛽 − 𝑘𝑎)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
( 𝛼 − 𝛾)(𝛾 − 𝑘𝑎)(𝛾 − 𝛽)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡









𝛼′ = 𝛼 
𝛽′ = 𝑘𝑎 
𝛾′ = 𝛾 
𝑘𝑎







Substituted into the three-compartment model: 
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝑘𝑎 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝑘𝑎 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝑘𝑎 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝛽)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡








(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝛽 − 𝛼)(𝛼 − 𝑘𝑎)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡
(𝛽 − 𝑘𝑎)(𝑘𝑎 − 𝛼)(𝑘𝑎 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝛽 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝑘𝑎)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡





𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝛽 − 𝛼)(𝛼 − 𝑘𝑎)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝛼 − 𝛽)(𝑘𝑎 − 𝛽)(𝛾 − 𝛽)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝛽 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝑘𝑎)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡




𝛼′ = 𝛼 
𝛽′ =  𝛽 
𝛾′ = 𝑘𝑎 
𝑘𝑎
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Substituted into the three-compartment model: 
𝐶 =
𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝑘𝑎 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝛾)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝑘𝑎 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝛾)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝑘𝑎 − 𝛾)(𝛾 − 𝛼)(𝛾 − 𝛽)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡








(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝛾 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝑘𝑎)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝛾 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝑘𝑎)
)
+ (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡
(𝛾 − 𝑘𝑎)(𝑘𝑎 − 𝛼)(𝑘𝑎 − 𝛽)
) + (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡





𝐹 ∙ 𝐷 ∙ 𝑘𝑎
𝑉𝑐
[(
(𝑘21 − 𝛼)(𝑘31 − 𝛼)𝑒𝑥𝑝
−𝛼∙𝑡
(𝛾 − 𝛼)(𝛼 − 𝛽)(𝛼 − 𝑘𝑎)
) + (
(𝑘21 − 𝛽)(𝑘31 − 𝛽)𝑒𝑥𝑝
−𝛽∙𝑡
(𝛾 − 𝛽)(𝛽 − 𝛼)(𝛽 − 𝑘𝑎)
)
+ (
(𝑘21 − 𝛾)(𝑘31 − 𝛾)𝑒𝑥𝑝
−𝛾∙𝑡
(𝛼 − 𝛾)(𝛽 − 𝛾)(𝑘𝑎 − 𝛾)
) + (
(𝑘21 − 𝑘𝑎)(𝑘31 − 𝑘𝑎)𝑒𝑥𝑝
−𝑘𝑎∙𝑡
(𝛾 − 𝑘𝑎)(𝑘𝑎 − 𝛼)(𝑘𝑎 − 𝛽)
)] 
 
Here, it is can be seen that the issue of local identifiability becomes a greater 
problem when the number of compartments (𝑛) increases [413]. The number of 
possible permutations of sets of parameter values for a given compartment 
model is 𝑛 + 1.  
Simulations under all the possible permutations for a one-, two- and three-
compartment model were performed to illustrate that the same input-output 
profile could be produced under different sets of parameter values. The 
simulations were performed in R (version 3.5.3) using the parameter values 
shown in Table A6.1.  
The simulated pharmacokinetic profiles for a one-, two- and three-
compartment model are shown in Figure A6.1. Here, it can be seen that the 
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Table A6.1 Parameter values used in the simulation 
Parameter 
Parameter values 
One- compartment Two-compartment Three-compartment 
𝐹 1 1 1 
𝐷 1 1 1 
𝑘𝑎 0.5 0.5 0.5 
𝑘 0.1   
𝑉𝑐 10 2 2 
𝛼  0.2 0.2 
𝛽  0.05 0.05 
𝛾   0.01 
𝑘21  0.1 0.1 
𝑘31   0.15 
𝑡 0:100 0:100 0:100 
𝐹  is bioavailability; 𝐷  is the dose; 𝑘𝑎  is the absorption rate constant; 𝑘 is the elimination rate 
constant; 𝑉𝑐 is the central compartment volume; 𝑡 is time; 𝑘21 and 𝑘31 are the first-order transfer 
rate constants of a drug from the peripheral compartment volume to a central compartment 
volume; 𝛼 is a macro-constant that describes the initial decline in drug concentrations. In a two-
compartment model 𝛽  is a macro-constant that describes the terminal decline in drug 
concentrations and in a three-compartment model it describes the intermediate decline in drug 
concentrations; 𝛾 is a macro-constant that describes the terminal decline in a three-compartment 
model.  
  






Figure A6.1 Simulations of permutations that provide the same input-output 
relationship for a one- (top), two- (middle) and three- (bottom) compartment model. 
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A6.2. Plasma metformin concentration time profiles of data analysed 
stratified by study  
In this section the plasma metformin concentration time profiles stratified 
by study are presented. This comprised data from the following sources: 
1. Dunedin Public Hospital 
2. Middlemore Hospital 
3. Metformin pharmacokinetic study by Pentikainen et al 
Dunedin Public Hospital. Plasma metformin concentration data sourced 
from the Dunedin Public Hospital are shown in Figures A6.2 and A6.3. Figure 
A6.2 is a plot of the metformin plasma concentration time profiles stratified by 
study participants, whilst Figure A6.3 is a plot of the concentration profiles of 
study participants stratified by their study enrolment group. 
Middlemore Hospital. Metformin concentration data sourced from 
Middlemore Hospital are shown in Figures A6.4 and A6.5. Figure A6.4 is a plot 
of the plasma metformin concentration time profiles stratified by study 
participants and Figure A6.5 is a plot of the plasma metformin concentration 
time profiles collected from the study participants stratified by the dose of 
metformin received. 
Metformin pharmacokinetic study by Pentikainen et al. The plasma 
metformin concentrations following oral administration of metformin in the 
study by Pentikainen et al is shown in Figure A6.6. The metformin plasma 
concentrations following intravenous administration of metformin is shown in 
Figure A6.7. 
  





Figure A6.2 Plasma metformin concentrations of study participants in the Dunedin 
Study. The top plot is a Cartesian plot and the bottom is a semi log plot. The dots 
represent single measures of plasma metformin concentration and the lines link 
repeated measures data for a single participant. 





Figure A6.3 Plasma metformin concentrations of study participants in the Dunedin 
Study stratified by renal enrolment groups. The top plot is a Cartesian plot and the 
bottom is a semi log plot. The dots represent single measures of plasma metformin 
concentration and the lines link repeated measures data for a single participant. 
 





Figure A6.4 Plasma metformin concentrations of study participants in the Middlemore 
Study. The top graph is a Cartesian plot and the bottom is a semi log plot. The dots 
represent single measures of plasma metformin concentration and the lines link 
repeated measures data for a single participant 





Figure A6.5 Plasma metformin concentrations of study participants in the Middlemore 
Study stratified by metformin dose received. The top graph is a Cartesian plot and the 
bottom is a semi log plot. The dots represent single measures of plasma metformin 
concentration and the lines link repeated measures data for a single participant. 





Figure A6.6 Plasma metformin concentrations of study participants in the Pentikainen 
et al study following a single oral metformin dose. The top graph is a Cartesian plot 
and the bottom is a semi log plot. The dots represent single measures of plasma 
metformin concentration and the lines link repeated measures data for a single 
participant. 





Figure A6.7 Plasma metformin concentrations of study participants in the Pentikainen 
et al study following an intravenous dose of metformin. The top graph is a Cartesian 
plot and the bottom is a semi log plot. The dots represent single measures of plasma 
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A6.3. Model evaluation  
In this section, the following diagnostic and evaluation plots are presented 
for the models explored in Chapter 8: 
i. Prediction corrected visual predictive check (section A6.3.1.) 
ii. Goodness of fit plots (section A6.3.2.) 
iii. ETA distributions (section A6.3.3.) 
A6.3.1. Prediction corrected visual predictive check 
A prediction corrected visual predictive check (pcVPC) for the base model 
parameterised using 𝐶𝐿, 𝑉 and 𝑘𝑎 is shown in Figure A6.8. The median, 5th and 
95th percentiles of the population pharmacokinetic model predicted plasma 
metformin concentrations follow the percentiles of the data well, suggesting that 
a one-compartment model provided a good fit to the data. 
 
Figure A6.8 Prediction corrected visual predictive check of the unconstrained base 
model parameterised using CL, V, ka developed using plasma metformin concentration 
data following oral administration only 
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A6.3.2. Goodness of fit plots 
For the models developed in Chapter 8 the following goodness of fit plots 
were graphed: 
1. DV versus PRED 
2. DV versus IPRED 
3. CWRES versus PRED 
4. CWRES versus TIME 
In these plots, DV stands for dependent variable and is the observed metformin 
concentration (mg/L), PRED stands for prediction and is the model predicted 
metformin concentration (mg/L), IPRED is the individual prediction of 
metformin concentration (mg/L), CWRES stands for conditional weighted 
residuals and TIME is time post metformin ingestion in hours. 
 




Figure A6.9 Goodness of fit plots for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.10 Goodness of fit plots for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.11 Goodness of fit plots for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.12 Goodness of fit plots for the unconstrained CL, V, ka parameterised 
model developed using initial estimates of k larger than ka and metformin 
concentrations following oral and intravenous metformin administration. 




Figure A6.13 Goodness of fit plots for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.14 Goodness of fit plots for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.15 Goodness of fit plots for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral and intravenous metformin administration. 
  




Figure A6.16 Goodness of fit plots for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.17 Goodness of fit plots for the partially constrained CL, V, ka parameterised 
model developed using metformin concentrations following oral metformin 
administration only. 




Figure A6.18 Goodness of fit plots for the partially constrained CL, V, ka parameterised 
model developed using metformin concentrations following oral and intravenous 
metformin administration. 




Figure A6.19 Goodness of fit plots for the partially constrained k, V, ka parameterised 
model developed using metformin concentrations following oral metformin 
administration only. 




Figure A6.20 Goodness of fit plots for the partially constrained k, V, ka parameterised 
model developed using metformin concentrations following oral and intravenous 
metformin administration. 




Figure A6.21 Goodness of fit plots for the fully constrained CL, V, ka parameterised 
model developed using metformin concentrations following oral metformin 
administration only. 




Figure A6.22 Goodness of fit plots for the fully constrained CL, V, ka parameterised 
model developed using metformin concentrations following oral and intravenous 
metformin administration. 




Figure A6.23 Goodness of fit plots for the fully constrained k, V, ka parameterised 
model developed using metformin concentrations following oral metformin 
administration only. 




FigureA6.24 Goodness of fit plots for the fully constrained k, V, ka parameterised model 
developed using metformin concentrations following oral and intravenous metformin 
administration. 
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A6.3.3. 𝜼 distribution 
The following are plots of histograms of individual 𝜂 values. 
 
 
Figure A6.25 η distribution for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.26 η distribution for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.27 η distribution for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.28 η distribution for the unconstrained CL, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.29 η distribution for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.30 η distribution for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral metformin administration only. 




Figure A6.31 η distribution for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k smaller than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.32 η distribution for the unconstrained k, V, ka parameterised model 
developed using initial estimates of k larger than ka and metformin concentrations 
following oral and intravenous metformin administration. 




Figure A6.33 η distribution for the partially constrained CL, V, ka parameterised model 
developed using metformin concentrations following oral metformin administration 
only 




Figure A6.34 η distribution for the partially constrained CL, V, ka parameterised model 
developed using metformin concentrations following oral and intravenous metformin 
administration. 




Figure A6.35 η distribution for the partially constrained k, V, ka parameterised model 
developed using metformin concentrations following oral metformin administration 
only 




Figure A6.36 η distribution for the partially constrained k, V, ka parameterised model 
developed using metformin concentrations following oral and intravenous metformin 
administration 




Figure A6.37 η distribution for the fully constrained CL, V, ka parameterised model 
developed using metformin concentrations following oral metformin administration 
only 




Figure A6.38 η distribution for the fully constrained CL, V, ka parameterised model 
developed using metformin concentrations following oral and intravenous metformin 
administration 




Figure A6.39 η distribution for the fully constrained k, V, ka parameterised model 
developed using metformin concentrations following oral metformin administration 
only 




Figure A6.40 η distribution for the fully constrained k, V, ka parameterised model 
developed using metformin concentrations following oral and intravenous metformin 
administration 
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A6.4. Example NONMEM control files for the unconstrained, partially 
constrained and fully constrained models  
Presented in this section are examples of the NONMEM control files for the 
unconstrained, partially constrained and fully constrained models 
parameterised using 𝐶𝐿, 𝑉, 𝑘𝑎. The example NONMEM control files shown are 
in the following sections as follows: 
i. Unconstrained model with initial estimates for the elimination rate 
constant being smaller than the absorption rate constant (section 
A6.4.1.)  
ii. Partially constrained model (section A6.4.2.) 
iii. Fully constrained model (section A6.4.3.) 
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A6.4.1. Example NONMEM control file for an unconstrained model 
$PROBLEM METFORMIN PK 
 
$INPUT C STUDY ID STUDYID TIME TAD UVOL DV AMT CMT=CMT1  
CMT2 CMT3 EVID DVID MDV BLQ AGE SEX HTCM WTKG BMI FFM  
GENTCL CR CG MDRD CKDEPI DWTKG BLACT BBICAR DSTART  
DSTOP DRETURN BFR DFR SA DIAL 
 
$DATA metformin_singledose3.csv 
      IGNORE = C 
      IGNORE = (BLQ.EQ.1) 
      IGNORE = (STUDY.EQ.3) 
      IGNORE = (STUDY.EQ.4) 
      IGNORE = (CMT1.EQ.3) 
      IGNORE = (CMT1.EQ.-3) 
 













; BETWEEN SUBJECT VARIABILITY 
CL=TVCL*EXP(ETA(1)) 












; SCALE CONCENTRATIONS 
S2 = V2 
 
$DES 
DADT(1) = -KA*A(1) 
DADT(2) = KA*A(1)-K20*A(2) 
 
$ERROR 
IPRED = F 
    W = SQRT(THETA(5)**2*IPRED**2+THETA(6)**2) 
    Y = IPRED+W*EPS(1) 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA 
(0, 25)          ; CL 
(0, 100)         ; V2 
(0, 0.5)         ; KA 
0.55 FIX         ; F1 
(0, 0.1)         ; Prop 
(0, 0.05)        ; Add 
 




0.1                       ; IIV CL 
0.01     0.1              ; IIV V2 
0.01     0.01     0.1     ; IIV KA 
 
$OMEGA 
0 FIX            ; IIV F1 
 
$SIGMA 
1 FIX ; Proportional PK S1 
 





$TABLE STUDY ID TIME DV MDV EVID CMT1 CMT2 CMT3 BLQ IPRED 
 IWRES CWRES ONEHEADER NOPRINT FILE=sdtab4e 
$TABLE STUDY ID CL V2 KA F1 ETA1 ETA2 ETA3 ONEHEADER  
NOPRINT FILE=patab4e 
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A6.4.2. Example NONMEM control file for a partially constrained model 
$PROBLEM METFORMIN PK 
 
$INPUT C STUDY ID STUDYID TIME TAD UVOL DV AMT CMT=CMT1 
CMT2 CMT3 EVID DVID MDV BLQ AGE SEX HTCM WTKG BMI FFM 
 GENTCL CR CG MDRD CKDEPI DWTKG BLACT BBICAR DSTART  
DSTOP DRETURN BFR DFR SA DIAL 
 
$DATA metformin_singledose3.csv 
      IGNORE = C 
      IGNORE = (BLQ.EQ.1) 
      IGNORE = (STUDY.EQ.3) 
      IGNORE = (STUDY.EQ.4) 
      IGNORE = (CMT1.EQ.3) 
      IGNORE = (CMT1.EQ.-3) 
 







; STRUCTURAL MODEL 






TVKA = (TVCL/TVV2)/(1+THETA(3)); absorption rate limited (ka<k) 




TVKA = (TVCL/TVV2)*(1+THETA(4)) ; elimination rate limited (ka>k) 
ENDIF 
 
TVF1 = THETA(5) 
 
; BETWEEN SUBJECT VARIABILITY 
CL = TVCL * EXP(ETA(1)) 
V2 = TVV2 * EXP(ETA(2)) 
KA = TVKA * EXP(ETA(3)) 
 
K20 = CL / V2 
 
; SCALE CONCENTRATIONS 
S2 = V2 
 
$DES 
DADT(1) = -KA*A(1) 
DADT(2) = KA*A(1)-K20*A(2) 
 
$ERROR 
IPRED = F 
    W = SQRT(THETA(6)**2*IPRED**2+THETA(7)**2) 
    Y = IPRED+W*EPS(1) 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA 
(0, 44.7)        ; CL 
(0, 157)         ; V2 
(0, 0.0001)      ; KA_SMALL 
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(0, 0.349)       ; KA_BIG 
0.55 FIX         ; F1 
(0, 0.258)       ; Prop 
(0, 0.018)       ; Add 
 
$OMEGA BLOCK(3) 
0.10                       ; IIV CL 
0.01     0.10              ; IIV V2 
0.01     0.01     0.10     ; IIV KA 
 
$SIGMA 
1 FIX ; Proportional PK S1 
 





$TABLE STUDY ID TIME DV MDV EVID CMT1 CMT2 CMT3 BLQ IPRED  
IWRES CWRES ONEHEADER NOPRINT FILE=sdtab4 
$TABLE STUDY ID CL V2 K20 KA ETA1 ETA2 ETA3 ONEHEADER  
NOPRINT FILE=patab4 
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A6.4.3. Example NONMEM control file for a fully constrained model 
$PROBLEM METFORMIN PK 
 
$INPUT C STUDY ID STUDYID TIME TAD UVOL DV AMT CMT=CMT1 
CMT2 CMT3 EVID DVID MDV BLQAGE SEX HTCM WTKG BMI FFM 
GENTCL CR CG MDRD CKDEPI DWTKG BLACT BBICAR DSTART 
 DSTOP DRETURN BFR DFR SA DIAL 
 
$DATA metformin_singledose3.csv 
      IGNORE = C 
      IGNORE = (BLQ.EQ.1) 
      IGNORE = (STUDY.EQ.3) 
      IGNORE = (STUDY.EQ.4) 
      IGNORE = (CMT1.EQ.3) 
      IGNORE = (CMT1.EQ.-3) 
 













; BETWEEN SUBJECT VARIABILITY 
;model is based on individually constraining cl=v*k, where k>ka | k<ka 




CL = TVCL*EXP(ETA(1)) 
V2 = TVV2*EXP(ETA(2)) 
 
IF(CG.GE.30)THEN 
 KA=(CL/V2)/(1+THETA(4)*EXP(ETA(3))); absorption rate limited (ka<k) 
ELSE 
 KA=(CL/V2)*(1+THETA(5)*EXP(ETA(3))); elimination rate limited (ka>k) 
ENDIF 
 
K20 = CL/V2 
 
; SCALE CONCENTRATIONS 
S2 = V2 
 
$DES 
DADT(1) = -KA*A(1) 
DADT(2) = KA*A(1)-K20*A(2) 
 
$ERROR 
IPRED = F 
    W = SQRT(THETA(6)**2*IPRED**2+THETA(7)**2) 
    Y = IPRED+W*EPS(1) 
 IRES = DV-IPRED 
IWRES = IRES/W 
 
$THETA 
(0, 41.1)        ; CL 
(0, 175)         ; V2 
0.55 FIX         ; F1 
(0, 0.00001)     ; KA_SMALL 
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(0, 0.74)        ; KA_BIG 
(0, 0.28)        ; Prop 
(0, 0.0204)      ; Add 
 
$OMEGA BLOCK(3) 
0.10                       ; IIV CL 
0.01     0.10              ; IIV V2 
0.01     0.01     0.10     ; IIV KA 
 
$SIGMA 
1 FIX ; Proportional PK S1 
 





$TABLE STUDY ID TIME DV MDV EVID CMT1 CMT2 CMT3 BLQ IPRED  
IWRES CWRES ONEHEADER NOPRINT FILE=sdtab4 
$TABLE STUDY ID CL V2 K20 KA ETA3 ONEHEADER NOPRINT  
FILE=patab4 
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A6.5. Identification of a cut-off to address local identifiability 
A creatinine clearance (𝐶𝐿𝑐𝑟𝐶𝐺) value calculated using the Cockcroft and 
Gault equation was determined to identify when the elimination and absorption 
rate constants were expected to be equal. The transition point was identified 
from subjects with both oral and intravenous metformin concentration data. A 
one-compartment model with first-order absorption and 𝐶𝐿𝑐𝑟𝐶𝐺as a covariate on 
clearance (𝐶𝐿) was developed. Model estimates of clearance (𝐶𝐿), volume of 
distribution (𝑉) and the absorption rate constant (𝑘𝑎) were used to determine the 
𝐶𝐿𝑐𝑟𝐶𝐺 value at which 𝑘 is expected to equal 𝑘𝑎 calculated as follows: 
 
𝑘𝑎 = 𝑘 








𝐶𝐿𝑐𝑟𝐶𝐺 =  100 ∙ (




Here, 𝑘𝑎 is the absorption rate constant (h-1), 𝑘 is the elimination rate constant (h-
1), 𝐶𝐿  is clearance (L/h) and 𝑉  is volume of distribution (L). The model 
parameter estimates used to theoretically derive the transition point for 
metformin are shown in Table A6.2. 
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Table A6.2 Parameter estimates for the population pharmacokinetic model 
Parameter Estimate (%RSE) 
θCL (L∙h-1) 27.85 (16) 
θV (L) 24.13 (8) 
θKA (h-1) 0.28 (13) 
θF1  0.50 (8) 
θCG_EFF  1 FIX 
Between subject variability  
ωKA (CV%) 31.4 (13) 
Residual error  
σadd (mg/L) 0.154 (44) 
σprop (CV%) 0.331(10) 
𝜃𝐶𝐿 is the mean population value for clearance, θV is the mean population value for the volume 
of distribution, 𝜃k𝑎  is the mean population value for the absorption rate constant, 𝜃𝐹1 is the mean 
population value for bioavailability, 𝜃𝐶𝐺_𝐸𝐹𝐹  is the estimated exponent on the covariate effect for 
creatinine clearance calculated using the Cockcroft and Gault equation [80]. ωk𝑎  is between 
subject variability for the absorption rate constant, σadd is additive residual error (mg/L) and 
σprop is proportional residual error (CV%).  
 















𝐶𝐿𝑐𝑟𝐶𝐺 = 24.36 
 
Here, a creatinine clearance value of 24.36 mL/min was calculated as the flip-
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